FUKUOKA Kazuya
Kindai University Hospital | Professor/Director |
Last Updated :2024/07/20
■Researcher comments
List of press-related appearances
1
■Researcher basic information
J-Global ID
Research Keyword
- 呼吸器内科学 癌化学療法 臨床腫瘍学 Medical Oncology
Research Field
■Career
Career
- 2019/10 - Today Kindai UniversityGenome Medical Center, Kindai University HospitalProfessor
- 2018/10 - Today Kindai University近畿大学病院 臨床研究センターセンター長
- 2016/04 - Today Kindai University近畿大学病院 臨床研究センター臨床教授
- 2018/10 - 2022/09 Kindai Universityライフサイエンス研究所副所長
- 2015/04 - 2016/03 Kindai University近畿大学病院 臨床研究センター准教授
- 2014/04 - 2015/03 Kindai University近畿大学医学部 堺病院 腫瘍内科准教授
- 2005/07 - 2013/03 兵庫医科大学内科学呼吸器・RCU科 胸部腫瘍学講座 がんセンター准教授
- 1998/07 - 2005/06 奈良県立医科大学内科学第二講座助教・講師
- 1995/04 - 1998/03 国立がんセンター研究所薬効試験部リサーチレジデント
- 1994/07 - 1995/03 奈良県立医科大学附属病院第二内科非常勤医
- 1990/07 - 1994/06 大阪府済生会吹田病院内科副医長
Educational Background
■Research activity information
Award
Paper
- がん遺伝子パネル検査FoundationOneによる肺癌の遺伝子変異の測定米阪 仁雄; 高濱 隆幸; 黒崎 隆; 川中 雄介; 金村 宙昌; 磯本 晃佑; 鈴木 慎一郎; 三谷 誠一郎; 中川 和彦; 白石 直樹; 小田 いつき; 西郷 和真; 池川 敦子; 福岡 和也; 武田 真幸; 西尾 和人肺癌 (NPO)日本肺癌学会 62 (5) 439 - 439 0386-9628 2022/10
- がん遺伝子パネル検査FoundationOneによる肺癌の遺伝子変異の測定米阪 仁雄; 高濱 隆幸; 黒崎 隆; 川中 雄介; 金村 宙昌; 磯本 晃佑; 鈴木 慎一郎; 三谷 誠一郎; 中川 和彦; 白石 直樹; 小田 いつき; 西郷 和真; 池川 敦子; 福岡 和也; 武田 真幸; 西尾 和人肺癌 (NPO)日本肺癌学会 62 (5) 439 - 439 0386-9628 2022/10
- Takayuki Takahama; Kimio Yonesaka; Naoki Shiraishi; Itsuki Oda; Atsuko Ikegawa; Kazumasa Saigoh; Kazuya Fukuoka; Kazuhiko NakagawaMedical Journal of Kindai University 近畿大学医学会 47 (1・2) 19 - 25 0385-8367 2022/06 [Refereed]
近年、次世代シークエンサー(NGS)の臨床応用が進み、がんに生じた遺伝子変化を網羅的に解析することが可能となった。包括的がんゲノムプロファイリング(CGP)検査を実施することで、がん化に関わる原因遺伝子が明らかになると同時に、治療の選択肢が増え、恩恵を受ける症例が出てきている。近畿大学病院ゲノム医療センターでは、2019年に日本においてCGP検査が保険適応を受けて以降、がん関連遺伝子検査がスムーズに進むよう業務を行っている。エキスパートパネルの運営を通して、患者や主治医への適切な遺伝子解析結果を届けることを目標とし、また二次的所見への対応などを行ってきた。本稿では、CGP検査の現状について概説し、特に課題の多い出口戦略について、治療への到達率を高めるために必要なことは何か考察をしたい。(著者抄録) - J Tanizaki; K Yonemori; K Akiyoshi; H Minami; H Ueda; Y Takiguchi; Y Miura; Y Segawa; S Takahashi; Y Iwamoto; Y Kidera; K Fukuoka; A Ito; Y Chiba; K Sakai; K Nishio; K Nakagawa; H HayashiAnnals of oncology : official journal of the European Society for Medical Oncology 33 (2) 216 - 226 2022/02BACKGROUND: Cancer of unknown primary (CUP) has a poor prognosis. Given the recent approval of immune checkpoint inhibitors for several cancer types, we carried out a multicenter phase II study to assess the efficacy of nivolumab for patients with CUP. PATIENTS AND METHODS: Patients with CUP who were previously treated with at least one line of systemic chemotherapy constituted the principal study population. Previously untreated patients with CUP were also enrolled for exploratory analysis. Nivolumab (240 mg/body) was administered every 2 weeks for up to 52 cycles. The primary endpoint was objective response rate in previously treated patients as determined by blinded independent central review according to RECIST version 1.1. RESULTS: Fifty-six patients with CUP were enrolled in the trial. For the 45 previously treated patients, objective response rate was 22.2% [95% confidence interval (CI), 11.2% to 37.1%], with a median progression-free survival and overall survival of 4.0 months (95% CI, 1.9-5.8 months) and 15.9 months (95% CI, 8.4-21.5 months), respectively. Similar clinical benefits were also observed in the 11 previously untreated patients. Better clinical efficacy of nivolumab was apparent for tumors with a higher programmed death-ligand 1 expression level, for those with a higher tumor mutation burden, and for microsatellite instability-high tumors. In contrast, no differences in efficacy were apparent between tumor subgroups based on estimated tissue of origin. Adverse events were consistent with the known safety profile of nivolumab. No treatment-related death was observed. CONCLUSIONS: Our results demonstrate a clinical benefit of nivolumab for patients with CUP, suggesting that nivolumab is a potential additional therapeutic option for CUP.
- 福岡和也; 中川和彦癌と化学療法 49 (6) 0385-0684 2022
- Recent topics in the development of anticancer drugsHirase C Sano; K; Fukuoka K(Med J Kindai Univ 46 (1-2) 13 - 31 2021/06 [Refereed]
- Masayuki Takeda; Takayuki Takahama; Kazuko Sakai; Shigeki Shimizu; Satomi Watanabe; Hisato Kawakami; Kaoru Tanaka; Chihiro Sato; Hidetoshi Hayashi; Yoshikane Nonagase; Kimio Yonesaka; Naoki Takegawa; Tatsuya Okuno; Takeshi Yoshida; Soichi Fumita; Shinichiro Suzuki; Koji Haratani; Kazumasa Saigoh; Akihiko Ito; Tetsuya Mitsudomi; Hisashi Handa; Kazuya Fukuoka; Kazuhiko Nakagawa; Kazuto NishioThe Oncologist Wiley 26 (4) e588-e596 1083-7159 2021/04BACKGROUND: Implementation of personalized medicine requires the accessibility of tumor molecular profiling in order to allow prioritization of appropriate targeted therapies for individual patients. Our aim was to study the role of comprehensive genomic profiling assays that may inform treatment recommendations for patients with solid tumors. MATERIALS AND METHODS: We performed a prospective study to evaluate the feasibility of application of the FoundationOne CDx panel-which detects substitutions, insertions and deletions, and copy number alterations in 324 genes, select gene rearrangements, and genomic signatures including microsatellite instability and tumor mutation burden (TMB)-to patients with advanced or recurrent solid tumors before its approval in Japan. RESULTS: A total of 181 samples were processed for genomic testing between September 2018 and June 2019, with data being successfully obtained for 175 of these samples, yielding a success rate of 96.7%. The median turnaround time was 41 days (range, 21-126 days). The most common known or likely pathogenic variants were TP53 mutations (n = 113), PIK3CA mutations (n = 33), APC mutations (n = 32), and KRAS mutations (n = 29). Among the 153 patients assessed for TMB, the median TMB was 4 mutations/Mb, and tumors with a high TMB (≥10 mutations/Mb) were more prevalent for lung cancer (11/32) than for other solid tumor types (9/121, Fisher's exact test p < .01). No clear trend toward increased efficacy for immune checkpoint inhibitor (ICI) monotherapy or ICI combination chemotherapy in patients with a high programmed cell death-ligand 1 tumor proportion score or a high TMB was apparent. Among the 174 patients found to harbor known or likely pathogenic actionable alterations, 24 individuals (14%) received matched targeted therapy. CONCLUSION: The FoundationOne CDx assay was performed with formalin-fixed, paraffin-embedded tumor specimens with a success rate of >95%. Such testing may inform the matching of patients with cancer with investigational or approved targeted drugs. IMPLICATIONS FOR PRACTICE: This prospective cohort study was initiated to investigate the feasibility and utility of clinical application of FoundationOne CDx. A total of 181 samples were processed for genomic testing between September 2018 and June 2019, with data being successfully obtained for 175 of these samples, yielding a success rate of 96.7%, and 24 individuals (14%) received matched targeted therapy.
- Mesothelin is useful biomarker and therapeutic target of malignant pleural mesotheliomaFUKUOKA KazuyaRespiratory Medicine 36 (1) 69 - 74 2019/07 [Invited]
- Masayuki Takeda; Kazuko Sakai; Takayuki Takahama; Kazuya Fukuoka; Kazuhiko Nakagawa; Kazuto NishioCancers 11 (6) 2019/05 [Refereed]
: Recent progress in understanding the molecular basis of cancer-including the discovery of cancer-associated genes such as oncogenes and tumor suppressor genes-has suggested that cancer can become a treatable disease. The identification of driver oncogenes such as EGFR, ALK, ROS1, BRAF and HER2 has already been successfully translated into clinical practice for individuals with solid tumor. Next-generation sequencing (NGS) technologies have led to the ability to test for multiple cancer-related genes at once with a small amount of cells and tissues. In Japan, several hospitals have started NGS-based mutational profiling screening in patients with solid tumor in order to guide patients to relevant clinical trials. The Ministry of Health, Labor, and Welfare of Japan has also approved several cancer gene panels for use in clinical practice. However, there is an urgent need to develop a medical curriculum of clinical variant interpretation and reporting. We review recent progress in the implementation of NGS in Japan. - Trend of Cancer Genome Medicine in JapanFUKUOKA KazuyaMed J Kindai Univ 43 (1-2) 11 - 16 2018/06 [Refereed]
- Biomarkers for diagnosis of malignant mesothelioma focused on soluble mesothelin-related peptidesFUKUOKA Kazuya医学のあゆみ 263 (13) 1145 - 1150 2017/12
- Institutional Base of Cancer Clinical Trials in JapanFUKUOKA KazuyaMed J Kindai Univ 42 (3-4) 91 - 97 2017/12 [Refereed]
- Recent Trend of Clinical Study in JapanFUKUOKA KazuyaMed J Kindai Univ 41 (3-4) 69 - 75 2016/12 [Refereed]
- 岡田 あすか; 福岡 和也; 西尾 和人; 高橋 慶一; 片山 公実子; 小口 展生; 村上 伸介; 竹中 英昭; 長 澄人; 鈴木 啓史; 西村 元宏肺癌 (NPO)日本肺癌学会 56 (6) 856 - 856 0386-9628 2016/11
- Seiki Hasegawa; Morihito Okada; Fumihiro Tanaka; Takeharu Yamanaka; Toshinori Soejima; Norihiko Kamikonya; Tohru Tsujimura; Kazuya Fukuoka; Kohei Yokoi; Takashi NakanoINTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY SPRINGER JAPAN KK 21 (3) 523 - 530 1341-9625 2016/06 [Refereed]
We conducted a prospective multi-institutional study to determine the feasibility of trimodality therapy (TMT) comprising induction chemotherapy followed by extrapleural pneumonectomy (EPP) and radiation therapy in Japanese patients with malignant pleural mesothelioma (MPM). Major eligibility criteria were histologically confirmed diagnosis of MPM, including clinical subtypes T0-3, N0-2, M0 disease; no prior treatment for the disease; age 20-75 years; Eastern Cooperative Oncology Group performance status 0 or 1; predicted postoperative forced expiratory volume > 1000 ml in 1 s; written informed consent. Treatment methods comprised induction chemotherapy using pemetrexed (500 mg/m(2)) plus cisplatin (60 mg/m(2)) for three cycles, followed by EPP and postoperative hemithoracic radiation therapy (54 Gy). Primary endpoints were macroscopic complete resection (MCR) rate for EPP and treatment-related mortality for TMT. Forty-two eligible patients were enrolled: median age 64.5 (range 43-74) years; M:F = 39:3, clinical stage I:II:III = 14:13:15; histological type epithelioid were sarcomatoid; biphasic; others = 28:1:9:4. Of 42 patients, 30 completed EPP with MCR and 17 completed TMT. The trial met the primary endpoints, with an MCR rate of 71 % (30/42) and treatment-related mortality of 9.5 % (4/42). Overall median survival time and 2-year survival rate for 42 registered patients were 19.9 months and 42.9 %, respectively. Two-year relapse-free survival rate of 30 patients who completed EPP with MCR was 37.0 %. This phase II study met the predefined primary endpoints, but its risk/benefit ratio was not satisfactory. - Toshio Shimizu; Kazuya Fukuoka; Masayuki Takeda; Tutomu Iwasa; Takeshi Yoshida; Joanna Horobin; Mitchell Keegan; Lou Vaickus; Ajit Chavan; Mahesh Padval; Kazuhiko NakagawaCANCER CHEMOTHERAPY AND PHARMACOLOGY SPRINGER 77 (5) 997 - 1003 0344-5704 2016/05 [Refereed]
Purpose VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and proline-rich tyrosine kinase-2. This phase 1 study evaluated the safety and tolerability, pharmacokinetics, and clinical activity of VS-6063 in Japanese subjects with advanced solid tumor malignancies in a first-in-Asian study setting. Methods VS-6063 was administered orally twice daily (b.i.d.) in 21-day cycles to cohorts of three subjects each with a standard 3 + 3 dose-escalation design until disease progression or unacceptable toxicity. Blood samples for pharmacokinetics were collected on Day 1 and 15. The assessments were performed using CTCAE v4.0 for adverse events (AEs), and the Response Evaluation Criteria In Solid Tumors, version v1.1 (RECIST v1.1) for tumor response. Results Nine patients were treated across three dose levels (200-600 mg BID). No dose-limiting toxicities were observed at any dose level. Most frequent treatment-related AEs were Grade 1/2 unconjugated hyperbilirubinemia, fatigue, decreased appetite, and diarrhea. Only one subject in the 200 mg BID cohort experienced reversible and transient Grade 3 unconjugated hyperbilirubinemia. PK analyses confirmed that the exposure at the recommended Phase 2 dose (RP2D) of 400 mg BID was comparable with exposures previously reported in non-Japanese subjects. Durable stable disease of approximately 24 weeks was confirmed in two subjects (malignant mesothelioma and rectal cancer). Conclusions VS-6063 was well tolerated at all dose levels investigated in this first-in-Asian study. These data support the administration of VS-6063 to Japanese subjects at the RP2D in clinical trials involving solid tumor malignancies. - Small cell lung cancer with isolated unitonsillar metastasis successfully treated with chemotherapy.FUKUOKA KazuyaArch Cancer Res. 4 (1) 62 - 65 2016/03 [Refereed]
- Lee M. Krug; Hedy L. Kindler; Hilary Calvert; Christian Manegold; Anne S. Tsao; Dean Fennell; Ronny Ohman; Ruth Plummer; Wilfried E. E. Eberhardt; Kazuya Fukuoka; Rabab M. Gaafar; Jean-Jacques Lafitte; Gunnar Hillerdal; Quincy Chu; Wieneke A. Buikhuisen; Gregory M. Lubiniecki; Xing Sun; Margaret Smith; Paul BaasLANCET ONCOLOGY ELSEVIER SCIENCE INC 16 (4) 447 - 456 1470-2045 2015/04 [Refereed]
Background Vorinostat is a histone deacetylase inhibitor that changes gene expression and protein activity. On the basis of the clinical benefit reported in patients with malignant pleural mesothelioma treated in a phase 1 study of vorinostat, we designed this phase 3 trial to investigate whether vorinostat given as a second-line or third-line therapy improved patients' overall survival. Methods This double-blind, randomised, placebo-controlled trial was done in 90 international centres. Patients with measurable advanced malignant pleural mesothelioma and disease progression after one or two previous systemic regimens were eligible. After stratification for Karnofsky performance status, histology, and number of previous chemotherapy regimens, patients were randomly assigned (1: 1) by use of an interactive voice response system with a block size of four to either treatment with vorinostat or placebo. Patients received oral vorinostat 300 mg (or matching placebo) twice daily on days 1, 2, 3, 8, 9, 10, 15, 16, and 17 of a 21-day cycle. The primary endpoints were overall survival and safety and tolerability of vorinostat. The primary efficacy comparison was done in the intention-to-treat population, and safety and tolerability was assessed in the treated population. This trial is registered with ClinicalTrials.gov, number NCT00128102. Findings From July 12, 2005, to Feb 14, 2011, 661 patients were enrolled and randomly assigned to receive either vorinostat (n= 329) or placebo (n= 332) and included in the intention-to-treat analysis. Median overall survival for vorinostat was 30.7 weeks (95% CI 26.7-36.1) versus 27.1 weeks (23.1-31.9) for placebo (hazard ratio 0.98, 95% CI 0.83-1.17, p= 0.86). The most common grade 3 or worse adverse events for patients treated with vorinostat were fatigue or malaise (51 [16%] patients in the vorinostat group vs 25 [8%] in the placebo group]) and dyspnoea (35 [11%] vs 45 [14%]). Interpretation In this randomised trial, vorinostat given as a second-line or third-line therapy did not improve overall survival and cannot be recommended as a therapy for patients with advanced malignant pleural mesothelioma. - Fukuoka K; Masachika E; Honda M; Tsukamoto Y; Nakano TMolecular and clinical oncology 3 (2) 397 - 399 2049-9450 2015/03 [Refereed]
- Yoshie Yoshikawa; Ayuko Sato; Tohru Tsujimura; Taiichiro Otsuki; Kazuya Fukuoka; Seiki Hasegawa; Takashi Nakano; Tomoko Hashimoto-TamaokiINTERNATIONAL JOURNAL OF CANCER WILEY-BLACKWELL 136 (3) 560 - 571 0020-7136 2015/02 [Refereed]
We detected low levels of acetylation for histone H3 tail lysines in malignant mesothelioma (MM) cell lines resistant to histone deacetylase inhibitors. To identify the possible genetic causes related to the low histone acetylation levels, whole-exome sequencing was conducted with MM cell lines established from eight patients. A mono-allelic variant of BRD1 was common to two MM cell lines with very low acetylation levels. We identified 318 homozygous protein-damaging variants/mutations (18-78 variants/mutations per patient); annotation analysis showed enrichment of the molecules associated with mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complexes and co-activators that facilitate initiation of transcription. In seven of the patients, we detected a combination of variants in histone modifiers or transcription factors/co-factors, in addition to variants in mSWI/SNF. Direct sequencing showed that homozygous mutations in SMARCA4, PBRM1 and ARID2 were somatic. In one patient, homozygous germline variants were observed for SMARCC1 and SETD2 in chr3p22.1-3p14.2. These exhibited extended germline homozygosity and were in regions containing somatic mutations, leading to a loss of BAP1 and PBRM1 expression in MM cell line. Most protein-damaging variants were heterozygous in normal tissues. Heterozygous germline variants were often converted into hemizygous variants by mono-allelic deletion, and were rarely homozygous because of acquired uniparental disomy. Our findings imply that MM might develop through the somatic inactivation of mSWI/SNF complex subunits and/or histone modifiers, including BAP1, in subjects that have rare germline variants of these transcription regulators and/or transcription factors/co-factors, and in regions prone to mono-allelic deletion during oncogenesis. What's new? Malignant mesotheliomas (MM) are highly aggressive neoplasms largely arising from asbestos exposure. Here, the authors investigated possible genetic causes for the low histone acetylation levels observed in MM cell lines resistant to histone deacetylase inhibitors. Using whole-exome sequencing, they are the first to present MM cases without history of familial MM with germline variants/mutations and somatic inactivation in multiple genes including mSWI/SNF. The genes containing rare germline variants/mutations were not limited to common tumor suppressor genes, and the molecular functions of these genes were related to transcriptional regulation. Such germline variants/mutations could be used as markers for MM predisposition. - Kozo Kuribayashi; Shin-ichiro Iida; Yasuhiro Nakajima; Norihiko Funaguchi; Chiharu Tabata; Kazuya Fukuoka; Yoshihiro Fujimori; Daizo Ihaku; Takashi NakanoJOURNAL OF ASTHMA TAYLOR & FRANCIS LTD 52 (7) 662 - 668 0277-0903 2015 [Refereed]
Objective: Carbon monoxide (CO) levels in expired gas are higher in patients with bronchial asthma than in healthy individuals. Heme oxygenase-1 (HO-1) is a rate-limiting enzyme that catalyzes the degradation of heme to yield biliverdin, CO and free iron. Thus, HO-1 is implicated in the pathogenesis of bronchial asthma. However, whether HO-1 expression and activity in lung tissue are related to allergic airway inflammation remains unclear. We investigated whether expression of HO-1 is related to allergic airway inflammation in lungs and whether HO-1 could influence airway hyperresponsiveness and eosinophilia in mice sensitized to ovalbumin (OVA). Methods: C57BL/6 mice immunized with OVA were challenged thrice with an aerosol of OVA every second day for 8 days. HO-1-positive cells were identified by immunostaining in lung tissue, and zinc protoporphyrin (Zn-PP), a competitive inhibitor of HO-1, was administered intraperitoneally to OVA-immunized C57BL/6 mice on day 23 (day before inhalation of OVA) and immediately before inhalation on the subsequent 4 days (total five doses). Mice were analyzed for effects of HO-1 on AHR, inflammatory cell infiltration and cytokine levels in lung tissue. Ethical approval was obtained from the concerned institutional review board. Results: Number of HO-1-positive cells increased in the subepithelium of the bronchi after OVA challenge, and HO-1 localized to alveolar macrophages. Zn-PP clearly inhibited AHR, pulmonary eosinophilia and IL-5 and IL-13 expression in the lung tissue. Conclusion: Expression of HO-1 is induced in lung tissue during attacks of allergic bronchial asthma, and its activity likely amplifies and prolongs allergic airway inflammation. - Yasumitsu Nishimura; Naoko Kumagai-Takei; Hidenori Matsuzaki; Suni Lee; Megumi Maeda; Takumi Kishimoto; Kazuya Fukuoka; Takashi Nakano; Takemi OtsukiBioMed research international 2015 238431 - 238431 2314-6133 2015 [Refereed]
Malignant mesothelioma is caused by exposure to asbestos, which is known to have carcinogenic effects. However, the development of mesothelioma takes a long period and results from a low or intermediate dose of exposure. These findings have motivated us to investigate the immunological effects of asbestos exposure and analyze immune functions of patients with mesothelioma and pleural plaque, a sign of exposure to asbestos. Here, we review our knowledge concerning natural killer (NK) cells and cytotoxic T lymphocytes (CTL). NK cells showed impaired cytotoxicity with altered expression of activating receptors upon exposure to asbestos, while induction of granzyme(+) cells in CD8(+) lymphocytes was suppressed by asbestos exposure. It is interesting that a decrease in NKp46, a representative activating receptor, is common between NK cells in PBMC culture with asbestos and those of mesothelioma patients. Moreover, it was observed that CD8(+) lymphocytes may be stimulated by some kind of "nonself" cells in plaque-positive individuals and in mesothelioma patients, whereas CTL in mesothelioma is impaired by poststimulation maintenance of cytotoxicity. These findings suggest that analysis of immunological parameters might contribute to the evaluation of health conditions of asbestos-exposed individuals and to a greater understanding of the pathology of malignant mesothelioma. - Kazue Yoneda; Fumihiro Tanaka; Nobuyuki Kondo; Masaki Hashimoto; Teruhisa Takuwa; Seiji Matsumoto; Yoshitomo Okumura; Noriaki Tsubota; Ayuko Sato; Tohru Tsujimura; Kozo Kuribayashi; Kazuya Fukuoka; Chiharu Tabata; Takashi Nakano; Seiki HasegawaANNALS OF SURGICAL ONCOLOGY SPRINGER 21 S472 - S480 1068-9265 2014/12 [Refereed]
Purpose. To investigate the diagnostic and prognostic value of circulating tumor cells (CTCs), a potential surrogate of micrometastasis, in malignant pleural mesothelioma (MPM). Methods. We prospectively evaluated CTCs in 7.5 mL of peripheral blood sampled from patients with a suspicion of MPM. A semiautomated system was used to capture CTCs with an antibody against the epithelial cell adhesion molecule. Results. Of 136 eligible patients, 32 were finally diagnosed with nonmalignant diseases (NM), and 104 had MPM. CTCs were detected in 32.7 % (34 of 104) of MPM patients but in only 9.4 % (3 of 32) of NM patients (P = 0.011). The CTC count was significantly higher in MPM patients than in NM patients (P = 0.007), and a receiver operating characteristic (ROC) curve analysis showed an insufficient capability of the CTC test in discrimination between MPM and NM, with an area under ROC curve of 0.623 (95 % confidence interval, 0.523-0.723; P = 0.036). Among MPM patients, CTCs were more frequently detected in patients with epithelioid subtype (39.7 %, 31 of 78) than in those with nonepithelioid subtypes (11.5 %, 3 of 26; P = 0.016). Positive CTCs (CTC count >= 1) were a significant factor to predict a poor prognosis among epithelioid patients (median overall survival, 22.3 months for positive CTCs vs. 12.6 months for negative CTCs; P = 0.004) and not in nonepithelioid patients (P = 0.649). A multivariate analysis showed that positive CTCs were a significant and independent factor to predict a poor prognosis (hazard ratio, 2.904; 95 % confidence interval, 1.530-5.511; P = 0.001) for epithelioid MPM patients. Conclusions. CTC was a promising marker in diagnosis and prediction of prognosis in MPM, especially in epithelioid MPM. - Kozo Kuribayashi; Hiroshi Hirano; Keiji Nakasho; Hideki Ohyama; Koji Yamanegi; Chiharu Tabata; Kazuya Fukuoka; Yoshihiro Fujimori; Takashi NakanoANTICANCER RESEARCH INT INST ANTICANCER RESEARCH 34 (6) 3061 - 3065 0250-7005 2014/06 [Refereed]
Aim: In order to determine if metastatic malignant mesothelioma cells are more aggressive than primary malignant mesothelioma cells, an analysis of the expression of the adhesion molecules E-cadherin and beta-catenin, concomitant with an assessment of the proliferative activity at primary and metastatic sites, was conducted in post-mortem samples. Materials and Methods: E-cadherin or beta-catenin expression was graded according to the percentage of positively-stained tumor cells. The proliferative activity was quantified by the Ki-67 labeling index. Results: Histologically, the majority of metastatic tumors matched the primary tumor. In the epithelioid component of primary tumors, E-cadherin and beta-catenin expression ranged from 1+ to 4+. Conclusion: Malignant mesothelioma cells acquire a higher proliferative potential after metastasis, without any significant changes in their histology, although metastasis produces no definite trend on the expression of E-cadherin or beta-catenin. - Naoko Kumagai-Takei; Yasumitsu Nishimura; Megumi Maeda; Hiroaki Hayashi; Hidenori Matsuzaki; Suni Lee; Takumi Kishimoto; Kazuya Fukuoka; Takashi Nakano; Takemi OtsukiJournal of immunology research 2014 670140 - 670140 2314-8861 2014 [Refereed]
It is known that asbestos exposure can cause malignant mesothelioma (MM) and that CD8(+) T cells play a critical role in antitumor immunity. We examined the properties of peripheral blood CD8(+) lymphocytes from asbestos-exposed patients with pleural plaque (PL) and MM. The percentage of CD3(+)CD8(+) cells in PBMCs did not differ among the three groups, although the total numbers of PBMCs of the PL and MM groups were lower than those of the healthy volunteers (HV). The percentage of IFN-γ (+) and CD107a(+) cells in PMA/ionomycin-stimulated CD8(+) lymphocytes did not differ among the three groups. Percentages of perforin(+) cells and CD45RA(-) cells in fresh CD8(+) lymphocytes of PL and MM groups were higher than those of HV. Percentages of granzyme B(+) and perforin(+) cells in PMA/ionomycin-stimulated CD8(+) lymphocytes were higher in PL group compared with HV. The MM group showed a decrease of perforin level in CD8(+) lymphocytes after stimulation compared with patients with PL. These results indicate that MM patients have characteristics of impairment in stimulation-induced cytotoxicity of peripheral blood CD8(+) lymphocytes and that PL and MM patients have a common character of functional alteration in those lymphocytes, namely, an increase in memory cells, possibly related to exposure to asbestos. - Fukuoka K; Kuribayashi K; Yamada S; Tamura K; Tabata C; Nakano TMolecular and clinical oncology 1 (6) 942 - 948 2049-9450 2013/11 [Refereed]
- Masaaki Kawahara; Shinji Atagi; Kiyoshi Komuta; Hiroshige Yoshioka; Masayuki Kawasaki; Yuka Fujita; Toshiro Yonei; Fumitaka Ogushi; Kaoru Kubota; Naoyuki Nogami; Michiko Tsuchiya; Kazuhiko Shibata; Yoshio Tomizawa; Koichi Minato; Kazuya Fukuoka; Kazuhiro Asami; Takeharu YamanakaANTICANCER RESEARCH INT INST ANTICANCER RESEARCH 33 (10) 4631 - 4637 0250-7005 2013/10 [Refereed]
Aim: Assessment of the efficacy of docetaxel plus carboplatin vs. paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC). Patients and Methods: Chemotherapy-naive patients were randomly assigned at a ratio of 2 to 1 to receive six cycles of either docetaxel (60 mg/m(2)) plus carboplatin [area under the curve (AUC)=6 mg/ml min] or paclitaxel (200 mg/m(2)) plus carboplatin (same dose), on day 1 every 21 days. The primary end-point was progression-free survival (PFS). Results: A total of 90 patients were enrolled. Overall response rate, median PFS and median survival time in the docetaxel-plus-carboplatin group and the paclitaxel-plus-carboplatin group were 23% vs. 33%, 4.8 months vs. 5.1 months, and 17.6 months vs. 15.6 months, respectively. The docetaxel-plus-carboplatin group had a higher incidence of grade 3 or 4 neutropenia (88% vs. 60%). Conclusion: Both regimens were similarly effective in Japanese patients with advanced NSCLC. - 浅野文祐; 青江 基; 大崎能伸; 岡田克典; 笹田真滋; 佐藤滋樹; 鈴木栄一; 千場 博; 福岡和也; 藤野昇三; 大森一光気管支学 (NPO)日本呼吸器内視鏡学会 35 (35) 367 - 371 0287-2137 2013/07 [Refereed]
目的.Endobronchial ultrasound-guided transbronchial needle aspiration(EBUS-TBNA)の実態を調査するために、日本呼吸器内視鏡学会が全国調査を行った。対象と方法.調査対象は2011年1月〜2012年6月までの1年半にコンベックス型超音波気管支鏡を使用して行ったEBUS-TBNA症例で、日本呼吸器内視鏡学会認定および認定関連施設520施設に質問用紙を郵送した。結果.回収率は87.5%で、調査期間内にEBUS-TBNAを施行したと回答した施設は47.6%であった。主たる施行医が気管支鏡専門医である施設は73.1%で、EBUS-TBNAの経験が20例未満の施設が64.2%であった。さらに28.0%の施設で主たる施行医がハンズオンに参加していなかった。ほぼ全例入院でEBUS-TBNAを施行している施設が73.5%、ほぼ全例静脈麻酔を併用している施設が61.9%であった。穿刺するリンパ節数が通常1個である施設が76.4%、1個のリンパ節に対する穿刺回数は2〜3回の施設が89.0%と多かった。結語.EBUS-TBNA症例経験数の少ない施設や施行医が多く、ハンズオンなどの教育、啓発活動が引き続き必要と思われる。(著者抄録) - Kuribayashi K; Miyata S; Fukuoka K; Murakami A; Yamada S; Tamura K; Hirayama N; Terada T; Tabata C; Fujimori Y; Nakano TMolecular and clinical oncology 1 (4) 639 - 642 2049-9450 2013/07 [Refereed]
- Fumihiro Asano; Motoi Aoe; Yoshinobu Ohsaki; Yoshinori Okada; Shinji Sasada; Shigeki Sato; Eiichi Suzuki; Hiroshi Semba; Kazuya Fukuoka; Shozo Fujino; Kazumitsu OhmoriRespiratory Research 14 (1) 50 1465-9921 2013/05 [Refereed]
Background: With the recent widespread use of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), there have been occasional reports on complications associated with its use. Previous reviews on EBUS-TBNA have been limited to studies by skilled operators, thus the results may not always be applicable to recent clinical practice. To assess the safety of EBUS-TBNA for the staging and diagnosis of lung cancer in Japan, a nationwide survey on its current usage status and complications associated with its use was conducted by the Japan Society for Respiratory Endoscopy (JSRE).Methods: A questionnaire about EBUS-TBNA performed between January 2011 and June 2012 was mailed to 520 JSRE-accredited facilities.Results: Responses were obtained from 455 facilities (87.5%). During the study period, EBUS-TBNA was performed in 7,345 cases in 210 facilities (46.2%) using a convex probe ultrasound bronchoscope, for 6,836 mediastinal and hilar lesions and 275 lung parenchymal lesions. Ninety complications occurred in 32 facilities. The complication rate was 1.23% (95% confidence interval, 0.97%-1.48%), with hemorrhage being the most frequent complication (50 cases, 0.68%). Infectious complications developed in 14 cases (0.19%) (Mediastinitis, 7 pneumonia, 4 pericarditis, 1 cyst infection, 1 and sepsis, 1). Pneumothorax developed in 2 cases (0.03%), one of which required tube drainage. Regarding the outcome of the cases with complications, prolonged hospitalization was observed in 14 cases, life-threatening conditions in 4, and death in 1 (severe cerebral infarction) (mortality rate, 0.01%). Breakage of the ultrasound bronchoscope occurred in 98 cases (1.33%) in 67 facilities (31.9%), and that of the puncture needle in 15 cases (0.20%) in 8 facilities (3.8%).Conclusions: Although the complication rate associated with EBUS-TBNA was found to be low, severe complications, including infectious complications, were observed, and the incidence of device breakage was high. Since the use of EBUS-TBNA is rapidly expanding in Japan, an educational program for its safe performance should be immediately established. © 2013 Asano et al. licensee BioMed Central Ltd. - Mototsugu Shimokawa; Seiki Hasegawa; Kazuya Fukuoka; Morihito Okada; Kohei Yokoi; Fumihiro Tanaka; Takeharu Yamanaka; Takashi Daimon; Takashi NakanoJapanese journal of clinical oncology 43 (5) 575 - 8 0368-2811 2013/05 [Refereed]
A prospective multi-institutional study has been initiated in Japan to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by pleurectomy/decortication aimed at macroscopic complete resection in patients with resectable malignant pleural mesothelioma. The study was initiated on September 2012, for which 24 patients will be recruited over a period of 2 years. The primary endpoint is the macroscopic complete resection rate, regardless of the surgical technique employed (i.e. pleurectomy/decortication or extrapleural pneumonectomy). The secondary endpoints are the pleurectomy/decortication rate, macroscopic complete resection rate by pleurectomy/decortication, pulmonary function at 3 months after surgery, adverse events, treatment-related mortality, response rate to chemotherapy and 3-year overall survival rate. - Y Tsutani; T Takuwa; Y Miyata; K Fukuoka; S Hasegawa; T Nakano; M OkadaAnnals of oncology : official journal of the European Society for Medical Oncology 24 (4) 1005 - 10 2013/04 [Refereed]
BACKGROUND: To select optimal candidates for extrapleural pneumonectomy (EPP), we retrospectively evaluated the usefulness of metabolic response by fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) after neoadjuvant chemotherapy to predict prognosis for patients with resectable malignant pleural mesothelioma (MPM) who underwent EPP in a multicenter study. PATIENTS AND METHODS: We carried out high-resolution CT (HRCT) and FDG-PET/CT before and after neoadjuvant platinum-based chemotherapy on 50 patients with clinical T1-3 N0-2 M0 MPM who underwent EPP ± postoperative hemithoracic radiotherapy. A decrease of ≥30% in the tumor maximum standardized uptake value (SUVmax) was defined as a metabolic responder. The radiologic response using the modified RECIST or metabolic response and surgical results were analyzed. RESULTS: The median overall survival (OS) from diagnosis was 20.5 months. Metabolic responders significantly correlated to OS with median OS for metabolic responders not reached versus 18.7 months for non-responders. No correlation was observed between OS and radiologic response with median OS for radiologic responders and non-responders. Based on the multivariate Cox analyses, decreased SUVmax and epithelioid subtype were significantly independent factors for OS. CONCLUSIONS: The metabolic response after neoadjuvant chemotherapy is an independent prognostic factor for patients with resectable MPM. Patients with metabolic responder or epithelioid subtype may be good candidates for EPP. - Kazue Yoneda; Fumihiro Tanaka; Nobuyuki Kondo; Hayato Orui; Masaki Hashimoto; Teruhisa Takuwa; Seiji Matsumoto; Yoshitomo Okumura; Noriaki Tsubota; Ayuko Sato; Tohru Tsujimura; Kozo Kuribayashi; Kazuya Fukuoka; Takashi Nakano; Seiki HasegawaANNALS OF SURGICAL ONCOLOGY SPRINGER 19 (13) 4229 - 4237 1068-9265 2012/12 [Refereed]
The purpose of this study was to investigate the diagnostic and prognostic value of circulating endothelial cell (CEC), a potential surrogate of tumor angiogenesis, in malignant pleural mesothelioma (MPM). We prospectively evaluated CEC count in 4.0 mL of peripheral blood sampled from patients with a suspicion of MPM. An automated system was used to capture CECs with an anti-CD146 antibody. Of 109 eligible patients, 30 were finally diagnosed with non-malignant diseases, and 79 were with MPM. CEC count was significantly higher in MPM patients than in NM patients (mean CEC count, 120.3 and 39.9, respectively; P = 0.001), and a receiver operating characteristic (ROC) curve analysis showed that CEC provided a significant diagnostic performance in discrimination between MPM and nonmalignant diseases with an area under curve (AUC-ROC) of 0.700 (95 % confidence interval [95 % CI], 0.595-0.806; P = 0.001). Among MPM patients, CEC count was positively correlated with intratumoral microvessel density (MVD), a measurement of tumor angiogenesis (Spearman correlation coefficiency [r] = 0.444; P = 0.001). Higher CEC count (> 50) was significantly associated with a poor prognosis (median overall survival, 11.4 months [95 % CI, 7.6-15.2] for higher CEC count patients versus 20.1 months [95 % CI, 16.0-24.2] for lower CEC count patients; P = 0.028). A multivariate analysis showed that higher CEC count was a significant and independent factor to predict a poor prognosis (hazard ratio [HR], 2.24, [95 % CI, 1.24-4.43]; P = 0.009). CEC, as a surrogate of tumor angiogenesis, was a promising marker in diagnosis and prediction of prognosis in MPM. - Akinobu Gotoh; Takeshi Kanno; Hisao Nagaya; Takashi Nakano; Chiharu Tabata; Kazuya Fukuoka; Masatoshi Tagawa; Tomoyuki NishizakiANTICANCER RESEARCH INT INST ANTICANCER RESEARCH 32 (9) 3743 - 3747 0250-7005 2012/09 [Refereed]
Background: Adenovirus vectors have been utilized for cancer gene therapies. The present study examined the oncolytic effects of adenovirus type 5 (Ad5) and fiber-substituted conditionally replicating adenovirus (CRAD) Ad5/F35 vectors on the human malignant mesothelioma cells MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452 cells. Materials and Method: For the adenovirus, the first mRNA/protein to be made (similar to 1 h after infection) is E1A. Ad5F35 and Ad5 CRAD vectors containing the El gene controlled by the human midkine promoter (Ad5F351MKp-E1 and Ad5/MKp-E1, respectively) were constructed. Western blotting and cell viability assays were carried out in cells transfected with Ad5/MKp-E1 and Ad5F35/MKp-E1. Results: Coxsackie and adenovirus receptor (CAR), a cell surface target of Ad5, and CD46, a cell surface target of Ad35, were expressed in all the malignant mesothelioma cell lines examined here, as much as in HEK293 cells, with no significant differences in the expression levels among cells. Both Ad5/MKp-E1 and Ad5F35/MKp-E1 induced oncolysis of malignant mesothelioma cells in a viral particle-dependent manner, with similar efficacy. Conclusion: The results of the present study suggest that both Ad5/MKp-E1 and Ad5F35/MKp-E1 are useful for the gene therapy of human malignant mesothelioma. - ネフローゼ症候群を来たした悪性胸膜中皮腫の2例平山 倫子; 岡田 あすか; 金村 晋吾; 柴田 英輔; 本田 実紀; 神谷 瞳; 大桑 久弥; 大搗 泰一郎; 前田 理沙; 寺田 貴普; 村上 亜紀; 山田 秀哉; 田村 邦宣; 田端 千春; 中野 孝司; 福岡 和也; 八尋 真名; 木田 有利; 中西 健; 羽尾 裕之; 塚本 吉胤; 廣田 誠一肺癌 (NPO)日本肺癌学会 52 (3) 351 - 351 0386-9628 2012/06
- Aki Murakami; Yoshihiro Fujimori; Yoshie Yoshikawa; Shusai Yamada; Kunihiro Tamura; Noriko Hirayama; Takayuki Terada; Kozo Kuribayashi; Chiharu Tabata; Kazuya Fukuoka; Tomoko Tamaoki; Takashi NakanoLUNG SPRINGER 190 (3) 333 - 337 0341-2040 2012/06 [Refereed]
Malignant mesothelioma is an aggressive tumor of serosal surfaces that is closely associated with asbestos exposure which induces oxidative stress. Heme oxygenase (HO)-1, a rate-limiting enzyme of heme degradation, plays a protective role against oxidative stress. The HO-1 gene promoter carries (GT)n repeats whose number is inversely related to transcriptional activity of the HO-1 gene. To investigate the relationship between the length polymorphism of (GT)n repeats and mesothelioma susceptibility, we analyzed the HO-1 promoter in 44 asbestos-exposed subjects without mesothelioma and 78 asbestos-exposed subjects with mesothelioma using PCR-based genotyping. The number of repeats ranged from 16 to 38, with two peaks at 23 and 30 repeats. Polymorphisms of (GT)n repeats were grouped into two classes of alleles, short (S) (< 24) and long (L) (a parts per thousand yen24), and three genotypes: L/L, L/S, and S/S. The proportions of allele frequencies in class L as well as genotypic frequencies of L allele carriers (L/L and L/S) were significantly higher in the asbestos-exposed subjects with mesothelioma than in those without mesothelioma. The findings of this study suggest that long (GT)n repeats in the HO-1 gene promoter are associated with a higher risk of malignant mesothelioma in the Japanese population. - Yoshie Yoshikawa; Ayuko Sato; Tohru Tsujimura; Mitsuru Emi; Tomonori Morinaga; Kazuya Fukuoka; Shusai Yamada; Aki Murakami; Nobuyuki Kondo; Seiji Matsumoto; Yoshitomo Okumura; Fumihiro Tanaka; Seiki Hasegawa; Takashi Nakano; Tomoko Hashimoto-TamaokiCANCER SCIENCE WILEY-BLACKWELL 103 (5) 868 - 874 1347-9032 2012/05 [Refereed]
In the present study, we analyzed genomic alterations of BRCA1-associated protein 1 (BAP1) in 23 malignant mesotheliomas (MMs), 16 epithelioid and seven non-epithelioid, consisting of 18 clinical specimens and five established cell lines. In examining these samples for homozygous deletions and sequence-level mutations, we found biallelic BAP1 gene alterations in 14 of 23 MMs (61%). Seven of these 14 MMs had homozygous deletions of the partial or entire BAP1 gene, another five had sequence-level mutations, including small deletions, a nonsense mutation, and missense mutations with additional monoallelic deletions, and the remaining two had homozygous mutations without allelic loss. All but one of the 14 BAP1 gene mutations were found in the epithelioid-type MMs; BAP1 mutations were found in 13 of 16 epithelioid-type MMs, but in only one of seven non-epithelioid-type MMs (13/16 vs 1/7; P similar to=similar to 0.005). There was no BAP1 mRNA expression in MMs with biallelic deletion and repressed expression was confirmed in MM specimens with deletion/mutation as compared with Met5a, SV40-transformed normal mesothelial cells. Western blot showed that seven of eight epithelioid MMs analyzed were BAP1 negative. Immunostaining with anti-BAP1 antibody in normal lung tissues revealed clear nuclear staining of normal mesothelial cells. No nuclear staining was observed among BAP1 mutation-positive MM tumors, whereas nuclear staining was observed among BAP1 mutation-negative MM tumors. These results suggest that the lack of the tumor suppressor BAP1 may be more specifically involved in the pathogenesis of epithelioid MM rather than non-epithelioid MM, and would be useful for diagnosis of epithelioid-type MM. (Cancer Sci 2012; 103: 868874) - Seiki Hasegawa; Nobuyuki Kondo; Seiji Matsumoto; Teruhisa Takuwa; Masaki Hashimoto; Hayato Orui; Shunichi Fukuda; Kazue Yoneda; Yoshitomo Okumura; Noriaki Tsubota; Kazuya Fukuoka; Ikuko Torii; Tohru Tsujimura; Takashi NakanoINTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY SPRINGER JAPAN KK 17 (1) 33 - 39 1341-9625 2012/02 [Refereed]
Malignant pleural mesothelioma (MPM) remains suffering poor prognosis in spite of recent diagnostic and therapeutic progress. Although there is currently no established evidence, early diagnosis and early intervention may play a key role to improve prognosis of MPM, similarly to other malignancies. As pleural effusion is usually the first clinical sign of MPM, pleural effusion cytology is often the first diagnostic examination to be carried out. Since the sensitivity of pleural effusion cytology is approximately 60%, however, false-negative diagnosis is given to almost half of true MPM patients at this clinical step. One practical way to reduce the number of misdiagnosed MPM is to encourage performing thoracoscopic pleural biopsy unless definitive diagnosis other than MPM is established. There still remain a considerable number of patients with radiological/thoracoscopic T0 MPM who are misdiagnosed with nonspecific pleuritis after a complete investigation including thoracoscopic biopsies. Such patients will turn out to be malignant during follow-up period, although they have the best opportunity for long-term survival if only early therapeutic intervention is given. Currently, we are performing diagnostic total parietal pleurectomy in highly selected patients, who are characterized with strong clinical suspicion, positive pleural effusion cytology but uncertain pathological diagnosis, excellent cardiopulmonary reserve, and with written informed consent for highly invasive diagnostic surgery for pathologically unproven disease. - Tohru Tsujimura; Ikuko Torii; Ayuko Sato; Misa Song; Kazuya Fukuoka; Seiki Hasegawa; Takashi NakanoINTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY SPRINGER JAPAN KK 17 (1) 40 - 47 1341-9625 2012/02 [Refereed]
Malignant mesothelioma is an asbestos-related malignancy that arises primarily from mesothelial cells on the serosal surfaces of the pleural, peritoneal, and pericardial cavities. Malignant pleural mesothelioma (MPM) is most common, and its incidence is dramatically increasing worldwide as a result of widespread use of asbestos. Morphological discrimination between MPM and reactive mesothelial hyperplasia is difficult, and the most reliable pathological criterion for malignancy is mesothelial proliferation invading deeply into subpleural adipose tissues. To establish radical cure of MPM, it is crucial to find early-stage MPM of epithelial type, in which mesothelial proliferation is localized on the serosal surface of parietal pleura or limited within the submesothelial fibrous tissues of parietal pleura. The initial clinical presentation for patients with MPM is frequently dyspnea and/or chest pain due to large pleural effusion, and cytological analysis of pleural effusions is valuable to find patients with early-stage MPM of epithelial type. Recently, cytological features of MPM in pleural effusion, molecular markers for MPM, and genetic alternations of MPM have been reported. In this review, we discuss major issues on pathological and molecular biological approaches for diagnosis of early-stage MPM of epithelial type. - 浅野 文祐; 青江 基; 大崎 能伸; 岡田 克典; 笹田 真滋; 佐藤 滋樹; 鈴木 栄一; 千場 博; 福岡 和也; 藤野 昇三; 大森 一光気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 34 S133 2012
- Tamura Kunihiro; Ohtsuki Tai-ichiro; Shibata Eisuke; Kanemura Shingo; Yasumitsu Akihiro; Tsukamoto Yoshitane; Komuta Kiyoshi; Tabata Chiharu; Fukuoka Kazuya; Nakano TakashiThe Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 34 (3) 228 - 233 0287-2137 2012Background. Malignant pleural mesothelioma (MPM) is a rapidly progressive malignancy with a median survival of 10 to 12 months. Mesothelioma usually shows a poor response to chemotherapy; complete response (CR) is rare. Case. A 74-year-old female patient presented with pleural effusion. She had worked as a baker for 30 years and had a history of asbestos exposure from the oven. She had experienced right chest pain since December 2005, and a chest X-ray revealed a right pleural effusion. Subsequently, she was referred to our hospital in February 2006. Thoracoscopic examination under local anesthesia with biopsies demonstrated multiple parietal pleura-based nodules and confirmed epithelioid malignant mesothelioma. She received 4 cycles of cisplatin + irinotecan + doxorubicin with radiologic CR which was maintained until October 2010. The patient is currently alive and has a good performance status (PS), although she shows signs of relapse. Conclusion. CR to chemotherapy is rare but could be possible for MPM with a number of good prognostic factors. This patient had (1) epithelioid subtype, (2) stage 1 disease on first presentation, (3) good PS, (4) female, (5) no thrombocytosis, (6) normal white blood cell count. Thoracoscopy under local anesthesia is a useful for diagnosis of early stage of MPM.
- 大搗 泰一郎; 福岡 和也; 平山 倫子; 金村 晋吾; 柴田 英輔; 神谷 瞳; 本田 実紀; 大桑 久弥; 前田 理沙; 寺田 貴普; 岡田 あすか; 村上 亜紀; 山田 秀哉; 田村 邦宣; 田端 千春; 中野 孝司; 坪田 紀明; 木田 有利; 中西 健; 塚本 吉胤; 廣田 誠一気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 34 (1) 95 - 95 2012
- Yoshitaka Nogi; Takeshi Kanno; Takashi Nakano; Yumiko Fujita; Chiharu Tabata; Kazuya Fukuoka; Akinobu Gotoh; Tomoyuki NishizakiCELLULAR PHYSIOLOGY AND BIOCHEMISTRY KARGER 30 (1) 61 - 74 1015-8987 2012 [Refereed]
Background/Aims: The present study investigated adenosine-induced apoptosis in human malignant pleural mesothelioma cells. Methods: MTT assay, TUNEL staining, flow cytometry using propidium iodide and annexin V-FITC, real-time RT-PCR, Western blotting, and assay of caspase-3, -8, and -9 activities were carried out using malignant pleural mesothelioma cell lines such as NCI-H28, NCI-H2052, NCI-H2452, and MSTO-211H cells, and p53 or A(3) adenosine receptor was knocked-down by transfecting each siRNA into cells. Results: Adenosine induced apoptosis in all the malignant pleural mesothelioma cells used here, independently of caspase activation. The adenosine effect was prevented by the adenosine transporter inhibitor dipyridamole, the adenosine kinase inhibitor ABT-702, or the A(3) adenosine receptor inhibitor MRS1191. Adenosine upregulated expression of the p53 mRNA and protein, that is abolished by ABT-702, but not by knocking-down A(3) adenosine receptor. Adenosine-induced apoptosis in NCI-H28 cells was significantly inhibited by knocking-down p53 and in part by knocking-down A(3) adenosine receptor. Conclusion: The results of the present study show that AMP converted from intracellularly transported adenosine upregulates p53 expression to induce caspase-independent apoptosis in malignant pleural mesothelioma cells and that A(3) adenosine receptor also participates partially in the apoptosis by the different mechanism. Copyright (c) 2012 S. Karger AG, Basel - Tai-ichiro Otsuki; Takeshi Kanno; Yumiko Fujita; Chiharu Tabata; Kazuya Fukuoka; Takashi Nakano; Akinobu Gotoh; Tomoyuki NishizakiCELLULAR PHYSIOLOGY AND BIOCHEMISTRY KARGER 30 (1) 210 - 220 1015-8987 2012 [Refereed]
Background/Aims: A(3) adenosine receptor mediates apoptosis in cancer cells via diverse signaling pathways. The present study examined A(3) adenosine receptor-mediated apoptosis in Lu-65 cells, a human giant cell lung carcinoma cell line. Methods: MTT assay, TUNEL staining, real-time RT-PCR, Western blotting, and assay of caspase-3, -8, and -9 activities were carried out in Lu-65 cells, and A(3) adenosine receptor or p53 was knocked-down by transfecting each siRNA into cells. Results: Extracellular adenosine induces Lu-65 cell apoptosis in a concentration (0.01-10 mM)-dependent manner, and the effect was inhibited by the A(3) adenosine receptor inhibitor MRS1191 or by knocking-down A(3) adenosine receptor or p53. Like adenosine, the A(3) adenosine receptor agonist 2-Cl-IB-MECA also induced Lu-65 cell apoptosis. Adenosine upregulated expression of p53 and Noxa mRNAs and activated caspase-3 and -9, but not caspase-8. Those adenosine effects were still inhibited by knocking-down A(3) adenosine receptor or p53. Conclusion: The results of the present study show that adenosine upregulates p53 expression via A(3) adenosine receptor, to promote p53-dependent Noxa gene transcription, causing activation of caspase-9 and the effector caspase-3 to induce Lu-65 cell apoptosis. Copyright (c) 2012 S. Karger AG, Basel - Hisaya Okuwa; Takeshi Kanno; Yumiko Fujita; Akinobu Gotoh; Chiharu Tabata; Kazuya Fukuoka; Takashi Nakano; Tomoyuki NishizakiCELLULAR PHYSIOLOGY AND BIOCHEMISTRY KARGER 30 (4) 995 - 1004 1015-8987 2012 [Refereed]
Background/Aims: Sphingosine regulates cellular differentiation, cell growth, and apoptosis. The present study aimed at understanding sphingosine-regulated mesothelioma cell proliferation. Methods: Human malignant mesothelioma cells such as NCI-H28, NCI-H2052, NCI-H2452, and MSTO-211H cells were cultured. The siRNA to silence the protein kinase C (PKC)-delta-targeted gene was constructed and transfected into cells. MTT assay, cell cycle analysis using a flow cytometry, and cell-free PKC-delta assay were carried out. Results: For all the cell types sphingosine inhibited cell growth in a concentration (1-100 mu M)-dependent manner. The sphingosine effect was not prevented by rottlerin, an inhibitor of protein kinase C-delta (PKC-delta); conversely, rottlerin further enhanced the sphingosine effect or rottlerin suppressed mesothelioma cell growth without sphingosine. In the cell-free PKC assay, sphingosine attenuated PKC-delta activity. Knocking-down PKC-delta induced cell cycle arrest at the G(0)/G(1) phase and inhibited cell growth. Conclusion: The results of the present study show that sphingosine suppressed mesothelioma cell proliferation by inhibiting PKC-delta, to induce cell cycle arrest at the G(0)/G(1) phase. Copyright (C) 2012 S. Karger AG, Basel - Yoshie Yoshikawa; Ayuko Sato; Tohru Tsujimura; Tomonori Morinaga; Kazuya Fukuoka; Shusai Yamada; Aki Murakami; Nobuyuki Kondo; Seiji Matsumoto; Yoshitomo Okumura; Fumihiro Tanaka; Seiki Hasegawa; Tomoko Hashimoto-Tamaoki; Takashi NakanoINTERNATIONAL JOURNAL OF ONCOLOGY SPANDIDOS PUBL LTD 39 (6) 1365 - 1374 1019-6439 2011/12 [Refereed]
Array-based comparative genomic hybridization analysis was performed on 21 malignant mesothelioma (MM) samples (16 primary cell cultures and 5 cell lines) and two reactive mesothelial hyperplasia (RM) primary cell cultures. The RM samples did not have any genomic losses or gains. In MM samples, deletions in 1 p, 3p21, 4q, 9p21, 16p13 and 22q were detected frequently. We focused on 3p21 because this deletion was specific to the epithelioid type. Especially, a deletion in 3p21.1 region carrying seven genes including SEMA3G was found in 52% of MM samples (11 of 14 epithelioid samples). The allele loss of 3p21.1 might be a good marker for the epithelioid MM. A homozygous deletion in this region was detected in two MM primary cell cultures. A heterozygous deletion detected in nine samples contained the 3p21.I region and 3p21.31 one carrying the candidate tumor suppressor genes such as semaphorin 3F (SEMA3F), SEMA3B and Ras association (RalGDS/AF-6) domain family member I (RASSFIA). SEMA3B, 3F and 3G are class 3 semaphorins and inhibit growth by competing with vascular endothelial growth factor (VEGF) through binding to neuropil in. All MM samples downregulated the expression of more than one gene for SEMA38, 3F and 3G when compared with Met5a, a normal pleura-derived cell line. Moreover, in 12 of 14 epithelioid MM samples the expression level of SEMA3A was lower than that in Met5a and the two RM samples. An augmented expression of VEGFA was detected in half of the MM samples. The expression ratio of VEGFA/SEMA3A was significantly higher in the epithelioid MMs than in Met5a, RMs and the non-epithelioid MMs. Our data suggest that the downregulated expression of SEMA3A and several SEMA3s results in a loss of inhibitory activities in tumor angiogenesis and tumor growth of VEGFA; therefore, it may play an important role on the pathogenesis of the epithelioid type of MM. - Shusai Yamada; Chiharu Tabata; Rie Tabata; Kazuya Fukuoka; Takashi NakanoCLINICAL CHEMISTRY AND LABORATORY MEDICINE WALTER DE GRUYTER & CO 49 (10) 1721 - 1726 1434-6621 2011/10 [Refereed]
Background: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure. MPM has a limited response to conventional chemotherapy and radiotherapy, so early diagnosis of MPM is very important. This study investigated the pleural effusion mesothelin levels in patients with MPM and compared them to those of a population with a non-malignant pleuritis or lung cancer involving malignant pleural effusion. Methods: The pleural effusion mesothelin concentrations were measured in 45 MPM patients and 53 non-MPM individuals (24 individuals with non-malignant pleural effusions and 29 individuals with lung cancer involving malignant pleural effusion). Results: This study demonstrated that patients with MPM had significantly higher pleural effusion mesothelin levels than a population with non-malignant pleuritis or lung cancer involving malignant pleural effusion. The difference in overall survival between the groups with pleural effusion mesothelin levels lower and higher than the assumed cut-off of 10 nM was significant. Conclusions: The data suggest that the pleural effusion mesothelin concentration could be useful as an aid for the diagnosis of MPM. - 悪性中皮腫細胞における3p21.1領域の欠失およびセマフォリン3ファミリー遺伝子の発現抑制(Deletion of the 3p21.1 region and downregulated expression of semaphorin 3 family genes in malignant mesothelioma)吉川 良恵; 森永 伴法; 佐藤 鮎子; 福岡 和也; 長谷川 誠紀; 辻村 亨; 中野 孝司; 玉置 知子[橋本]日本癌学会総会記事 (一社)日本癌学会 70回 201 - 201 0546-0476 2011/09
- Takemi Otsuki; Takashi Nakano; Seiki Hasegawa; Morihito Okada; Tohru Tsujimura; Yoshitaka Sekido; Shinya Toyokuni; Hiroshi Nishimoto; Kazuya Fukuoka; Fumihiro Tanaka; Naoko Kumagai; Megumi Maeda; Yasumitsu NishimuraNihon eiseigaku zasshi. Japanese journal of hygiene 66 (3) 543 - 52 0021-5082 2011/05 [Refereed]
The research project entitled "Comprehensive approach on asbestos-related diseases" supported by the "Special Coordination Funds for Promoting Science and Technology (H18-1-3-3-1)" began in 2006 and was completed at the end of the Japanese fiscal year of 2010. This project included four parts; (1) malignant mesothelioma (MM) cases and specimen registration, (2) development of procedures for the early diagnosis of MM, (3) commencement of clinical investigations including multimodal approaches, and (4) basic research comprising three components; (i) cellular and molecular characterization of mesothelioma cells, (ii) immunological effects of asbestos, and (iii) elucidation of asbestos-induced carcinogenesis using animal models. In this special issue of the Japanese Journal of Hygiene, we briefly introduce the achievements of our project. The second and third parts and the third component of the fourth part are described in other manuscripts written by Professors Fukuoka, Hasegawa, and Toyokuni. In this manuscript, we introduce a brief summary of the first part "MM cases and specimen registration", the first component of the fourth part "Cellular and molecular characterization of mesothelioma cells" and the second component of the fourth part "Immunological effects of asbestos". In addition, a previous special issue presented by the Study Group of Fibrous and Particulate Substances (SGFPS) (chaired by Professor Otsuki, Kawasaki Medical School, Japan) for the Japanese Society of Hygiene and published in Environmental Health and Preventive Medicine Volume 13, 2008, included reviews of the aforementioned first component of the fourth part of the project. Taken together, our project led medical investigations regarding asbestos and MM progress and contributed towards the care and examination of patients with asbestos-related diseases during these five years. Further investigations are required to facilitate the development of preventive measures and the cure of asbestos-related diseases, particularly in Japan, where asbestos-related diseases are predicted to increase in the next 10 to 20 years. - Fukuoka K; Tanaka F; Tsujimura T; Hashimoto-Tamaoki T; Hasegawa S; Nakano TNihon eiseigaku zasshi. Japanese journal of hygiene The Japanese Society for Hygiene 66 (3) 553 - 557 0021-5082 2011/05 [Refereed]
Malignant mesothelioma (MM) is a highly aggressive, incurable neoplasm associated with asbestos exposure. Early detection of MM is not easy and radiological surveillance is imperfect. The use of blood-based biomarkers might solve this difficulty and allow detection of MM at an early stage when combined treatment involving surgery, chemotherapy and radiotherapy might be effective. In the research project entitled "Comprehensive approach on asbestos-related diseases" supported by the "Special Coordination Funds for Promoting Science and Technology (H18-1-3-3-1)", we conducted an exploratory study on the detection of markers for diagnosing early-stage MM.
In this study, we have shown that serum soluble mesothelin-related peptide (SMRP) is a highly specific and moderately sensitive biomarker for diagnosing MM. SMRP levels in pleural effusion were elevated not only in advanced-stage malignant pleural mesothelioma (MPM), but also in early-stage disease. SMRP in pleural effusion can be an MPM-specific biomarker with greater sensitivity than in serum, especially for the early stage of the disease. Circulating tumor cells (CTCs) and circulating endothelial cells (CECs) were considered to be useful surrogate markers of disease progression in MPM, although the lack of sensitivity for early-stage disease remains to be improved. Cytological analysis with gene expression profiling has been more effective in detecting early-stage MPM with pleural effusion.
In conclusion, blood or effusion-based biomarkers, possibly in combination with other new modalities, such as a thoracoscopy combined with the advanced imaging systems consisting of autofluorescence imaging (AFI) and narrow band imaging (NBI), will show some promise for curing MPM if the disease is detected at an early stage. - Seiki Hasegawa; Fumihiro Tanaka; Morihito Okada; Takeharu Yamanaka; Norihiko Kamikonya; Toshinori Soejima; Tohru Tsujimura; Kazuya Fukuoka; Takashi NakanoNihon eiseigaku zasshi. Japanese journal of hygiene 66 (3) 558 - 61 0021-5082 2011/05 [Refereed]
The feasibility and efficacy of trimodality therapy for malignant pleural mesothelioma (MPM) are still controversial mainly due to the lack of clinical evidence. Although three major clinical trials on this therapy have been recently reported from North America and Europe, it remains unclear whether results in Caucasian populations may be directly applicable to Asian populations. In this context, as a project of the "Comprehensive approach on asbestos-related diseases" supported by the "Special Coordination Fund for Promoting Science and Technology of MEXT, Japan", a prospective multi-institutional study has been planned to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation in patients with resectable MPM. Primary endpoints are macroscopic complete resection rate by EPP and treatment-related mortality for trimodality therapy. The study was initiated in May 2008 and patient enrollment was finished in November 2010. - Kazuya Fukuoka; Kozo Kuribayashi; Yoshihiro Fujimori; Takashi NakanoJapanese Journal of Lung Cancer 51 (2) 109 - 112 0386-9628 2011/04 [Refereed]
Objective. To evaluate the safety profile of combination therapy of pemetrexed plus cisplatin for malignant pleural mesothelioma (MPM) in an outpatient clinic. Methods. Patients received an intravenous infusion of 500 mg/m2 pemetrexed followed by an intravenous infusion of 60-75 mg/m2 cisplatin, on day 1 of every 21 days, concomitantly with vitamins. Results. We analyzed total of 105 patients who received combination therapy of pemetrexed plus cisplatin, after a histological diagnosis of MPM, but who had received no prior systemic chemotherapy, 77 (64 men, 13 women) of whom continued to receive this combination therapy as outpatients. The median age was 62.2 (range, 44 to 77). Epithelioid histology was present in 65 patients and 12 patients had non-epithelioid histology. There were 285 cycles administered in the outpatient setting, with a median cycle of 3 (range, 1 to 11). Hematological toxicities of grade ≥3 included leukopenia in 10 patients (13.0%), neutropenia in 15 patients (19.5%), and anemia in 8 patients (10.4%). Neither febrile neutropenia nor neutropenic infection was observed. Common non-hematological toxicities were gastrointestinal toxicities, such as nausea, constipation, anorexia, and vomiting, although toxicities of grade ≥3 were not observed. Other grade 3 adverse events were neurotoxicity and allergic reaction in 1 and 2 patients, respectively. The most common abnormal laboratory findings were increased creatinine levels in 21 patients (27.3%), followed by increased aminotransferase levels in 12 patients (15.6%). There were no treatment-related deaths. Conclusion. The safety of this combination therapy was confirmed in outpatients with MPM. © 2011 The Japan Lung Cancer Society. - Ryoji Eguchi; Yoshihiro Fujimori; Hiromi Takeda; Chiharu Tabata; Toshiro Ohta; Kouzo Kuribayashi; Kazuya Fukuoka; Takashi NakanoJOURNAL OF CELLULAR PHYSIOLOGY WILEY-BLACKWELL 226 (3) 762 - 768 0021-9541 2011/03 [Refereed]
Malignant mesothelioma is an aggressive tumor of serosal surfaces, which is refractory to current treatment options. Arsenic trioxide (As2O3) is used clinically to treat acute promyelocytic leukemia, and also to inhibit proliferation of several solid tumors including hepatoma, esophageal, and gastric cancer in vitro. Here we found that As2O3 inhibited cell viability of a mesothelioma cell line, NCI-H2052. As2O3 induced apoptosis of NCI-H2052 cells, which was accompanied by activation of c-Jun NH2-terminal kinase (JNK) 1/2, extracellular signal-regulated kinase (ERK) 1/2, and caspase-3. zVAD-fmk, a broad-spectrum caspase inhibitor, inhibited As2O3-induced apoptosis and activation of caspase-3, but not that of JNK1/2 and ERK1/2. Small interfering RNAs (siRNAs) targeting JNK1/2 suppressed As2O3-induced caspase-3 activation and apoptosis, indicating that JNK1/2 regulate As2O3-induced apoptosis though caspase cascade. Furthermore, JNK1 siRNA abrogated As2O3-induced JNK2 phosphorylation and JNK2 siRNA abrogated As2O3-induced JNK1 phosphorylation, suggesting that JNK1 and JNK2 interact with each other. Moreover, JNK1 siRNA, but not JNK2 siRNA, abrogated As2O3-induced ERK1/2 phosphorylation. JNK2 siRNA together with PD98059, a specific MAPK/ERK kinase inhibitor, suppressed As2O3-induced apoptosis more significantly than JNK2 siRNA alone. These results indicated that As2O3 induces apoptosis of NCI-H2052 cells mainly through JNK1/2 activation, and that ERK1/2 is involved in As2O3-induced apoptosis when JNK1/2 are inactivated. J. Cell. Physiol. 226: 762-768, 2011. (C) 2010 Wiley-Liss, Inc. - 大搗 泰一郎; 福岡 和也; 金村 晋吾; 柴田 英輔; 政近江 利子; 神谷 瞳; 本田 実紀; 大桑 久弥; 前田 理沙; 平山 倫子; 寺田 貴普; 岡田 あすか; 村上 亜紀; 山田 秀哉; 田村 邦宣; 田端 千春; 中野 孝司; 芳川 浩男; 大類 隼人; 橋本 昌樹; 多久和 輝尚; 松本 成司; 近藤 展行; 長谷川 誠紀; 坪田 紀明; 塚本 吉胤; 廣田 誠一気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 33 (5) 382 - 382 2011
- 大搗 泰一郎; 福岡 和也; 政近 江利子; 大桑 久弥; 神谷 瞳; 本田 実紀; 安光 亮洋; 前田 理沙; 三上 浩司; 野木 佳孝; 平山 倫子; 寺田 貴普; 岡田 あすか; 村上 亜紀; 山田 秀哉; 田村 邦宣; 栗林 康造; 田端 千春; 坪田 紀明; 中野 孝司気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 33 S150 2011
- Yamada Shusai; Fukuoka Kazuya; Tabata Chiharu; Yasumitsu Akihiro; Masachika Eriko; Maeda Risa; Okuwa Hisaya; Kamiya Hitomi; Honda Miki; Otsuki Taiichiro; Mikami Koji; Nogi Yoshitaka; Hirayama Noriko; Terada Takayuki; Okada Asuka; Murakami Aki; Tamura Kunihiro; Kuribayashi Kozo; Nakano TakashiThe Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 33 (4) 250 - 255 0287-2137 2011Background. Thoracoscopy under local anesthesia is useful in patients with retention of pleural fluid. Case. A 75-year-old woman had undergone a standard radical mastectomy followed by adjuvant chemotherapy for right breast cancer at the age of 60 in January 1995. Her subsequent progress was monitored by endocrine therapy with tamoxifen and fluorouracil for 2 years. She was referred to our hospital 15 years later for medical evaluation and treatment after right pleural effusion was detected on chest X-ray films taken during a regular medical checkup in October 2009. ^<18>F-fluorodeoxyglucose positron-emission tomography (^<18>FDG-PET) showed abnormal accumulation in the lower lobe of the patient's right lung, cervical vertebrae and thoracic vertebrae. Her serum CA15-3 level was elevated (30.9U/ml) and breast cancer with pulmonary metastasis and multiple bone metastasis were suspected. Examination of her pleural effusion obtained by thoracocentesis did not yield a definitive diagnosis, so thoracoscopy under local anesthesia and bronchoscopy were performed. Recurrent breast cancer with carcinomatous pleuritis, pulmonary metastasis, and multiple bone metastasis were diagnosed. Conclusion. Respiratory endoscopy was very useful in the diagnosis of recurrent breast cancer with carcinomatous pleuritis, pulmonary metastasis and also for the differentiation of the lung cancer lesion.
- 本田 実紀; 大搗 泰一郎; 福岡 和也; 政近 江利子; 神谷 瞳; 大桑 久弥; 三上 浩司; 前田 理沙; 野木 佳孝; 平山 倫子; 寺田 貴普; 安光 亮洋; 岡田 あすか; 村上 亜紀; 山田 秀哉; 田村 邦宣; 栗林 康造; 田端 千春; 中野 孝司; 大類 隼人; 橋本 昌樹; 塩見 和; 松本 成司; 近藤 展行; 田中 文啓; 長谷川 誠紀; 坪田 紀明; 塚本 吉胤; 廣田 誠一気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 33 (2) 138 - 138 2011
- Noriko Hirayama; Chiharu Tabata; Rie Tabata; Risa Maeda; Akihiro Yasumitsu; Shusai Yamada; Kozo Kuribayashi; Kazuya Fukuoka; Takashi NakanoRESPIRATORY MEDICINE W B SAUNDERS CO LTD 105 (1) 137 - 142 0954-6111 2011/01 [Refereed]
Background: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure. MPM has a limited response to conventional chemotherapy and radiotherapy so early diagnosis of MPM is very important. Vascular endothelial growth factor (VEGF), a potent mitogen for the vascular endothelium, is also known to be an autocrine growth factor for MPM. Here, we investigated the pleural effusion VEGF levels in patients with MPM and compared them to those of a population with a non-malignant pleuritis or lung cancer involving malignant pleural effusion. Methods: The pleural effusion VEGF concentrations were measured in 46 MPM patients and 45 individuals with non-MPM individuals (25 individuals with non-malignant pleural effusions, and 20 individuals with lung cancer involving malignant pleural effusion). Results: We demonstrated that patients with MPM had significantly higher pleural effusion VEGF levels than a population with non-malignant pleuritis or lung cancer involving malignant pleural effusion, and the patients with advanced stage MPM showed higher levels of VEGF than the early stage MPM patients. The difference in overall survival between the groups with pleural effusion VEGF levels lower and higher than the assumed cut-off of 2000 pg/ml was significant. Conclusions: Our data suggest that the pleural effusion VEGF concentration could be useful as an aid for the diagnosis of MPM and as a prognostic factor. (C) 2010 Elsevier Ltd. All rights reserved. - C. Tabata; N. Hirayama; R. Tabata; A. Yasumitsu; S. Yamada; A. Murakami; S. Iida; K. Tamura; K. Fukuoka; K. Kuribayashi; T. Terada; T. NakanoEuropean Respiratory Journal 36 (5) 1099 - 1105 0903-1936 2010/11 [Refereed]
Malignant pleural mesothelioma (MPM) is an aggressive malignant tumour associated with asbestos exposure that has only a limited response to conventional therapy therefore, diagnosing MPM early is very important. We have previously reported that angiopoietin (Ang)-1 was correlated with bleomycin-induced pulmonary fibrosis. Here, we investigated the association of Ang-1 with the development of MPM cells, which originate from mesenchymal cells similar to lung fibroblasts, and demonstrated that Ang-1 stimulated the growth and migration of MPM cells in vitro. We also demonstrated that patients with MPM had significantly higher serum levels of Ang-1 in comparison to a population who had been exposed to asbestos but had not developed MPM. The patients with advanced-stage MPM showed higher levels of Ang-1 than the early-stage MPM patients and the Kaplan-Meier method revealed a significant correlation between serum Ang-1 levels and survival. We propose the possibility that Ang-1 plays an important role in MPM tumour growth and our data suggest that the serum concentration of Ang-1 could be useful as prognostic factor. Copyright©ERS 2010. - 悪性中皮腫細胞におけるBAP1(BRCA1 associated protein 1)遺伝子の高頻度欠失(Frequent genome deletions of BAP1 (BRCA1-associated protein 1) in malignant mesothelioma cells)吉川 良恵; 森永 伴法; 佐藤 鮎子; 福岡 和也; 辻村 亨; 玉置 知子[橋本]; 中野 孝司日本癌学会総会記事 (一社)日本癌学会 69回 486 - 486 0546-0476 2010/08
- Akihiro Yasumitsu; Chiharu Tabata; Rie Tabata; Noriko Hirayama; Aki Murakami; Shusai Yamada; Takayuki Terada; Shinichiro Iida; Kunihiro Tamura; Kazuya Fukuoka; Kozo Kuribayashi; Takashi NakanoJOURNAL OF THORACIC ONCOLOGY LIPPINCOTT WILLIAMS & WILKINS 5 (4) 479 - 483 1556-0864 2010/04 [Refereed]
Introduction: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure. MPM has a limited response to conventional chemotherapy and radiotherapy so diagnosing MPM early is very important. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for MPM. Here, we investigated the serum levels of VEGF in patients with MPM in comparison with a population that had been exposed to asbestos without developing MPM. Methods: Serum concentrations of VEGF were measured in 51 patients with MPM and 42 individuals with benign asbestos-related diseases (asbestosis or pleural plaques) or who were healthy despite asbestos exposure. Results: We demonstrated that patients with MPM had significantly higher serum levels of VEGF than a population who had been exposed to asbestos but had not developed MPM, and the patients with advanced stage MPM showed higher levels of VEGF than the early stage patients with MPM. The difference in overall survival between the groups with VEGF serum levels lower and higher than the assumed cutoff of 460 pg/ml was significant. Conclusions: Our data suggest that the VEGF serum concentration could be a useful marker for screening MPM among asbestos-exposed individuals and as a prognostic factor. - Ikuko Torii; Masaki Hashimoto; Takayuki Terada; Nobuyuki Kondo; Hiroaki Fushimi; Kohki Shimazu; Shin-ichi Takeda; Teruhisa Takuwa; Yoshitomo Okumura; Ayuko Sato; Tadashi Yamamoto; Kazuya Fukuoka; Fumihiro Tanaka; Takashi Nishigami; Takashi Nakano; Seiki Hasegawa; Tohru TsujimuraLUNG CANCER ELSEVIER IRELAND LTD 67 (2) 244 - 247 0169-5002 2010/02 [Refereed]
Well-differentiated papillary mesothelioma (WDPM) is an uncommon tumor with a papillary architecture, bland cytologic features, a tendency toward superficial spread without invasion, and good prognosis with prolonged survival. WDPM occurs primarily in the peritoneum of women, but also rarely in the pleura. We here report a case of 48-year-old woman who developed WDPM in the pleura with no history of asbestos exposure. Tumors were multifocal and widespread with a velvety appearance on the surface of parietal and visceral pleurae resected by extrapleural pneumonectomy (EPP). Tumors showed papillary structures with fibrovascular cores and lined by epithelioid cells. lmmunohistochemically, these epithelioid tumor cells were positive for epithelial membrane antigen (EMA), a marker of malignant mesothelioma, with more than 50% positive for p53. Tumor cells microinvaded into subpleural parenchyma of the lung and minimally spread to adipose tissues of the mediastinal lesion. In addition, tumor cells invaded into the chest wall with a trabecular or glandular architecture. Based on these findings, this case is pathologically considered as WDPM of the pleura with malignant potential. (C) 2009 Elsevier Ireland Ltd. All rights reserved. - 安光 亮洋; 福岡 和也; 前田 理紗; 野木 佳孝; 三上 浩司; 寺田 貴普; 平山 倫子; 岡田 あすか; 村上 亜紀; 山田 秀哉; 田村 邦宣; 栗林 康造; 田端 千春; 坪田 紀明; 中野 孝司気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 32 S110 2010
- 山田 秀哉; 福岡 和也; 田端 千春; 栗林 康造; 田村 邦宣; 村上 亜紀; 岡田 あすか; 安光 亮洋; 寺田 貴普; 平山 倫子; 野木 佳孝; 三上 浩司; 大搗 泰一郎; 前田 理沙; 政近 江利子; 大桑 久弥; 本田 実紀; 神谷 瞳; 中野 孝司; 塚本 吉胤; 廣田 誠一気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 32 (5) 467 - 467 2010
- 安光 亮洋; 福岡 和也; 前田 理沙; 野木 佳孝; 三上 浩司; 寺田 貴普; 平山 倫子; 岡田 あすか; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 栗林 康造; 田端 千春; 中野 孝司; 坪田 紀明; 塚本 吉胤; 廣田 誠一; 宮本 良文気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 32 (1) 91 - 91 2010
- Kazuya Fukuoka; Fumihiro Hommura; Hideo Kunitoh; Toyoaki Hida; Kazuhiko Nakagawa; Kenichi Gemba; Tetsu Shinkai; Yukito Ichinose; Yoshihiro Nambu; Takashi NakanoJapanese Journal of Lung Cancer 49 (7) 988 - 993 0386-9628 2009/12 [Refereed]
Objective. To examine safety and efficacy of combination therapy with LY231514 (pemetrexed) plus cisplatin in malignant pleural mesothelioma. Methods. Patients aged between 20 and 75 years who were not candidates for surgery, who were given histological diagnoses of malignant pleural mesothelioma, had received no prior systemic chemotherapy, with a performance status (PS) of 0 or 1, and who had normal major organ function were enrolled. On day 1 of a 21-day cycle, patients received intravenous infusion of 500 mg/m2 pemetrexed, followed by intravenous infusion of 75 mg/m2 cisplatin, concomitantly with vitamin preparations. Results. Ten men and two women with a mean age of 63 years (range 50 to 73) were analyzed. The histological subtype was epithelioid in 8 patients, sarcomatoid in 2 patients, and biphasic in 2 patients. Ten patients had stage III/IV disease. Seven patients had a history of asbestos exposure. Hematological toxicities of grade 3 or more included decreased white blood cell count in 1 patient (8.3%) and decreased neutrophil count in 1 patient (8.3%), decreased lymphocyte count in 2 patients (16.7%) and decreased red blood cell count in 2 patients (16.7%), decreased hemoglobin in 4 patients (33.3%), and decreased platelet count in 2 patients (16.7%). Pneumonia was observed in 1 patient (8.3%). Common non-hematological toxicities included gastrointestinal toxicities, such as nausea, vomiting, and anorexia. The response rate was 25.0%. Conclusion. Safety of this combination therapy was confirmed in patients with malignant pleural mesothelioma. © 2009 The Japan Lung Cancer Society. - C. Tabata; R. Tabata; N. Hirayama; A. Yasumitsu; S. Yamada; A. Murakami; S. Iida; K. Tamura; T. Terada; K. Kuribayashi; K. Fukuoka; T. NakanoEuropean Respiratory Journal 34 (5) 1159 - 1166 0903-1936 2009/11 [Refereed]
Malignant pleural mesothelioma (MPM) is an aggressive malignant tumour of mesothelial origin associated with asbestos exposure. Because MPM has limited response to conventional chemotherapy and radiotherapy, the prognosis is very poor. Several researchers have reported that cytokines such as interleukin (IL)-6 play an important role in the growth of MPM. Previously, it was reported that all-trans-retinoic acid (ATRA) inhibited the production and function of IL-6 and transforming growth factor (TGF)-β1 in experiments using lung fibroblasts. We investigated whether ATRA had an inhibitory effect on the cell growth of MPM, the origin of which was mesenchymal cells similar to lung fibroblasts, using a subcutaneous xenograft mouse model. We estimated the tumour growth and performed quantitative measurements of IL-6, TGF-β1 and platelet-derived growth factor (PDGF) receptor (PDGFR)-β mRNA levels both of cultured MPM cells and cells grown in mice with or without the administration of ATRA. ATRA significantly inhibited MPM tumour growth. In vitro studies disclosed that the administration of ATRA reduced 1) mRNA levels of TGF-β1, TGF-β1 receptors and PDGFR-β, and 2) TGF-β1-dependent proliferation and PDGF-BB-dependent migration of MPM cells. These data may provide a rationale to explore the clinical use of ATRA for the treatment of MPM. Copyright©ERS Journals Ltd 2009. - Fumihiro Tanaka; Kazue Yoneda; Nobuyuki Kondo; Masaki Hashimoto; Teruhisa Takuwa; Seiji Matsumoto; Yoshitomo Okumura; Shakibur Rahman; Noriaki Tsubota; Tohru Tsujimura; Kozo Kuribayashi; Kazuya Fukuoka; Takashi Nakano; Seiki HasegawaCLINICAL CANCER RESEARCH AMER ASSOC CANCER RESEARCH 15 (22) 6980 - 6986 1078-0432 2009/11 [Refereed]
Purpose: To investigate the diagnostic performance of circulating tumor cells (CTC) in discrimination between primary lung cancer and nonmalignant diseases as well as in prediction of distant metastasis. Patients and Methods: We prospectively evaluated CTCs in 7.5-mL samples of peripheral blood sampled from patients with a suspicion or a diagnosis of primary lung cancer. A semiautomated system was used to capture CTCs with an antibody against epithelial cell adhesion molecule. Results: Of 150 eligible patients, 25 were finally diagnosed as having nonmalignant disease, and 125 were diagnosed as having primary lung cancer with (n = 31) or without (n = 94) distant metastasis. CTCs were detected in 30.6% of lung cancer patients and in 12.0% of nonmalignant patients. CTC count was significantly higher in lung cancer patients than in nonmalignant patients, but a receiver operating characteristic (ROC) curve analysis showed an insufficient capability of the CTC test in discrimination between lung cancer and nonmalignant diseases with an area under ROC curve of 0.598 (95% confidence interval, 0.488-0.708; P = 0.122). Among lung cancer patients, CTC count significantly increased along with tumor progression, especially with development of distant metastasis. The area under ROC curve for CTC count in prediction of distant metastasis was 0.783 (95% confidence interval, 0.679-0.886; P < 0.001). When patients with one or more CTCs were judged as having metastatic disease, sensitivity and specificity of the CTC test were 71.0% and 83.0%, respectively. Conclusions: CTC is a useful surrogate marker of distant metastasis in primary lung cancer. (Clin Cancer Res 2009;15(22):6980-6) - 中皮腫細胞の形態を科学する 中皮腫細胞診断の現状と問題点 胸水細胞診から科学する早期中皮腫の病態と細胞像辻村 亨; 鳥井 郁子; 佐藤 鮎子; 片岡 竜貴; 西上 隆之; 山本 格士; 福岡 和也; 田中 文啓; 長谷川 誠紀; 中野 孝司日本臨床細胞学会雑誌 (公社)日本臨床細胞学会 48 (Suppl.2) 430 - 430 0387-1193 2009/09
- 辻村 亨; 佐藤 鮎子; 鳥井 郁子; 玉置 知子; 吉川 良恵; 福岡 和也; 田中 文啓; 長谷川 誠紀; 中野 孝司肺癌 (NPO)日本肺癌学会 49 (4) 376 - 379 0386-9628 2009/08目的.早期中皮腫病変(EM)と反応性中皮過形成(RM)との鑑別は治療方針を決定する上で極めて重要であるが、これらの病変を形態的に鑑別することは難しい。我々は悪性胸膜中皮腫(MPM)ではp16INK4A遺伝子やNF2遺伝子が高頻度に欠失することに着目し、これらの遺伝子異常がEMとRMの鑑別に有用であるのかどうかを検討した。方法.形態的特徴に免疫組織化学染色を加えて評価し、MPM(16例)、RM(3例)、EM(2例)を選別した。これらの症例についてp16INK4A遺伝子とNF2遺伝子の欠失領域のプライマーを作製し、ゲノムDNAを鋳型にしたリアルタイムPCRにより遺伝子欠失の有無を検討した。結果.全てのRM症例でp16INK4A遺伝子とNF2遺伝子はともに保存されていたのに対して、MPMの全ての症例でp16INK4A遺伝子が欠失するとともにNF2遺伝子も高頻度に欠失していた。また、EMの2症例でp16INK4A遺伝子の欠失がみられ、その内の1例はNF2遺伝子も欠失していた。結論.p16INK4AとNF2の遺伝子診断は、EMとRMの鑑別に極めて有用であると考えられる。(著者抄録)
- 胸壁浸潤を示した高分化乳頭型悪性胸膜中皮腫の1例鳥井 郁子; 佐藤 鮎子; 西上 隆之; 辻村 亨; 寺田 貴普; 福岡 和也; 中野 孝司; 橋本 昌樹; 長谷川 誠紀肺癌 (NPO)日本肺癌学会 49 (4) 528 - 528 0386-9628 2009/08
- 肺原発のMucinous("colloid")adenocarcinomaの1切除例田村 邦宣; 福岡 和也; 三上 浩司; 前田 理沙; 野木 佳孝; 平山 倫子; 岡田 あすか; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 田中 文啓; 長谷川 誠紀; 鳥井 郁子; 佐藤 鮎子; 辻村 亨肺癌 (NPO)日本肺癌学会 49 (4) 530 - 530 0386-9628 2009/08
- Rina Ohashi; Ken Tajima; Fumiyuki Takahashi; Ri Cui; Tao Gu; Kazue Shimizu; Kazuto Nishio; Kazuya Fukuoka; Takashi Nakano; Kazuhisa TakahashiANTICANCER RESEARCH INT INST ANTICANCER RESEARCH 29 (6) 2205 - 2214 0250-7005 2009/06 [Refereed]
Background: Although serum osteopontin (OPN) concentration is elevated in patients with malignant pleural mesothelioma (MPM), the role of OPN in the pathogenesis and development of MPM remains unknown. Materials and Methods: To determine the roles of OPN in MPM, immunohistochemical staining was performed to investigate the concentration of OPN in the pleural tumor of patients with mesothelioma; cell adhesion, proliferation and migration assays of H28 cells, an MPM cell line, were also carried out in vitro. Results: H28 cells cultured on OPN-coated plates revealed enhanced adhesion, proliferation, migration, cell survival and phosphorylated focal adhesion kinase activities. As expected, these enhancements were markedly suppressed with the addition of anti-alpha v beta 3 antibody or arginine-glycine-aspartic acid serine (RGDS) peptide to the medium. Conclusion: OPN is speculated to play an important role in the enhancement of adhesion, proliferation and migration activities of H28 cells, presumably by interacting with the alpha v beta 3 integrin. - 村上 亜紀; 福岡 和也; 平山 倫子; 寺田 貴普; 安光 亮洋; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 田中 文啓; 長谷川 誠紀; 吉川 良恵; 玉置 知子; 佐藤 鮎子; 辻村 亨日本呼吸器学会雑誌 (一社)日本呼吸器学会 47 (増刊) 237 - 237 1343-3490 2009/05
- 限局型悪性胸膜中皮腫の1例山田 秀哉; 福岡 和也; 栗林 康造; 田端 千春; 田村 邦宣; 飯田 慎一郎; 村上 亜紀; 安光 亮洋; 寺田 貴普; 平山 倫子; 中野 孝司; 坪田 紀明; 橋本 昌樹; 多久和 輝尚; 奥村 好邦; 近藤 展行; 田中 文啓; 長谷川 誠紀; 鳥井 郁子; 佐藤 鮎子; 辻村 亨肺癌 (NPO)日本肺癌学会 49 (2) 222 - 222 0386-9628 2009/04
- のう胞形成性脳転移をきたした悪性胸膜中皮腫の1例村上 亜紀; 寺田 貴普; 平山 倫子; 安光 亮洋; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 福岡 和也; 中野 孝司; 坪田 紀明; 田中 文啓; 長谷川 誠紀; 佐藤 鮎子; 鳥井 郁子; 辻村 亨肺癌 (NPO)日本肺癌学会 49 (2) 222 - 223 0386-9628 2009/04
- Takeharu Yamanaka; Fumihiro Tanaka; Seiki Hasegawa; Morihito Okada; Toshinori Soejima; Norihiko Kamikonya; Kazuya Fukuoka; Takashi NakanoJAPANESE JOURNAL OF CLINICAL ONCOLOGY OXFORD UNIV PRESS 39 (3) 186 - 188 0368-2811 2009/03 [Refereed]
A prospective multi-institutional study has been commenced in Japan to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation in patients with resectable malignant pleural mesothelioma. The study was initiated on May 2008 and 40 patients will be recruited over 3 years. Primary endpoints are macroscopic complete resection rate by EPP and treatment-related mortality for trimodality therapy. Secondary endpoints include treatment completion rate, adverse events, response rate by chemotherapy and 2-year overall and relapse-free survival. - 田村 邦宣; 福岡 和也; 平山 倫子; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 田中 文啓; 長谷川 誠紀; 辻村 亨気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 31 (2) 109 - 109 2009
- 平山 倫子; 福岡 和也; 三上 浩司; 前田 理沙; 野木 佳孝; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 多久和 輝尚; 田中 文啓; 長谷川 誠紀; 塚本 吉胤気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 31 (5) 334 - 334 2009
- 平山 倫子; 福岡 和也; 三上 浩司; 前田 理沙; 野木 佳孝; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 田中 文啓; 長谷川 誠紀; 辻村 亨気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 31 S109 2009
- 安光 亮洋; 福岡 和也; 寺田 貴普; 田村 邦宣; 平山 倫子; 三上 浩司; 前田 理沙; 野木 佳孝; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 坪田 紀明; 中野 孝司気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 31 S134 2009
- 奥村 好邦; 橋本 昌樹; 多久和 輝尚; 近藤 展行; 田中 文啓; 長谷川 誠紀; 福岡 和也; 中野 孝司; 坪田 紀明気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 31 S83 2009
- Yasumitsu Nishimura; Y. Miura; M. Maeda; N. Kumagai; S. Murakami; H. Hayashi; K. Fukuoka; T. Nakano; T. OtsukiInternational Journal of Immunopathology and Pharmacology 22 (3) 579 - 590 0394-6320 2009Asbestos is well-known for its tumorigenic activity, but its effect on anti-tumor immunity remains unclear. Therefore, we prepared a sub-line of YT-A1 human NK cells exposed to chrysotile B (CB) asbestos (YT-CB5) as an in vitro model to analyze the effect of asbestos exposure on NK cells, and examined cytotoxicity and expressions of its related molecules. The cytotoxicity of YT-CB5 against K562 cells decreased compared with the original line of YT-A1 (YT-Org). YT-CB5 exhibited significant decreases in expressions of cell surface NKG2D, 2B4 and intracellular granzyme A. YT-CB5 also exhibited a decrease in the 2B4-dependent cytotoxicity. In addition, the degranulations stimulated via cell surface NKG2D and 2B4 also decreased in YT-CB5. Therefore, peripheral blood NK cells in patients with malignant mesothelioma (MM) were examined and compared with healthy volunteers. NK cells in patients with MM also showed decreases in cytotoxicity against K562. Although the expressions of NKG2D and 2B4 did not decrease in NK cells of MM patients, the expression of cell surface NKp46 decreased. To confirm the effect of asbestos exposure on peripheral blood NK cells, PBMCs were cultured under exposure to CB. NK cells in PBMCs exposed to CB in vitro showed a significant decrease in the expression of NKp46, whereas NK cells in PBMCs exposed to glass wool did not show such a decrease. These results indicate that exposure to asbestos has the potential to impair the cytotoxicity of NK cells and alter the expression of NK cell-activating receptors including NKG2D, 2B4 and NKp46 and intracellular perforin/granzymes. Copyright © by BIOLIFE, s.a.s.
- Naoto Azuma; Naoaki Hashimoto; Akihiro Yasumitsu; Kazuya Fukuoka; Kazunori Yokoyama; Hisashi Sawada; Aki Nishioka; Masahiro Sekiguchi; Masayasu Kitano; Takanori Kuroiwa; Kiyoshi Matsui; Hajime SanoINTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 48 (24) 2145 - 2149 0918-2918 2009 [Refereed]
We report a case of cytomegalovirus (CMV) pneumonitis that presented as a cavitary lung lesion in a patient with systemic lupus erythematosus receiving immunosuppressive treatment. The lesion was confirmed by positive polymerase chain reaction (PCR) for CMV in bronchoalveolar lavage fluid (BALF) and CMV antigenemia. PCR for CMV in BALF was demonstrated to be useful for the diagnosis of CMV pneumonitis on the basis of high sensitivity and specificity. After initiating ganciclovir, the lesion gradually regressed. A cavitary lung lesion associated with CMV is extremely rare. This presentation suggests that the differential diagnosis of cavitary lung lesion in immunocompromised individuals should include CMV. - 福岡 和也; 栗林 康造; 寺田 貴普; 平山 倫子; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 中野 孝司; 田中 文啓; 長谷川 誠紀; 佐藤 鮎子; 鳥井 郁子; 辻井 亨; 坪田 紀明肺癌 (NPO)日本肺癌学会 48 (5) 438 - 438 0386-9628 2008/10
- 村上 亜紀; 福岡 和也; 平山 倫子; 寺田 貴普; 安光 亮洋; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 田中 文啓; 長谷川 誠紀; 吉川 良恵; 玉置 知子; 佐藤 鮎子; 辻村 亨肺癌 (NPO)日本肺癌学会 48 (5) 509 - 509 0386-9628 2008/10
- 悪性中皮腫より樹立細胞株のアレイCGH解析(Array CGH analysis of cell lines established from malignant mesotheliomas)吉川 良恵; 佐藤 鮎子; 山田 秀哉; 福岡 和也; 辻村 亨; 家本 敦子; 長谷川 誠紀; 玉置 知子[橋本]; 中野 孝司日本癌学会総会記事 (一社)日本癌学会 67回 66 - 66 0546-0476 2008/09
- IMAI Kentaro; USUDA Jitsuo; ICHINOSE Shuji; ISHIZUMI Taichiro; HIRATA Takeshi; INOUE Tatsuya; OHTANI Keishi; MAEHARA Sachio; KUBOTA Mitsuhiro; TSUNODA Yoshihiko; YAMADA Masae; KUROIWA Yukari; Tsutsui Hidemitsu; YAMADA Kimito; FURUKAWA Kinya; OKUNAKA Tetsuya; FUKUOKA Kazuya; NAKANO Takashi; KATO HarubumiJJSLSM Japan Society for Laser Surgery and Medicine 29 (1) 12 - 17 0288-6200 2008/04Malignant pleural mesothelioma is an aggressive malignancy which can be associated with asbesto's exposure. There is no proven curative modality and the median survival ranges from 6-18 months. Recently, the multitargeted antifolate pemetrexed (ALIMTA®) has been approved as the front-line agent in combination with cisplatin for the treatment of malignant mesothelioma. However, the overall outcome remains very poor despite current available therapies. In this study, we developed a new treatment strategy for malignant mesothelioma by photodynamic therapy (PDT) using Laserphyrin® and an LED (light emitting diode). We performed sensitivity tests on human malignant mesothelima cell lines, MSTO-211H, NCI-H2052, NCI-H2452, NCI-H28 cells against PDT using LED in vitro. PDT using LED and Laserphyrin® had strong anti-tumor effect. Furthermore, we transplanted MSTO-211H cells into Balb/c nude mice, and we performed PDT in vivo. PDT using an LED cured the tumor as completely as PDT using laser in vivo.
We conclude that PDT using LEDs can be useful for malignant mesothelioma in the experiment clinically and we hope to develop LEDs system for the thoracic wall. we will conduct clinical study combining PDT using LEDs and anti-cancer agents for malignant mesothelioma. - Megumi Maeda; Yoshie Miura; Yasumitsu Nishimura; Shuko Murakami; Hiroaki Hayashi; Naoko Kumagai; Tamayo Hatayama; Minako Katoh; Naomi Miyahara; Shoko Yamamoto; Kazuya Fukuoka; Takumi Kishimoto; Takashi Nakano; Takemi OtsukiClinical medicine. Circulatory, respiratory and pulmonary medicine 2 11 - 7 1178-1157 2008/03 [Refereed]
It is common knowledge that asbestos exposure causes asbestos-related diseases such as asbestosis, lung cancer and malignant mesothelioma (MM) not only in people who have handled asbestos in the work environment, but also in residents living near factories that handle asbestos. These facts have been an enormous medical and social problem in Japan since the summer of 2005. We focused on the immunological effects of asbestos and silica on the human immune system. In this brief review, we present immunological changes in patients with MM and outline their experimental detection. For example, there is over-expression of bcl-2 in CD4+ peripheral T-cells, high plasma concentrations of interleukin (IL)-10 and transforming growth factor (TGF)-ß, and multiple over-representation of T cell receptor (TcR)-Vß in peripheral CD3+ T-cells found in MM patients. We also detail an experimental long-term exposure T-cell model. Analysis of the immunological effects of asbestos may help our understanding of the biological effects of asbestos. - Yoshie Miura; Yasumitsu Nishimura; Megumi Maeda; Shuko Murakami; Hiroaki Hayashi; Kazuya Fukuoka; Takumi Kishimoto; Takashi Nakano; Takemi OtsukiEnvironmental health and preventive medicine 13 (2) 55 - 9 1342-078X 2008/03 [Refereed]
It is common knowledge that exposure to asbestos causes asbestos-related diseases, such as asbestosis, lung cancer and malignant mesothelioma, not only in people who have had long-term contact with asbestos in their work environment but also in residents living near factories that handle asbestos. Since the summer of 2005, these revelations turned into a large medical problem and caused and social unrest. We have focused on the immunological effects of both asbestos and silica on the human immune system. In this brief review, we introduce immunological alterations found in patients with malignant mesothelioma and describe the experimental background in which these were found. Analyzing the immunological effects of asbestos may improve our understanding of the biological effects of asbestos. - 田村 邦宣; 福岡 和也; 平山 倫子; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 30 (5) 331 - 331 2008
- 奥村 好邦; 橋本 昌樹; 多久和 輝尚; 近藤 展行; 田中 文啓; 長谷川 誠紀; 福岡 和也; 中野 孝司日本呼吸器外科学会雑誌 特定非営利活動法人 日本呼吸器外科学会 22 (3) 419 - 419 2008
- Uesaka Ayuko; Fukuoka Kazuya; Miyake Mitsutomi; Murakami Aki; Yamada Syusai; Tamura Kunihiro; Iida Shin-ichiro; Nobuyama Seiichi; Kuribayashi Kozo; Miyata Shigeru; Takuwa Teruhisa; Matsumoto Seiji; Okumura Yoshitomo; Tanaka Fumihiro; Hasegawa Seiki; Nakano TakashiThe Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 30 (1) 5 - 12 0287-2137 2008Background and Objective. Thoracoscopy is an essential procedure for the definitive diagnosis of malignant pleural mesothelioma(MPM). However, in some cases of early-stage MPM, it is difficult to detect a lesion even through conventional thoracoscopy. In the present study, to improve the diagnostic accuracy of thoracoscopy on MPM, autofluorescence imaging(AFI) and a narrow band imaging(NBI) system were assessed in combination with the conventional method. Subjects and Methods. Thoracoscopy combined with AFI and NBI was performed on 12 patients with pleural fluid retention, suspected of MPM. Thoracoscopy under local anesthesia and video-assisted thoracoscopic surgery(VATS) were performed on 7 and 5 patients, respectively. Examination was carried out using a flexible bronchoscope(Olympus BF-F260) for AFI and a conventional white light thoracoscope(Olympus LTF-240) for NBI. Results. In 7 of 12 patients, a diagnosis of MPM was made by pleural biopsy using thoracoscopy combined with AFI and NBI. Autofluorescence thoracoscopy showed that nodules suspicious for mesothelioma were clearly visualized as magenta fluorescence, while the intact pleura appeared green in color. In the cases of MPM, thoracoscopy with NBI demonstrated emphasized irregularity of the pleura compared with findings on conventional white light thoracoscopy, and abnormal pink/white nodules with increased vessel growth were easily detected. Conclusion. Thoracoscopy combined with AFI and NBI is a novel tool for the diagnosis of MPM. There is a possibility that this procedure may make it possible to distinguish between pleural lesions due to MPM and the intact pleura more accurately.
- 山田 秀哉; 福岡 和也; 栗林 康造; 田端 千春; 田村 邦宣; 飯田 慎一郎; 村上 亜紀; 安光 亮洋; 平山 倫子; 寺田 貴普; 中野 孝司; 田中 文啓; 長谷川 誠紀; 坪田 紀明気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 30 S208 2008
- 安光 亮洋; 福岡 和也; 寺田 貴普; 平山 倫子; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 栗林 康造; 田端 千春; 坪田 紀明; 中野 孝司気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 30 S144 2008
- 栗林 康造; 福岡 和也; 寺田 貴普; 平山 倫子; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 中野 孝司; 坪田 紀明気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 30 S115 2008
- 福岡 和也; 辻村 亨; 玉置 知子; 安光 亮洋; 平山 倫子; 寺田 貴晋; 村上 亜紀; 山田 秀哉; 田端 千春; 飯田 慎一郎; 田村 邦宣; 栗林 康造; 田中 文啓; 長谷川 誠紀; 坪田 紀明; 中野 孝司気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 30 S113 2008
- 中野 孝司; 福岡 和也; 栗林 康造; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 安光 亮洋; 平山 倫子; 坪田 紀明; 長谷川 誠紀; 田中 文啓気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 30 S97 2008
- Kuribayashi Kozo; Fukuoka Kazuya; Yasumitsu Akihiro; Terada Takayuki; Hirayama Noriko; Murakami Aki; Yamada Syusai; Iida Shinichiro; Tamura Kunihiro; Tabata Chiharu; Nakano TakashiThe Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 30 (6) 406 - 411 0287-2137 2008Case 1. A 73-year-old man was admitted to our hospital for evaluation of a pulmonary nodule in the right S^<10> segment and #3, #7 mediastinal lymphadenopathy. On ^<18>F-fluorodeoxyglucose positron emission tomography (^<18>FDG-PET), the nodule showed substantial uptake of ^<18>F-fluorodeoxyglucose. Bronchoscopic biopsy did not yield diagnostic material. Mediastinoscopic lymph node biopsy showed fibroblasts and histiocytes. Case 2. A 74-year-old man was admitted to our hospital for evaluation of #3, #7 mediastinal lymphadenopathy. On ^<18>FDG-PET, the nodule showed substantial uptake of ^<18>F-fluorodeoxyglucose. Mediastinoscopic lymph node biopsy showed granuloma formation with multinuclear Langhans giant cells. Conclusion. Asbestosis should be considered as a possibility when interpreting the ^<18>FDG-PET of patients with mediastinal lymphadenopathy.
- Kuribayashi K; Fukuoka K; Nakajima T; Miyake M; Miyata S; Tamura K; Iida S; Yamada S; Murakami A; Hirano H; Nakano TNihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 46 (1) 3 - 9 1343-3490 2008/01 [Refereed]
- 辻村 亨; 佐藤 鮎子; 鳥井 郁子; 玉置 知子; 吉川 良恵; 福岡 和也; 田中 文啓; 長谷川 誠紀; 中野 孝司肺癌 (NPO)日本肺癌学会 47 (5) 448 - 448 0386-9628 2007/10
- Yamada S; Fukuoka K; Miyake M; Miyata S; Nakajima T; Tamura K; Tabata C; Iida S; Kuribayashi K; Uesaka A; Murakami A; Yasumitsu A; Nakano TNihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 45 (9) 720 - 725 1343-3490 2007/09 [Refereed]
- Takemi Otsuki; Megumi Maeda; Shuko Murakami; Hiroaki Hayashi; Yoshie Miura; Masayasu Kusaka; Takashi Nakano; Kazuya Fukuoka; Takumi Kishimoto; Fuminori Hyodoh; Ayako Ueki; Yasumitsu NishimuraCellular & molecular immunology 4 (4) 261 - 8 1672-7681 2007/08 [Refereed]
Silicosis patients (SILs) and patients who have been exposed to asbestos develop not only respiratory diseases but also certain immunological disorders. In particular, SIL sometimes complicates autoimmune diseases such as systemic scleroderma, rheumatoid arthritis (known as Caplan syndrome), and systemic lupus erythematoses. In addition, malignant complications such as lung cancer and malignant mesothelioma often occur in patients exposed to asbestos, and may be involved in the reduction of tumor immunity. Although silica-induced disorders of autoimmunity have been explained as adjuvant-type effects of silica, more precise analyses are needed and should reflect the recent progress in immunomolecular findings. A brief summary of our investigations related to the immunological effects of silica/asbestos is presented. Recent advances in immunomolecular studies led to detailed analyses of the immunological effects of asbestos and silica. Both affect immuno-competent cells and these effects may be associated with the pathophysiological development of complications in silicosis and asbestos-exposed patients such as the occurrence of autoimmune disorders and malignant tumors, respectively. In addition, immunological analyses may lead to the development of new clinical tools for the modification of the pathophysiological aspects of diseases such as the regulation of autoimmunity or tumor immunity using cell-mediated therapies, various cytokines, and molecule-targeting therapies. In particular, as the incidence of asbestos-related malignancies is increasing and such malignancies have been a medical and social problem since the summer of 2005 in Japan, efforts should be focused on developing a cure for these diseases to eliminate nationwide anxiety. - Masayuki Takeda; Tokuzo Arao; Hideyuki Yokote; Teruo Komatsu; Kazuyoshi Yanagihara; Hiroki Sasaki; Yasuhide Yamada; Tomohide Tamura; Kazuya Fukuoka; Hiroshi Kimura; Nagahiro Saijo; Kazuto NishioCLINICAL CANCER RESEARCH AMER ASSOC CANCER RESEARCH 13 (10) 3051 - 3057 1078-0432 2007/05 [Refereed]
Purpose: AZD2171 is an oral, highly potent, and selective vascular endothelial growth factor signaling inhibitor that inhibits all vascular endothelial growth factor receptor tyrosine kinases. The purpose of this study was to investigate the activity of AZD2171 in gastric cancer.Experimental Design: We examined the antitumor effect of AZD2171 on the eight gastric cancer cell lines in vitro and in vivo.Results: AZD2171 directly inhibited the growth of two gastric cancer cell lines (KATO-III and OCUM2M), with an IC50 of 0.15 and 0.37 mu mol/L, respectively, more potently than the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib. Reverse transcription-PCR experiments and immunoblotting revealed that sensitive cell lines dominantly expressed COOH terminus truncated fibroblast growth factor receptor 2 (FGFR2) splicing variants that were constitutively phosphorylated and spontaneously dimerized. AZD2171 completely inhibited the phosphorylation of FGFR2 and downstream signaling proteins (FRS2, AKT, and mitogen-activated protein kinase) in sensitive cell lines at a 10-fold lower concentration (0.1 mu mol/L) than in the other cell lines. An in vitro kinase assay showed that AZD2171 inhibited kinase activity of immunoprecipitated FGFR2 with submicromolar K-i values (similar to 0.05 mu mol/L). Finally, we assessed the antitumor activity of AZD2171 in human gastric tumor xenograft models in mice. Oral administration of AZD2171 (1.5 or 6 mg/kg/d) significantly and dose-dependently inhibited tumor growth in mice bearing KATO-III and OCUM2M tumor xenografts.Conclusions: AZD2171 exerted potent antitumor activity against gastric cancer xenografts overexpressing FGFR2. The results of these preclinical studies indicate that AZD2171 may provide clinical benefit in patients with certain types of gastric cancer. - 安光 亮洋; 栗林 康造; 福岡 和也; 三宅 光富; 宮田 茂; 田端 千春; 田村 邦宣; 飯田 慎一郎; 山田 秀哉; 村上 亜紀; 中野 孝司気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 29 (5) 318 - 318 2007
- 南 高正; 栗林 康造; 三宅 光富; 宮田 茂; 中嶋 楽典; 田村 邦宣; 飯田 慎一郎; 上板 亜由子; 山田 秀哉; 村上 亜紀; 福岡 和也; 中野 孝司; 松田 育雄; 廣田 誠一気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 29 (1) 64 - 64 2007
- Fukuoka Kazuya; Uesaka Ayuko; Kuribayashi Kozo; Miyake Mitsutomi; Miyata Shigeru; Nakajima Taisuke; Iida Shin-ichiro; Nobuyama Seiichi; Tamura Kunihiro; Yamada Syusai; Murakami Aki; Takuwa Teruhisa; Matsumoto Seiji; Okumura Yoshitomo; Tanaka Fumihiro; Hasegawa Seiki; Nakano TakashiThe Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 29 (3) 177 - 185 0287-2137 2007Purpose. We evaluated the efficacy of respiratory endoscopy on subjects requiring further detailed examinations as a result of initial asbestos-related disease screening. Methods. The subjects consisted of 132 participants who underwent asbestos-related disease screening in our hospital between July 2005 and March 2006. According to their history of screening, the participants were classified into the initial screening group and the second screening group. The former consisted of 76 participants without prior screening, while the latter consisted of 56 participants who were referred to our hospital for the detailed examinations as a result of initial screening undergone elsewhere. The participants were examined concerning their history of asbestos exposure, and then underwent chest X-ray followed by chest computed tomography (CT). Respiratory endoscopic examinations were mainly performed in participants with suspected chest malignancies. Results. There were no significant differences in the distribution of age or gender between the two screening groups. In both screening groups, more than 70% of the participants had a history of occupational exposure to asbestos. Radiological abnormalities were observed in 110 (83%) of all participants. Asbestos-related diseases were detected in a total of 90 (68%) cases. The breakdown of the 90 cases by disease was as follows: 60 cases had pleural plaque, 13 pulmonary fibrosis, 5 lung cancer (LC), 4 benign asbestos pleurisy, 4 round atelectasis, 2 diffuse pleural thickening, and 2 malignant pleural mesothelioma (MPM). The disease detection rate of LC and MPM was 3.8% and 1.5%, respectively. Respiratory endoscopic examinations were performed in a total of 15 cases. The breakdown of the 15 cases by examination was as follows: bronchoscopy was performed in 6 cases, thoracoscopy including video-assisted thoracoscopic surgery (VATS) in 8, and mediastinoscopy in 4. Two cases with early LC were diagnosed by videothoracoscopic lung biopsy. A diagnosis of MPM was made by pleural biopsy under VATS. There were no examination-related complications. Conclusion. Respiratory endoscopic examinations should be actively performed in participants with suspected chest malignancies as a result of asbestosrelated disease screening, because the procedure has a high diagnostic rate and can be safely performed.
- 栗林 康造; 上坂 亜由子; 三宅 光富; 宮田 茂; 中嶋 泰典; 田村 邦宣; 延山 誠一; 飯田 慎一郎; 山田 秀哉; 村上 亜紀; 福岡 和也; 中野 孝司; 奥村 好邦; 多久和 輝尚; 松本 成司; 田中 文啓; 長谷川 誠紀気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 28 (3) 171 - 171 2006
- 上坂 亜由子; 三宅 光富; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 延山 誠一; 中嶋 泰典; 栗林 康造; 宮田 茂; 福岡 和也; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 28 (3) 157 - 157 2006
- 三宅 光富; 栗林 康造; 上坂 亜由子; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 延山 誠一; 田村 邦宣; 宮田 茂; 中嶋 泰典; 福岡 和也; 中野 孝司気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 28 (3) 172 - 172 2006
- 福岡 和也; 上坂 亜由子; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 延山 誠一; 中島 泰典; 栗林 康造; 宮田 茂; 三宅 光富; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 28 (3) 156 - 156 2006
- 延山 誠一; 宮田 茂; 三宅 光富; 田村 邦宣; 飯田 慎一郎; 栗林 康造; 山田 秀哉; 上坂 亜由子; 村上 亜紀; 大串 晶子; 福岡 和也; 中野 孝司; 奥村 好邦; 松本 成司; 多久和 輝尚; 田中 文啓; 長谷川 誠紀気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 28 (1) 83 - 83 2006
- 奥村 好邦; 多久和 輝尚; 松本 成司; 田中 文啓; 栗林 康造; 福岡 和也; 中野 孝司; 長谷川 誠紀日本呼吸器外科学会雑誌 特定非営利活動法人 日本呼吸器外科学会 20 (3) 817 - 817 2006
- 中嶋 泰典; 福岡 和也; 栗林 康造; 宮田 茂; 飯田 慎一郎; 延山 誠一; 田村 邦宣; 上坂 亜由子; 山田 秀哉; 村上 亜紀; 三宅 光富; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀; 新長 真由美; 伊藤 敬; 廣田 誠一気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 28 (5) 396 - 396 2006
- Y. Nishimura; Y. Miura; M. Maeda; H. Hayashi; M. Dong; H. Katsuyama; M. Tomita; F. Hyodoh; M. Kusaka; A. Uesaka; K. Kuribayashi; K. Fukuoka; T. Nakano; T. Kishimoto; Takemi OtsukiInternational Journal of Immunopathology and Pharmacology 19 (4) 795 - 805 0394-6320 2006 [Refereed]
To explore the effects of asbestos and silica on the human immune system, an experimental model of low-dose and long-term exposure was established using a human HTLV-1-immortalized polyclonal T cell line, MT-2 (MT-2Org). MT-2 cells were continuously exposed to asbestos at a concentration (10 μg/ml) which does not induce complete cell death during short-term exposure. After acquiring resistance to CB-induced apoptosis (designated MT-2Rst), an immunological comparison was made between the MT-2Org and MT-2Rst lines in terms of T cell receptor-Vβ (TcR-Vβ) expression. MT-2Rst cells showed excess expression of various TcR-Vβ, although TcR-Vβ-overpresenting cells were characterized as undergoing apoptosis due to first contact with CB. Patients with asbestos-related diseases (ARD), such as asbestosis and malignant mesothelioma, were compared with silicosis (SIL) patients as a disease control and with healthy donors (HD). SIL and ARD not only differed in their causative materials, silica and asbestos as mineral silicates, but also in terms of complications; autoimmune disorders in SIL and tumors in ARD. ARD patients showed a restricted overpresentation of TcR-Vβ without clonal expansion, whereas SIL patients revealed significant overpresentation of TcR-Vβ 7.2. These experimental and clinical analyses indicate the superantigenic and dysregulation of autoimmunity-inducing effects of asbestos and silica, respectively. Copyright © by Biolife, s.a.s. - Kazuya FukuokaINTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 45 (15) 881 - 882 0918-2918 2006 [Refereed]
- 古林 郁乃; 勝見 祥子; 浅田 秀夫; 宮川 幸子; 福岡 和也; 木村 弘日本皮膚科学会雑誌 (公社)日本皮膚科学会 114 (6) 1107 - 1113 0021-499X 2004/05非小細胞肺癌に対する分子標的治療薬である上皮成長因子受容体チロシンキナーゼ阻害薬のゲフィチニブを内服中に皮膚症状を生じた症例について検討した.その結果,ゲフィチニブ250mg/日,内服中に皮膚症状を生じた5症例ではゲフィチニブを隔日内服に減量したところ,皮膚症状は消失または軽快したことから用量依存性であることが確認された.挫創様皮疹・爪郭炎または浸潤性紅斑を生じた3症例の皮膚生検結果では,臨床症状が異なるにもかかわらず組織所見はいずれも表皮または毛包壁のbasal layerとsuprabasal layerに共通して障害が認められた.以上より,表皮ケラチノサイトにおけるepidermal growth factor reseptorを介する情報伝達のゲフィチニブによる阻害作用が皮膚症状の発症に関与している可能性が示唆された
- 熊本 牧子; 玉置 伸二; 本津 茂人; 友田 恒一; 福岡 和也; 濱田 薫; 木村 弘(奈良県立医科大学第2内科1); 前田 光一(同総合医療・病態検査学); 善本 英郎(同感染症センター); 小林 武彦; 家根 旦有; 細井 裕司(同耳鼻咽喉科)気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 26 (6) 574 - 574 2004
- 玉置 伸二; 前田 光一; 福岡 和也; 友田 恒一; 善本 英一郎; 濱田 薫; 木村 弘気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 26 (3) 232 - 232 2004
- Hiroshi Kimura; Yuichi Takiguchi; Naoaki Sugimoto; Kazuya Fukuoka; Hiroshi Miyazawa; Mizuto Otsuji; Keiichi Nagao; Takehiko Fujisawa; Takayuki KuriyamaJapanese Journal of Lung Cancer Japan Lung Cancer Society 44 (4) 219 - 224 0386-9628 2004 [Refereed]
Objective. When chemotherapy is conducted for the treatment of non-small cell lung cancer (NSCLC), we must pay attention to the degree of impairment of pulmonary function. So far, it is not clear whether the smoking affects pulmonary function in a different manner according to the histological types of lung cancer squamous cell carcinoma and adenocarcinoma of the lung. In order to clarify these issues, we investigated the relation of smoking index (SI), location of cancerous lesions, and pulmonary function in patients with NSCLC. Study design. A total of 307 cases (squamous cell carcinoma 117, adenocarcinoma 190), with bronchial lesions located at sites proximal to the orifice of segmental bronchi (central lesions), or beyond (peripheral lesions) using fiberoptic bronchoscopy, was divided into two groups according to SI. There were 159 cases with an SI of more than 800 (high SI), and 148 less than 400 (low SI). Results. Age and SI were higher in squamous cell carcinoma than in adenocarcinoma, and restrictive and obstructive disturbances and a decrease in DLco and widened alveolar-arterial oxygen difference (AaDO2) were more prominent in squamous cell carcinoma than in adenocarcinoma. Similar results were obtained from analyses in the patients with peripheral lesions. In particular, disturbance of diffusion capacity was more prominent in squamous cell carcinoma than in adenocarcinoma. Moreover, when the subjects were limited to the patients with peripheral lesions, pulmonary functions in the high SI group tended to be more markedly disturbed than in the low SI group. In squamous cell carcinoma, however, V̇25/Ht and DLco did not show a significant difference between high SI and low SI groups with deteriorations of these parameters being observed even in patients with low SI. Conclusion. It is concluded that the disturbance of respiratory function is more prominent in squamous cell carcinoma than in adenocarcinoma. Smoking affects the disturbance of respiratory functions in NSCLC with peripheral lesions. Squamous cell carcinoma shows greater impairment of the peripheral airways and diffusion capacity than adenocarcinoma, even in patients with an SI of less than 400. - K Fukuoka; Y Nakano; A Nakajima; S Hontsu; H KimuraRESPIRATORY MEDICINE W B SAUNDERS CO LTD 97 (12) 1261 - 1264 0954-6111 2003/12 [Refereed]
Mycobacterium avium (M. avium) has been described traditionally as an opportunistic organism that causes disseminated disease in the human immunodeficiency virus (HIV)-positive population and that acts as a pulmonary pathogen in patients with underlying lung disease such as chronic obstructive pulmonary disease (COPD) or previously diagnosed tuberculosis.' Pulmonary involvement of M. avium may range from asymptomatic colonization of the airway to invasive parenchymal or cavitary disease. However, endobronchial lesions involved in M. avium infection are rare in either immunocompetent or immunosuppressed hosts.(2-6) We report here endobronchial mycobacterial infection in a HIV-negative patient. - K Kasahara; K Fukuoka; M Konishi; K Hamada; K Maeda; K Mikasa; H KimuraINTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 42 (12) 1215 - 1218 0918-2918 2003/12 [Refereed]
Neurilemmomas are benign tumors which originate from Schwann cells. They rarely occur in the trachea or bronchus. We encountered two cases of endobronchial neurilemmoma and in this context, reviewed 48 cases previously reported in Japan. Neurilemmomas can occur in all regions of the bronchial tree and they often progress into both intraluminal and extraluminal spaces. Incomplete resection results in a local recurrence, despite being rare. As for appropriate therapies, surgery, bronchofiberoptic removal and yttrium aluminum garnet (YAG) laser resection can be chosen depending on the patient's status. - 福岡 和也; 本津 茂人; 武田 真幸; 甲斐 吉郎; 小林 真也; 木村 弘日本呼吸器学会雑誌 (一社)日本呼吸器学会 41 (増刊) 143 - 143 1343-3490 2003/03
- 肺癌組織における腫瘍関連糖鎖抗原発現プロファイルの検討福岡 和也; 本津 茂人; 武田 真幸; 甲斐 吉郎; 小林 真也; 木村 弘日本内科学会雑誌 (一社)日本内科学会 92 (Suppl.) 245 - 245 0021-5384 2003/02
- 豊田 幸; 玉置 伸二; 竹中 英昭; 善本 英一郎; 前田 光一; 福岡 和也; 濱田 薫; 木村 弘気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 25 (1) 56 - 56 2003
- 武田 真幸; 福岡 和也; 奥田 由佳; 玉置 伸二; 善本 英一郎; 竹中 英昭; 濱田 薫; 木村 弘; 前田 光一; 徳山 猛; 北田 裕陸; 東口 隆一気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 25 (6) 485 - 485 2003
- J Usuda; M Inomata; H Fukumoto; Y Iwamoto; T Suzuki; HJ Kuh; K Fukuoka; H Kato; N Saijo; K NishioINTERNATIONAL JOURNAL OF ONCOLOGY PROFESSOR D A SPANDIDOS 22 (1) 81 - 86 1019-6439 2003/01 [Refereed]
The human leukemia K562 cell line does not express wild-type p53 protein. Due to the loss of one p53 allele and an insertion mutation in exon 5 of the other allele resulting in a frameshift mutation, K562 cells express a truncated p53 protein of 148 amino acids. A human leukemia phorbol ester-resistant subline, K562/TPA, is cross-resistant to some anticancer agents. A remarkable difference in cell cycle progression at G1/S phase was observed in the synchronised K562/TPA cells as compared with K562 cells. Southern blot and DNA sequence analysis revealed no mutation in exon 5 of the p53 gene in K562/TPA cells. p21(Cip1) expression was also restored in K562/TPA cells confirming that the reversal of this p53 gene mutation restored wild-type p53 function in these cells. This is a unique report describing reversal of p53 gene mutation by drugs. This was associated with the expression of wild-type p53 mRNA and protein in K562/TPA cells. The K562/TPA cell line may provide a very useful tool for the investigation of the relationship between p53 status and chemosensitization. - Takahashi K; Fukuoka K; Konishi M; Takenaka H; Sakamoto M; Okamoto Y; Yoshikawa M; Nishimoto Y; Kikkawa K; Imai T; Yoneda T; Narita N; Kimura HNihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 40 (11) 900 - 904 1343-3490 2002/11 [Refereed]
- 福岡 和也; 本津 茂人; 甲斐 吉郎; 小林 真也; 木村 弘肺癌 (NPO)日本肺癌学会 42 (5) 352 - 352 0386-9628 2002/10
- 局所進行非小細胞肺癌におけるInduction therapyを含む集学的治療法の検討福岡 和也; 本津 茂人; 木村 弘; 櫛部 圭司; 高濱 誠; 川口 剛史; 根津 邦基; 谷口 繁樹; 甲斐 吉郎; 小林 真也; 竹澤 祐一日本癌治療学会誌 (一社)日本癌治療学会 37 (2) 235 - 235 0021-4671 2002/09
- 先行する核医学検査が診断に有用であった胸部悪性腫瘍症例の検討本津 茂人; 福岡 和也; 甲斐 吉郎; 小林 真也; 木村 弘; 今井 照彦日本呼吸器学会雑誌 (一社)日本呼吸器学会 40 (増刊) 239 - 239 1343-3490 2002/03
- 古西 満; 善本 英一郎; 高橋 賢; 笠原 敬; 玉置 伸二; 竹中 英昭; 福岡 和也; 前田 光一; 濱田 薫; 今井 照彦気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 24 (3) 162 - 162 2002
- 玉置 伸二; 北村 友宏; 平川 遼一; 本津 茂人; 善本 英一郎; 天野 逸人; 竹中 英昭; 坂本 正洋; 前田 光一; 森井 武志; 福岡 和也; 濱田 薫; 木村 弘気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 24 (1) 58 - 58 2002
- Tsurutani,J; Komiyama,T; Uejima,H; Tada,H; Negoro,S; Oka,M; Kohno,S; Fukuoka,K; Nakagawa,KLung Cancer 35 (1) 11 - 16 0169-5002 2002 [Refereed]
Recently, several studies have suggested that a major mechanism of resistance to paclitaxel might involve mutations in the β-tubulin gene in tumor cells. To investigate the frequency of β-tubulin mutations in Japanese patients with small and non-small cell lung cancer, direct sequence analysis following reverse transcription-polymerase chain reaction (RT-PCR) of the β-tubulin gene was performed using total RNA from 20 lung cancer cell lines and 22 specimens from lung cancer patients. First-strand cDNA sequence analysis of the 42 samples showed silent mutations at codon 180 of the β-tubulin gene, which encodes the GTP-binding site of the protein, and codons 195 and 217. However, neither missense nor non-sense mutations affecting microtubule dynamics, within or near the GTP-binding site of the β-tubulin gene, were detected. These results indicate that β-tubulin gene mutations might not play a major role in the mechanism of resistance to paclitaxel in Japanese lung cancer patients. Further investigations are needed to clarify the mechanism of drug resistance. © 2002 Elsevier Science Ireland Ltd. All rights reserved. - 伊藤 武文; 福岡 和也; 岡本 行功; 坂本 正洋; 竹中 英昭; 善本 英一郎; 濱田 薫; 木村 弘; 今井 照彦; 前田 光一気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 23 (6) 573 - 573 2001
- Yoshimoto Eiichiro; Konishi Mitsuru; Takahashi Ken; Majima Toshimasa; Murakawa Kouichi; Takenaka Hideaki; Sakamoto Masahiro; Fukuoka Kazuya; Maeda Koichi; Okamoto Yukinori; Hamada Kaoru; Mikasa Keiichi; Imai Teruhiko; Narita NobuhiroThe Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 23 (6) 527 - 531 0287-2137 2001We studied the BALF findings in 11 HIV-infected patients with Pneumocystis carinii pneumonia(PCP). Blood examinations revealed that mean counts of CD4 positive T cells were 45/μl and that serum LDH and CRP values had increased. In BALF findings we recognized mean total cell counts had not increased greatly. The findings of BALF revealed an increase in the percentage of the lymphocytes and decrease of the CD4/8 ratio. There was no significant difference in the BALF findings of non-smokers and smokers with PCP. We compared KL-6 concentration of BALF of HIV-infected patients with and without PCP. KL-6 concentration was significantly higher in patients with PCP than without PCP. We recognized a significant relationship between BALF KL-6 concentration and serum LDH value.
- 笠原 敬; 福岡 和也; 古西 満; 善本 英一郎; 竹中 英昭; 坂本 正洋; 岡本 行功; 濱田 薫; 成田 亘啓; 今井 照彦; 前田 光一気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 23 (3) 286 - 286 2001
- 前田 光一; 高橋 賢; 善本 英一郎; 坂本 正洋; 竹中 英昭; 福岡 和也; 岡本 行功; 古西 満; 濱田 薫; 成田 亘啓; 今井 照彦気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 22 (3) 210 - 210 2000
- 甲斐 吉郎; 岡本 行功; 福岡 和也; 善本 英一郎; 竹中 英昭; 坂本 正洋; 前田 光一; 濱田 薫; 成田 亘啓; 今井 照彦気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 22 (4) 319 - 320 2000
- 武田 研一; 前田 光一; 福岡 和也; 岡本 行功; 坂本 正洋; 善本 英一郎; 竹中 英昭; 濱田 薫; 成田 亘啓; 今井 照彦; 吉村 均; 大石 元気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 22 (1) 67 - 67 2000
- 福岡 和也; 緑川 沢樹; 岡本 行功; 前田 光一; 坂本 正洋; 竹中 英昭; 善本 英一郎; 小林 厚; 成田 亘啓; 今井 照彦; 木村 道孝; 高濱 誠; 櫛部 圭司; 根津 邦基; 牧之段 潔気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 21 (3) 233 - 233 1999
- 甲斐 吉郎; 福岡 和也; 岡本 行功; 前田 光一; 坂本 正洋; 竹中 英昭; 善本 英一郎; 小林 厚; 成田 亘啓; 今井 照彦; 大石 元気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 21 (5) 370 - 370 1999
- 森 啓; 古西 満; 寺本 正治; 竹中 英昭; 坂本 正洋; 福岡 和也; 前田 光一; 岡本 行功; 成田 亘啓; 佐々木 義明; 今井 照彦気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 20 (6) 531 - 531 1998
- Munehiro Nakaya; Takahiro Yoneda; Atsushi Kobayashi; Yasuhito Onohara; Yukihiro Ikoma; Atsuhiko Fukuoka; Koichi Tomoda; Hideaki Takenaka; Hideo Okamura; Chinaru Yamamoto; Kazuya Fukuoka; Takeshi Tokuyama; Yukinori Okamoto; Masanori Yoshikawa; Katsuhiko Tsukaguchi; Nobuhiro NaritaKekkaku 72 (6) 403 - 410 0022-9776 1997/06 [Refereed]
Interferon-γ (IFN-γ) and interleukin-10 (IL-10)-producing ability of peripheral blood plastic-dish adherent cells and non-adherent cells obtained from patients with active pulmonary tuberculosis (N=17) and healthy controls (N=14) upon stimulation with purified protein derivatives (PPD) were assessed. Adherent cells and non-adherent cells were obtained two times from each patient with active pulmonary tuberculosis without any underlying diseases, on admission before the initiation of administrering anti- tuberculous drugs and 2 months later from the negative conversion of Mycobacterium tuberculosis in sputum culture. ELISA was performed to measure IFN-γ and IL-10 levels in culture media of adherent cells and non-adherent cells stimulated with PPD. IFN-γ levels produced by non adherent cells on admission were significantly higher than that of healthy controls (p< 0.001). Elevated IFN-γ levels on admission was reduced after treatment for tuberculosis (p< 0.03), but still remained higher than that in healthy controls. IL-10 levels of non adherent cells of patients were lower than those of healthy controls, although the defference was not significant. IL- 10 levels produced by non adherent cells on admission correlated with the time needed for negative conversion of bacilli in sputum culture (p< 0.05). IL-10 level produced by adherent cells from nutritionally normal patients were significantly higher than that of healthy controls (p< 0.05), and elevated IL-10 level was significantly reduced after therapy (p< 0.05). In the normonourished patients, the time needed for negative conversion of the bacilli in sputum culture of patients kept higher level of L-10 of non- adherent cells (N=5) was significantly longer than that of patients reduced IL-10 level after therapy. These results suggest that IL-10 produced by monocytes may diminish the TH1 responses of patients with pulmonary tuberculosis. - ONOHARA Yasuhito; TOMODA Koichi; NAKAYA Munehiro; YOSHIKAWA Masanori; TSUKAGUCHI Katsuhiko; TOKUYAMA Takeshi; HU Akihiro; HUKUOKA Kazuya; YAMAMOTO Chinaru; YONEDA Takahiro; NARITA NobuhiroKekkaku(Tuberculosis) JAPANESE SOCIETY FOR TUBERCULOSIS 71 (7) 435 - 438 0022-9776 1996/07It is assumed that soluble tumor necrosis factor receptor I and II (sTNF-R I, II) play important roles in the regulation of tumor necrosis factor alpha (TNF-α) activity.
We measured the levels of circulating sTNF-R in patients with active pulmonary tuberculosis (n=31) and the correlation between TNF-α and sTNF-R in serum level was investigeted. We also compared sTNF-R levels before and after the treatment in 7 cases.
Significant increase of circulating sTNF-R were found in patients with tuberculosis compared with the normal controls (n=28) (p<0.01). Moreover, significnt positive correlations were found between TNF-α and sTNF-RI and II (r=0.520, r=0.553) in serum comparing sTNF-R levels before and after the treatment for patients with tuberculosis, significant fall was found in sTNF-R I, but not in sTNF-R II.
As a result, it is suggested that sTNF-R regulates TNF-α activity in patients with tuberculosis, and that sTNF-R I levels could be used as one of the indices to evaluate the clinical activity of tuberculosis. - Fukuoka Kazuya; Tsukaguchi Nobuhiko; Choh Sumito; Hamada Kaoru; Takenaka Hideaki; Ikoma Yukihiro; Tomoda Kouichi; Yoshikawa Masanori; Yoneda Takahiro; Narita NobuhiroJJLC The Japan Lung Cancer Society 36 (1) 7 - 13 0386-9628 1996In order to elucidate the factors causing respiratory infections (RI) during anticancer chemotherapy, we prospectively analyzed the changes in pharyngeal bacterial floras and the host's defensive potential against infections in lung cancer patients receiving anticancer chemotherapy with the passage of time. Twenty of primary lung cancer patients receiving systemic chemotherapy were selected for this study and 32 treatment courses, including 15 treatment courses with RI (A) and 17 treatment courses without RI (B), could be evaluated.
In treatment course A, the changes in pharyngeal bacterial floras tended to demonstrate that pathogenic organisms were continuously isolated during, or newly isolated after anticancer chemotherapy. There were significant differences between the two treatment courses, in the frequency of patients with a poor performance status (PS) before anticancer chemotherapy, the nadirs of white blood cell counts and the changing pattern of pharyngeal bacterial floras. Multivariate analysis revealed that the changes in pharyngeal bacterial floras and PS before anticancer chemotherapy are important factors influencing susceptibility to RI during anticancer chemotherapy.
In conclusion, these results suggested that both the changes in pharyngeal bacterial floras and the deterioration of the host's defensive potential against infections might be responsible for the development of RI during anticancer chemotherapy against lung cancer. - T. Yoneda; M. Yoshikawa; A. Fu; T. Tokuyama; Y. Okamoto; K. Fukuoka; C. Yamamoto; E. Okamura; H. Takenaka; K. Tomoda; Y. Onohara; M. Nakaya; A. Kobayashi; K. Tsukaguchi; N. NaritaJapanese Journal of Thoracic Diseases 34 79 - 85 0301-1542 1996 [Refereed]
Weight loss is common in patients with chronic obstructive pulmonary disease (COPD). Comprehensive nutritional assessment was conducted in two large groups of patients with COPD who were enrolled in the Respiratory failure Research Program sponsored by the Japanese Ministry of Health and Welfare and the Kinki COPD Research Group. The incidences of mild malnutrition (%IBW < 90%) were 74% and 62%, respectively. The incidences of hypoalbuminemia were low: 10.0% and 6.5%, respectively. The incidence of imbalance in plasma amino acids, which was defined as an abnormally low BCAA/AAA ratio, was as high as 93% in patients with COPD and chronic respiratory failure. The %IBW was significantly related to the FEV1 and to the DL(co)/V3. The moderately-malnourished subpopulation was characterized by a greater degree of hyperinflation and hypercapnea: the measured resting energy expenditure (REE) was significantly higher than the values in age- matched healthy controls. REE/REE(pred) was significantly and inversely related to BCAA/AAA and to P(1max). REE was inversely related to FEV1%. REE in the subgroup with severe hyperinflation was significantly higher than REE in those with milder hyperinflation. Among patients with an FEV1% of less than 50%, mortality tended to be higher in those with lower body weight, and this relationship was stronger in patients with an FEV1% of more than 50%. When patients were given a BCAA-enriched enteral formula in addition to their usual diet for 3 months, there was a significant increase in body weight, transferrin level, and P(1max). - Nagahiro Saijo; Kazuto Nishio; Sei Ohta; Hitoshi Arioka; Yasunori Funayama; Kazuya Fukuoka; Hirokazu Kurokawa; Taisuke Nomoto; Tomoyuki Ishida; Nobuyuki Yamamoto; Tomohide Tamura; Tetsu Shinkai; Kenji Eguchi; Yuichiro Ohe; Hideo Kunito; Tomoko Ohtsu; Yasutsuna SasakiCancer Chemotherapy and Pharmacology, Supplement 38 S11 - S15 0943-9404 1996 [Refereed]
- 生駒 行拡; 竹中 英昭; 長 澄人; 橋本 和明; 福岡 和也; 成田 亘啓; 川上 万平; 佐々木 進次郎気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (1) 108 - 108 1995
- 生駒 行拡; 福岡 和也; 竹中 英昭; 木田 敦子; 橋本 和明; 長 澄人; 成田 亘啓気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (1) 101 - 101 1995
- 岡田 徹; 徳山 猛; 友田 恒一; 福岡 和也; 前田 光一; 濱田 薫; 成田 亘啓; 佐々木 義明; 今井 照彦気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (1) 108 - 108 1995
- Takenaka Hideaki; Choh Sumito; Fukuoka Kazuya; Ikoma Yukihiro; Tsukaguchi Nobuhiko; Tomoda Koichi; Suzuki Yuko; Hamada Kaoru; Narita NobuhiroThe Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 17 (6) 501 - 505 0287-2137 1995A 75-year-old male was admitted for further examination of a mass shadow in the right upper lung field on chest X-ray film. Large cell carcinoma was diagnosed by percutaneous needle biopsy. A small smooth-surfaced polypoid tumor was detected unexpectedly on the anterior wall of the lower trachea by bronchoscopy, and was completely removed by biopsy forceps. The biopsy specimen revealed chondroma. We considered this case to be the first report of endotracheal chondroma in Japan.
- 福岡 和也; 濱田 薫; 徳山 猛; 前田 光一; 成田 亘啓; 今井 照彦; 佐々木 義明; 大石 元; 長 澄人; 竹中 英昭; 生駒 行拡気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (3) 260 - 260 1995
- Munehiro Nakaya; Takahiro Yoneda; Masanori Yoshikawa; Katsuhiko Tsukaguchi; Takeshi Tokuyama; Akihiro Fu; Yukinori Okamoto; Kazuya Fukuoka; Chinaru Yamamoto; Atsuhiko Fukuoka; Koichi Tomoda; Yasuto Onohara; Nobuhiro Narita; Nagakazu ShimadaKekkaku 70 (8) 461 - 466 0022-9776 1995 [Refereed]
We investigated the serum level of IL-8 and TNF-α using ELISA in 16 patients with active pulmonary tuberculosis before administration of antituberculous drugs and in age-, smoking habit-matched 20 healthy controls. The mean level of serum IL-8 in patients with active pulmonary tuberculosis was significantly higher than that in healthy controls (P< 0.001). The mean level of serum TNF-α in tuberculosis patients was also high, while TNF-α was not detectable in the sera of healthy controls. We also examined the relationship between clinical pictures mainly defined by radio graphic findings and the serum levels of IL-8 and TNF-α. The serum IL-8 level of 9 patients with tuberculous cavity is significantly higher than that of 7 patients without cavity. (P< 0.05) We classified the patients with cavities into two subgroups according to the radiographic classification of the Japanese Society of Tuberculosis. Four patients with advanced lesions on chest X-ray showed higher serum IL-8 level than 5 patients with moderate lesions (P< 0.05). On the other hand, there was no correlation between serum TNF-α level and radiographic findings. These results suggest that IL-8 appears to be involved in the formation of tuberculous cavitary lesion. © 1995, JAPANESE SOCIETY FOR TUBERCULOSIS. All rights reserved. - Koichi Tomoda; Takahiro Yoneda; Katsuhiko Tsukaguchi; Masanori Yoshikawa; Takeshi Tokuyama; Akihiro Fu; Yukinori Okamoto; Kazuya Fukuoka; Chinaru Yamamoto; Munehiro Nakaya; Nobuhiro Narita; Hiromichi TasakaKekkaku 70 (7) 415 - 421 0022-9776 1995 [Refereed]
Production of Interleukin-1 β(IL-1β) and granulocyte macrophage-colony stimulating factor (GM-CSF) by peripheral blood monocytes (PBMs) from patients with Mycobacterium avium-intracellulare complex (MAC) infection was assesed and the relationship with their clinical course was analyzed. PBMs were obtained from MAC-infected patients in their active stage as well as in the inactive stage and the healthy controls. Spontaneous release of IL-1β by PBMs from patients in the active stage was higher than those by the cells in the inactive stage or the healthy controls. On the other hand, spontaneous GM-CSF release by PBMs from patients in the active stage was higher than the healthy controls. When PBMs were stimulated with MAC-derived purified protein derivatives (PPD-B), increased production of both IL-1β and GM-CSF were obtained for PBMs in their active stage. While these enhanced production upon stimulation with PPD-B related to the persistent infection with MAC, the increased IL-1β production correlated with the exhausted nutritional state. Both IL-1β and GM-CSF produced by PBMs seemed to be closely related with the clinical course of human MAC infection. © 1995, JAPANESE SOCIETY FOR TUBERCULOSIS. All rights reserved. - K. Tomoda; T. Yoneda; K. Tsukaguchi; M. Yoshikawa; T. Tokuyama; A. Fu; K. Fukuoka; M. Nakaya; N. Narita; H. TasakaJapanese Journal of Thoracic Diseases 33 (6) 618 - 621 0301-1542 1995 [Refereed]
The production of tumor necrosis factor alpha (TNFα) and of interleukin- 6 (IL-6) by peripheral blood monocytes (PBMs) from patients infected with Mycobacterium avium intracellular complex (MAC) were assessed. Spontaneous release of both TNFα and IL-6 were greater during the active stage than during the inactive stage and in healthy controls. When the cells were stimulated with MAC-derived purified protein derivative B (PPD-B), TNFα production by PBMs in the active stage increased and IL-6 production by cells in both the active and inactive stages decreased. Moreover, the in vitro increase in TNFα production after stimulation in the active stage seemed to be related to the persistent MAC infection, which resulted in an exhaustion of nutrition. These results suggest that the ability of PBMs to produce TNFα and IL-6 in vitro is closely related to the clinical stage of MAC infection. - K. Tomoda; T. Yoneda; K. Tsukaguchi; M. Yoshikawa; T. Tokuyama; A. Fu; Y. Okamoto; K. Fukuoka; C. Yamamoto; M. Nakaya; N. Narita; Y. Sasaki; T. Imai; H. OhishiKekkaku 70 (9) 499 - 504 0022-9776 1995 [Refereed]
Mucociliary transport (MCT) was studied in 22 patients with atypical mycobacteriosis (Group 1 : 16 with M. avium-intracellulare complex (MAC), Group II : 6 with M. kansasii) by aerosol inhalation cine-scintigraphy. In most of the patients, the MCT was abnormally slow both in the main bronchus and in the trachea, while in healthy controls the transport of the inhaled aerosol in the bronchus and the trachea were rapid and smooth. In both groups, the tracheal MCT was impaired in two thirds of the patients, while the MCT in the main bronchus was impaired in all except one in Group I and in two thirds in Group II. The results indicate that the grade of bronchial impairment was higher in MAC than in M. kansasii infections. In atypical mycobacteriosis, especially in MAC infections, such impairment of MCT could be closely related to the disruption of local defence mechanisms in the airways. - Kazuya Fukuoka; Sumito Choh; Kaoru Hamada; Takahiro Yoneda; Nobuhiro NaritaKekkaku 70 (2) 111 - 115 0022-9776 1995 [Refereed]
A 58-year-old woman, not having any history of pulmonary tuberculosis, was admitted to our hospital to examine a tender lump in her right breast. A breast echogram disclosed a well-defined hypoechoic mass lesion, indicating a pyogenic breast abscess. The patient underwent incision, drainage and resection of the tumor under local anesthesia. Histological findings of the resected tumor revealed epitheloid cell granulomas with caseous necrosis in mammary glands, suggesting tuberculosis of the breast. After operation, treatment with isoniazid, rifampisin and ethambutol hydrochloride was begun. After one year, she had complete healing without any indication of recurrence. During the last 10 years, 12 cases of tuberculosis of the breast have been reported. Their ages ranged from 28 to 84 years with an average of 42.8 years. Only one cases had a past history of tuberculosis and in the other cases tuberculosis of the breast was considered to be a primary disease. Axillary lymph-nodes involvement and formation of pyogenic breast abscess occurred in each 7 cases. Acid-fast bacilli were demonstrated in 25% of the reported cases. The histological findings of resected specimens and punch biopsy revealed epitheloid cell granulomas with caseous necrosis in 11 of 12 cases. Seven of 11 cases were treated with combination of surgery and antituberculous chemotherapy. © 1995, JAPANESE SOCIETY FOR TUBERCULOSIS. All rights reserved. - K. Mori; M. Yoshikawa; T. Nakamura; K. Tomoda; M. Nakaya; A. Fu; T. Tokuyama; K. Fukuoka; C. Yamamoto; K. Tsukaguchi; T. Yoneda; N. NaritaKekkaku 70 (9) 511 - 515 0022-9776 1995 [Refereed]
A 46-years-old male was admitted to our hospital because of productive cough and infiltrates on the chest roentgenogram. The patient had a history of left upper bullectomy ten years prior to the admission. The CT scan of the chest on admission showed infiltrates with cavitation in the left apex and multiple bullae in almost whole lung. Microscopical examination of smears of sputum and bronchoalveolar lavage fluid revealed acid-fast bacilli. They were identified as Mycobacterium szulgai by DNA-DNA hybridization method. The patient was treated with isoniazid, streptomycin and rifampicin. After treatment for about a month, the culture of sputum converted to negative for M. szulgai. After about three months hospitalization, the infiltrates decreased and the cavity wall became thin, and no recurrence sign has been observed after the discharge. There are a few case reports of pulmonary infection due to M. szulgai associated with bullous disease of the lung in Japan. - K. Tomoda; T. Yoneda; K. Tsukaguchi; M. Yoshikawa; T. Tokuyama; A. Fu; K. Fukuoka; M. Nakaya; N. Narita; H. TasakaKekkaku 69 (5) 361 - 365 0022-9776 1994 [Refereed]
We investigated the responsiveness of peripheral blood lymphocytes (PBLs) from patients with M. avium-intracellulare complex (MAC) infection to the stimulation with PPDs by measuring their IFN-γ producing ability. PBLs were ohtained from MAC patients at active stage (culture-positive after three-month chemotherapy), those at inactive stage (culture-negative for three months after or during chemotherapy), and healthy donors. PPDs used were PPD-S prepared from M. tuberculosis, PPD-B from M. intracellulare, and PPD-Y from M. kansasii. PBLs from active MAC patients did not produce IFN-γ to a significant extent by stimulation with any of three PPDs, while PBLs from inactive MAC patients showed higher responses to each PPD compared to those from active patients. In inactive MAC patients, the maximal response was observed to PPD-B among three PPDs. On the other hand, PBLs from healthy controls produced different levels of IFN-γ in response to three different PPDs, and their response was most remarkable to PPD-S. These results indicated that the responsiveness of patients' PBLs to PPDs was impaired during active stage of MAC infection and restored on recovery from the disease. - Kazuya Fukuoka; Takahiro Yoneda; Yoshizumi Kohnoike; Kohichi Tomoda; Masanori Yoshikawa; Hitoshi Katada; Nobuhiro Narita; Teruhiko Imai; Sougo IokaHaigan 34 (2) 161 - 170 0386-9628 1994 [Refereed]
We investigated lectin binding to normal bronchus and lung, metaplastic bronchial epithelium, and 42 cases of primary non-small cell lung carcinoma consisting of 23 squamous cell carcinomas and 19 adenocarcinomas. Fresh frozen sections were stained with 6 fluorescein isothiocyanate (FITC) -conjugated lectins of Dolichos biflorus (DBA), Ulex europaeus (UEA-I), Ricinus communis (RCA-I), Triticum vulgare (WGA), Canavalia ensiformis (ConA), Arachis hypogaea (PNA) and a microphotometer was used for objective evaluation of the fluorescence intensity. UEA-I, RCA-I, WGA, ConA, and PNA with the neuraminidase treatment (PNA · N (+)) were bound to most nontumorous bronchial and lung tissues, metaplastic bronchial epithelium, and lung carcinomas. However, the binding pattern of UEA-I differed from those of RCA-I, WGA, ConA, and PNA · N (+) in terms of localization of its binding sites. DBA was bound to nontumorous and metaplastic bronchial epithelium, bronchial glands, and a part of the bronchiolar epithelium and alveolar septum, but not to alveolar epithelium. The positivity of DBA binding to lung carcinomas was 61.9% (adenocarcinoma, 84.2% squamous cell carcinoma, 43.5%) the positivity of adenocarcinoma being significantly higher than that of squamous cell carcinoma. These results suggest that DBA is an important lectin for the analysis of differences of carbohydrate structures in cell surface membrane between nontumorous bronchus, lung, and the different histological types of non-small cell lung carcinomas. © 1994, The Japan Lung Cancer Society. All rights reserved. - Masanori Yoshikawa; Takahiro Yoneda; Junko Maegawa; Katsuhiko Tsukaguchi; Takeshi Tokuyama; F. U. Akihiro; Kazuya Fukuoka; Koichi Tomoda; Munehiro Nakaya; Atsuhiko Fukuoka; Chinaru Yamamoto; Nobuhiro Narita; Yasuyoshi Enoki; Riichiro MikamiKekkaku 69 (4) 307 - 316 0022-9776 1994 [Refereed]
A survey on the nutritional status and cell-mediated immune function of 47 hospitalized patients with active pulmonary tuberculosis and healthy controls was conducted. In the patients group: 1) Anthropometric measurements, such as %ideal body weight (%IBW), %arm circum ference (%AC), %arm muscle circumference (%AMC) and %triceps skin fold (%TSF), were significantly reduced. 2) Visceral proteins including serum albumin (Alb), transferrin (Tf), prealbumin (PA) and retinol binding protein (RBP) were significantly reduced. 3) The imbalance of plasma amino acids, which was characterized by the depression of Fischer ratio, a molar ratio of branched chain amino acids (BCAA) to aromatic amino acids (AAA), was observed. Fischer ratio was significantly correlated with anthropometric measurements (YDIBW, %AC and %AMC). Delayed-type hypersensitivity to DNCB (2, 4-dinitrochlorobenzene) and iymptiocyte transformation to phytohemagglutinin (PHA) and concanavalin A (Con A) were significantly impaired in the patients group, whereas NK cell activity was higher than that of controls. Alb, PA, RBP and Fischer ratio were significantly lower in the patients with reduced DNCB reaction than in those with normal responses. Lymphocyte transformation was signifcantly correlated with Fischer ratio, and NK cell activity was significantly correlated with Alb, PA, RBP. These data may suggest that the imbalance of plasma amino acids represented by the reduction of Fischer ratio and the depletion of visceral proteins are closely related to the impairment of lymphocyte function in the patients with active pulmonary tuberculosis. Copyright © 1994, The Japan Neurosurgical Society. All rights reserved. - Keiichi Mikasa; Masayoshi Sawaki; Kaoru Hamada; Mitsuru Konishi; Kouichi Maeda; Shoji Teramoto; Shoji Takeuchi; Kazuya Fukuoka; Masahiro Sakamoto; Masayuki Tsujimoto; Kei Mori; Mikikazu Kunimatsu; Nobuhiro Narita; Eiji Kita; Shuzo KashibaCHEMOTHERAPY 42 (11) 1293 - 1298 0009-3165 1994 [Refereed]
The present authors investigated the utility and mechanism of long-term chemotherapy with erythromycin (EM) in the treatment of chronic lower respiratory tract infections. In parallel, we found that EM-clarithromycin (CAM) possesses properties as a biological response modifier (BRM), stimulating the activities of natural killer cells and producing various cytokines. Given these characteristics of CAM, investigations were performed on the effects of CAM on the survival of lung cancer patients receiving long-term administration of CAM. The subjects were 50 inpatients with primary lung cancer not indicated for surgical operation. They consisted of 43 males and 7 females, 41-82 years of age (64.5±9.8). Patients received concomitant application of radiotherapy with chemotherapy including CDDP after discharge, they were allocated randomly into a CAM administration group and nonadministration group at their initial visit to the outpatient clinic, and subsequent survival times were compared between the two groups. Survival rate data were analyzed using the Kaplan-Meier method and differences between the two groups were compared by the generalized Wilcoxon method and LongranK method. There were no significant differences between the two groups in terms of age, sex, stage, tissue type, basic treatment or efficacy rate. Results indicated that the survival curves of patients with small cell cancer were not significantly different between the two groups, but the 50% survival time of patients with non-small cell cancer was 930 days in the CAM administration group and 299 days in CAM non-administration group, indicating significant prolongation of survival in the CAM administration group (p=0.003). In conclusion, CAM was suggested to have potential as a BRM in eliciting prolongation of survival time in patients with lung cancer. © 1994, Japanese Society of Chemotherapy. All rights reserved. - 長 澄人; 濱田 薫; 徳山 猛; 前田 光一; 堅田 均; 成田 亘啓; 佐々木 義明; 今井 照彦; 尾辻 秀章; 飯岡 壮吾; 福岡 和也; 渋谷 惇夫気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 15 (4) 353 - 353 1993
- Fukuoka Kazuya; Katada Hitoshi; Cho Sumito; Hamada Kaoru; Maeda Koichi; Mikasa Keiichi; Kohnoike Yoshizumi; Konishi Mitsuru; Watanabe Hiroyuki; Narita Nobuhiro; Imai TeruhikoThe Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 15 (3) 216 - 223 1993In order to elucidate airway lesions and disorders of mucociliary transport system in Mycoplasma pneumoniae (M. pneumoniae) pneumonia, bronchofiberscopy, broncho-alveolar lavage (BAL), and aerosol inhalation cine-scintigraphy (AICS) were conducted in 6 cases of M. pneumoniae pneumonia. Bronchofiberscopic findings revealed redness and swelling of the bilateral bronchial mucosa in all cases and purulent secretion in 5 of 6 cases. Histological findings of bronchofiberscopic biopsy showed the desquamation and swelling of bronchial epithelial cells, broncho-bronchiolitis and alveolitis. The analysis of broncho-alveolar lavage fluid (BALF) contents demonstrated an increase of total cell counts and proportion of lymphocytes and neutrophils. AICS findings at one month from the onset disclosed that in 3 of 4 cases, either bolus formations or movements were absent, indicating severe impairment of mucociliary clearance. Futhermore, the impairment of mucociliary clearance still remained even 3 months from the onset in one subject. These findings suggested that there were both extensive and severe airway disorders in M. pneumoniae pneumonia.
- K. Fukuoka; H. Katada; Y. Kohnoike; N. Narita; S. IokaJapanese Journal of Thoracic Diseases 31 (1) 88 - 93 0301-1542 1993 [Refereed]
- Koichi Tomoda; Kaoru Hamada; Nobuhiro Narita; Kazuya Fukuoka; Keiichi Saitoh; Yoshizumi KohnoikelJapanese Journal of Lung Cancer 33 (2) 261 - 267 0386-9628 1993 [Refereed]
A 66-year-old man was admitted with small cell carcinoma of the lung (T2, N2, MO, stage III A), accompanied by SVC syndrome. With chemo- and radiotherapy, the SVC syndrome temporarily improved, but recurred. Because the SVC syndrome wasthought to be refractory to these therapeutic modalities, a Gianturco expandable metallic stent (EMS) was inserted into the stenotic SVC. Immediately, many symptoms related to SVC syndrome, edema of the face and upper extremities and dyspnea, improved. A month after placement of the EMS he died of pneumonia but without any side effects induced by the EMS. Autopsy demonstrated that there were no thromboses over the EMS, which was covered with white sheets composed of proliferating intima. © 1993, The Japan Lung Cancer Society. All rights reserved. - Fukuoka Kazuya; Katada Hitoshi; Tsujimoto Masayuki; Cho Sumito; Hamada Kaoru; Mikasa Keiichi; Kohnoike Yoshizumi; Narita Nobuhiro; Imai Teruhiko; Ioka SougoThe Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 14 (4) 339 - 345 1992A 70-year-old man, heavy smoker, consulted his family doctor because of cough and sputum. He was subsequently admitted to our hospital as chest X-ray film showed a tumor shadow in the left hilum and cytological examination of the sputum proved positive. Bronchofiberscopic findings on admission revealed a nodular tumor with superficial infiltration at the orifice of left B^<1-2> and at the bifurcation between the right middle and lower bronchi, thickening of the right upper trifurcation and complete occlusion of left B^6 by a tumor. Apart from the lesion in left B^6, the other three lesions were consistent with endoscopic hilar early lung cancer. Histopathological findings demonstrated squamous cell carcinoma, one was carcinoma in situ. As the four lesions were mutually isolated and there were no metastase to lymph nodes or distant organs, this was considered to be a case of primary quadruple lung cancer. After bronchial arterial infusion and systemic chemotherapy using CDDP, VDS and MMC, bronchofiberscopic findings revealed no cancerous tissue remaining, indicating the effectiveness of chemotherapy for quadruple lung cancer. Subsequently radiotherapy of the tumor in left S^6 was performed in addition to the chemotherapy. The patient has survived for three years since treatment, with no apparent recurrence of lung cancer.
- Katada Hitoshi; Nishikawa Kiyoshi; Imai Teruhiko; Konoike Yoshizumi; Fukuoka Kazuya; Hamada Kaoru; Cho Sumito; Kasuga Hirotomo; Ito Shinsaku; Narita Nobuhiro; Mikami RiichiroThe Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 14 (1) 75 - 84 1992Time-related changes in bronchoalveolar lavage were observed in three cases of summer-type hypersensitivity pneumonia over a period of 2 to 3 years. When symptoms were present, the total cell count, lymphocyte and neutrophil ratio increased, while the CD4/CD8 ratio decreased. In winter, spring and symptomless summer, the total cell count, neutrophil ratio and CD4/CD8 all tended to normalize, but the lymphocyte ratio still remained high. A case undergoing steroid therapy showed a recovery of lymphocyte ratio as well as other parameters, but the lymphocyte ratio showed abnormal values after cessation of steroid therapy. House removal and/or reconstruction of their residence suppressed symptom recurrence, causing slow improvement of the CD4/CD8 and a decrease in the fungal antibody titer, but those still remained the lymphocyte ratio high.
- Fukuoka Kazuya; Katada Hitoshi; Cho Sumito; Hamada Kaoru; Fujimura Masashi; Kohnoike Yoshizumi; Sawaki Masayoshi; Narita Nobuhiro; Imai Teruhiko; Watanabe Hiroyuki; Ohishi Hazime; Ioka Sougo; Kitamura SouichirouThe Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 14 (1) 31 - 37 1992A 57-year-old man had undergone right upper lobectomy and S^6a partial segmental resection for squamous cell carcinoma that developed in B^3b and had been complicated with pulmonary tuberculosis. Seven months after the operation, he was readmitted complaining of persistent cough and dyspnea on exertion. The chest roentgenogram showed severe loss of volume of the right middle lobe and compensatory overinflation of the right lower lobe. Bronchofiberscopy of the right bronchus revealed stenosis of the truncus intermedius and the middle lobe bronchus and protrusions in the orifice of the basal segmental bronchus. As bronchography, pulmonary arteriography, ventilation and perfusion scintigraphy and aerosol inhalation scintigraphy suggested that the residual bronchial stenosis widely disturbed the ventilation and perfusion of the right lung, he underwent pneumonectomy. The pathological investigation of the resected lung revealed that the protrusions of the bronchial wall were composed of folded bronchial cartilage. It was considered that in this case, stenosis and protrusions of the residual bronchus developed by bending of the bronchus and folding of the bronchial wall caused by movement and reexpansion of the residual lung after right upper lobectomy and S^6a partial segmental resection.
- 塚口 信彦; 福岡 和也; 梅村 康義; 濱田 薫; 長 澄人; 成田 亘啓気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 14 (6) 621 - 621 1992
- Kazuya Fukuoka; Michiaki Shiozaki; Mitsuru Konishi; Kaoru Hamada; Sumito Cho; Nobuhiro NaritaHaigan 32 (2) 271 - 277 0386-9628 1992 [Refereed]
A 72-year-old woman was admitted to our hospital with exertional dyspnea (Hugh-Jones III). Chest X-ray films showed right pleural effusion and pleural biopsy revealed pleural carcinomatosis (adenocarcinoma). Despite the intrathoracic administration of MMC and OK-432, an encapsulated pleural effusion remained and pulmonary lymphangitic carcinomatosis developed. Subsequently, a subcutaneous tumor that showed cancer cell infiltration became palpable at the site where the intrathoracic catheter had been inserted, and diffuse subcutaneous swelling extended over the right side of the trunk with right axillary lymphadenopathy. CT scans of the chest and abdomen showed a network of high density lesions in the subcutaneous tissue of the trunk. These physical and CT findings suggested diffuse subcutaneous infiltration of adenocarcinoma. Although systemic chemotherapy with CBDCA and VP-16 was performed, she died of respiratory failure. Autopsy findings revealed that the tumor was a poorly differentiated adenocarcinoma that originated from the right lower lobe, and both direct tumor infiltration from the pleura and the chest wall into the subcutaneous tissue and cutaneous lymphangitic carcinomatosis caused the diffuse subcutaneous swelling. © 1992, The Japan Lung Cancer Society. All rights Reserved. - Teramatsu TakashiJJLC The Japan Lung Cancer Society 31 (2) 193 - 200 0386-9628 1991A joint study was carried out in western Japan by 30 institutions (Society of Adjuvant Chemotherapy for Lung Cancer Surgery in West Japan) to examine the survival period, disease-free period, and side effects of postoperative adjuvant chemotherapy.Absolutely or relatively curatively resected patients were randomized to a group treated with MMC+ Tegafur (Group A) or one treated with MMC+UFT (Group B) and results were compared. Of 224 patients 80.8% were eligible for this study.
No difference was observed in background factors, medication, 3-year survival rate, and 3-year disease-free rate between the two groups. The results were better in Group B in relatively curatively resected cases and Stage III patients, and significantly better in patients with N2 lesions than in Group A. - Hamada Kaoru; Cho Sumito; Fujimura Masashi; Fukuoka Kazuya; Katada Hitoshi; Sawaki Masayoshi; Narita Nobuhiro; Watanabe Hiroyuki; Imai Teruhiko; Oishi Hajime; Higashiguchi Ryuuichi; Nishiura KimiakiThe Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 13 (3) 249 - 258 1991Intratumoral injection of absolute (99.5%) ethanol via a flexible bronchofiberscope was attempted on 10 cases with tracheobronchial stenosis or obstruction by neoplasia. Out of 7 cases with lung cancer, ethanol injections were effective in 1 case, and temporarily effective in 3 cases, while they were ineffective in the others. Though the results were ineffective in pulmonary metastasis, effects were obtained in a case of tracheal cancer and one of tracheal papillomatosis was improved. In some cases, radio- or chemotherapy were performed in combination with ethanol injection. There were no complications except for mild cough. This method was effective against polypoid proliferative tumors but ineffective for superficial or submucosally infiltrating tumor. However, even in effective cases, long term prognosis was not so good. Though it is palliative, intratumoral ethanol injection can be useful for bronchoscopic treatment from the standpoint of the patient's quality of life.
- Hamada Kaoru; Cho Sumito; Fujimura Masashi; Fukuoka Kazuya; Katada Hitoshi; Sawaki Masayoshi; Narita Nobuhiro; Watanabe Hiroyuki; Imai Teruhiko; Ooishi HajimeThe Journal of the Japan Society for Respiratory Endoscopy The Japan Society for Respiratory Endoscopy 13 (4) 349 - 357 1991The heat probe method is commonly used endoscopically for gastrointestinal bleeding. The authors studied the effects of heat coagulation on normal tracheal tissue and tried clinically to halt bronchial bleeding in case of lung cancer and to treat tracheal cancer. In the membranous portion of the trachea, almost all of the fibrocartilage plates showed injury with 90J heating, but without peribronchial tissue damage. On the cartilage of the trachea, 150J heating could not change cartilage tissue histologically. Five cases with bronchial bleeding caused by biopsy in case of lung cancer were treated with heat probe. One case of tracheal cancer was treated with it and severe inflmmatory changes of the mucosa were seen a week after heating. Healing changes were seen two weeks after heating, but histologically cancer remained. The heat probe was considered to be useful for bronchoscopic treatment of bleeding from carcinoma and does not cause severe complication.
- 濱田 薫; 長 澄人; 福岡 和也; 堅田 均; 成田 亘啓; 今井 照彦; 渡辺 裕之; 大石 元; 松田 成器気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 13 (1) 101 - 101 1991
- 川崎 恭; 丸谷 正実; 濱田 薫; 長 澄人; 藤村 昌史; 小山 泰弘; 鴻池 義純; 福岡 和也; 佐々木 義明; 塚口 勝彦; 堅田 均; 成田 亘啓; 今井 照彦; 渡辺 裕之; 大石 元気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 13 (1) 101 - 101 1991
- 長 澄人; 塩谷 直久; 小山 泰弘; 浜田 薫; 藤村 昌史; 福岡 和也; 堅田 均; 成田 亘啓; 今井 照彦; 渡辺 裕之; 大石 元; 渋谷 惇夫気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 12 83 - 83 1990
- 濱田 薫; 長 澄人; 藤村 昌史; 福岡 和也; 堅田 均; 澤木 政好; 成田 亘啓; 渡辺 裕之; 今井 照彦; 大石 元; 東口 隆一; 西浦 公章気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 12 121 - 121 1990
- 濱田 薫; 長 澄人; 藤村 昌史; 福岡 和也; 堅田 均; 澤木 政好; 成田 亘啓; 渡辺 裕之; 今井 照彦; 大石 元気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 12 121 - 121 1990
- 福岡 和也; 堅田 均; 長 澄人; 濱田 薫; 藤村 昌史; 鴻池 義純; 澤木 政好; 成田 亘啓; 大塚 浩史; 東条 尚; 飯岡 壮吾; 北村 惣一郎; 今井 照彦; 渡辺 裕之; 大石 元気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 12 (4) 447 - 447 1990
- 長 澄人; 福岡 和也; 夫 彰啓; 濱田 薫; 藤村 冒史; 菅原 聡; 鴻池 義純; 堅田 均; 成田 亘啓; 今井 照彦; 渡辺 裕之; 大石 元気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 12 (3) 336 - 337 1990
- 福岡 和也; 堅田 均; 藤村 昌史; 長 澄人; 濱田 薫; 辻本 正之; 杉村 祐子; 鴻池 義純; 澤木 政好; 成田 亘啓; 今井 照彦; 大石 元; 飯岡 壮吾; 東条 尚; 北村 惣一郎気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 11 (6) 617 - 618 1989
- 福岡 和也; 堅田 均; 藤村 昌史; 長 澄人; 夫 彰啓; 三笠 桂一; 鴻池 義純; 水本 保子; 古西 満; 渡辺 裕之; 前田 光一; 中尾 宰子; 小林 秀明; 澤木 政好; 成田 亘啓; 今井 照彦; 大石 元気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 11 (2) 209 - 209 1989
- 福岡 和也; 堅田 均; 藤村 昌史; 長 澄人; 三笠 桂一; 古西 満; 鴻池 義純; 水本 保子; 渡辺 裕之; 澤木 政好; 成田 亘啓; 今井 照彦; 大石 元気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 11 124 - 124 1989
- 藤村 昌史; 堅田 均; 福岡 和也; 長 澄人; 三笠 桂一; 澤木 政好; 成田 亘啓; 今井 照彦; 大石 元; 増谷 喬之; 播金 収気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 11 143 - 143 1989
- K. Fukuoka; K. Kasuga; S. Morikawa; H. Watanabe; K. Mikasa; H. Ka tada; M. Sawaki; N. Narita; T. Imai; H. Oishi; H. Otsuzi; H. Uchid aJapanese Journal of Thoracic Diseases 27 (11) 1362 - 1366 0301-1542 1989 [Refereed]
- Kazuya Fukuoka; Hitoshi Katada; Hiromichi Kitada; Nobuhtro Narita; Masahiro Tsutsumi; Yoichi Konishihaigan 29 (4) 391 - 396 0386-9628 1989 [Refereed]
A 80-year-old male had complained of cough and general fatigue. The chest roentogenogram showed a mass shadow in right S3. Fiberoptic bronchoscopy revealed a white necrotic polypoid tumor obstructing the orifice of right B3. Right upper lobectomy and lymph node dissection was performed. Histological examination of the resected specimen showed that the tumor was composed of mesenchymal chondrosarcoma and moderately differentiated squamous cell carcinoma. Since these two were separate, this case was considered double lung carcinoma. In spite of postoperative chemotherapy, he died of metastatic brain tumor, pneumonia and DIC after six months. Autopsy revealed multiple skin neurofibromatous lesions, and that the mesenchymal chondrosarcoma did not originate from bones or soft tissue. Metastases to the cerebrum, small intestine and mesenteric lymph nodes were recognized. We reported a rare double lung carcinoma associated with multiple neurofibromatosis. © 1989, The Japan Lung Cancer Society. All rights reserved. - 山中 貴世; 藤村 昌史; 福岡 和也; 鴻池 義純; 堅田 均; 成田 亘啓; 今井 照彦; 大石 元; 宮原 裕; 松永 喬気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 10 (4) 454 - 454 1988
- 吉田 英里; 堅田 均; 吉岡 真理子; 福岡 和也; 夫 彰啓; 北田 裕陸; 成田 亘啓; 今井 照彦; 西浦 公章; 浜田 信夫; 東条 尚; 飯岡 壮吾気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 10 (2) 225 - 226 1988
- Keiichi Mikasa; Masayoshi Sawaki; Mikikazu Kunimatsu; Masashi Fujimura; Kazuya Fukuoka; Koichi Maeda; Nobuhiro NaritaCHEMOTHERAPY 36 214 - 218 0009-3165 1988 [Refereed]
We assessed the clinical efficacy of sulbactam·ampicillin (SBT·ABPC) in a study of 19 patients with respiratory tract infections. The drug was administered by intravenous infusion in a dose of 1.5g twice a day. Those detected included H.influenzae in 10 patients, S.pneumoniae in 8, B.catarrhalis in 2, H.parahaemolyticus in 2, K.pneumoniae in 1 and Peptostreptococcus in 1. In 5 patients the organisms detected by transtracheal aspiration together with other organisms. 1) Efficacy was judged to be excellent in 2 patients, good in 16 and poor in 1, the efficacy rate being 94.7%. 2) The organisms were all eradicated except H.influenzae (1 strain) and K.pneumoniae (1 strain). 3) Nausea as a side effect was observed in 1 patient, but no abnormal laboratory findings were observed. From these findings, we believe this drug to be useful in the treatment of respiratory tract infections. © 1988, Japanese Society of Chemotherapy. All rights reserved.
MISC
- 高濱隆幸; 高濱隆幸; 米阪仁雄; 米阪仁雄; 谷崎潤子; 田中薫; 鈴木慎一郎; 金村宙昌; 磯本晃佑; 白石直樹; 坂井和子; 福岡和也; 福岡和也; 福岡和也; 西尾和人; 中川和彦; 中川和彦; 林秀敏 日本肺癌学会学術集会号 64th (CD-ROM)- 2023
- 谷崎 潤子; 鈴木 慎一郎; 金村 宙昌; 岩朝 勤; 川上 尚人; 田中 薫; 吉田 健史; 米阪 仁雄; 伊藤 彰彦; 坂井 和子; 木寺 康裕; 福岡 和也; 千葉 康敬; 西尾 和人; 中川 和彦; 林 秀敏 近畿大学医学雑誌 46- (3-4) 20A -20A 2021/12
- 西郷和真; 池川敦子; 木戸滋子; 川上尚人; 武田真幸; 岩朝勤; 巽純子; 福岡和也; 西尾和人; 田村和朗; 中川和彦; 松村謙臣 日本遺伝カウンセリング学会誌 41- (4) 2021
- Junko Tanizaki; Kan Yonemori; Kohei Akiyoshi; Hironobu Minami; Hiroki Ueda; Yuichi Takiguchi; Chihiro Nakayama Kondoh; Yoshihiko Segawa; Shin Takahashi; Yasuo Iwamoto; Yasuhiro Kidera; Kazuya Fukuoka; Yasushi Nakamura; Yasutaka Chiba; Kazuto Nishio; Kazuhiko Nakagawa; Hidetoshi Hayashi JOURNAL OF CLINICAL ONCOLOGY 38- (15) 2020/05
- Junko Tanizaki; Hidetoshi Hayashi; Hironobu Minami; Makoto Arai; Shin Takahashi; Yoshihiko Segawa; Yukinori Ozaki; Hiroki Ueda; Kohei Akiyoshi; Yasuo Iwamoto; Kan Yonemori; Yasuhiro Kidera; Kazuya Fukuoka; Kazuto Nishio; Kazuhiko Nakagawa ANNALS OF ONCOLOGY 29- 2018/10
- 武田 真幸; 坂井 和子; 林 秀敏; 田中 薫; 高濱 隆幸; 原谷 浩司; 福岡 和也; 中川 和彦; 西尾 和人 日本癌治療学会学術集会抄録集 56回- O2 -2 2018/10
- Afatinib投与によって、原発巣にpathological CRが得られたEGFR遺伝子変異陽性(del.19)肺腺癌の1例岡田 あすか; 福岡 和也; 西尾 和人; 高橋 慶一; 片山 公実子; 小口 展生; 村上 伸介; 竹中 英昭; 長 澄人; 鈴木 啓史; 西村 元宏 肺癌 56- (6) 856 -856 2016/11
- Hiroyasu Kaneda; Satomi Nishida; Tsutomu Iwasa; Toshio Shimizu; Kazuya Fukuoka; Kazuhiko Nakagawa ANNALS OF ONCOLOGY 26- 126 -126 2015/11
- 浅野 文祐; 大崎 能伸; 藤野 昇三; 千場 博; 佐藤 滋樹; 笹田 真滋; 各務 博; 鈴木 栄一; 岡田 克典; 青江 基; 福岡 和也; 日本呼吸器内視鏡学会安全対策委員会 気管支学 35- (3) 1 -48 2013/05
- S. Yamada; C. Tabata; T. Nakano; K. Fukuoka ANNALS OF ONCOLOGY 23- 147 -147 2012/10
- 悪性中皮腫の血清診断における可溶性メソテリン関連ペプチド(SMRP:Soluble Mesothelin-related Peptides)の有用性に関する多施設共同試験福岡 和也; 関戸 好孝; 樋田 豊明; 河原 邦光; 太田 三徳; 松村 晃秀; 岡田 守人; 岸本 卓巳; 中野 喜久雄; 中野 孝司 医学と薬学 68- (1) 177 -183 2012/07
- Yasuhiro Tsutani; Teruhisa Takuwa; Yoshihiro Miyata; Kazuya Fukuoka; Seiki Hasegawa; Takashi Nakano; Morihito Okada JOURNAL OF CLINICAL ONCOLOGY 30- (15) 2012/05
- Kazue Yoneda; Fumihiro Tanaka; Shunichi Fukuda; Hayato Orui; Masaki Hashimoto; Teruhisa Takuwa; Yoshitomo Okumura; Seiji Matsumoto; Nobuyuki Kondo; Ayuko Sato; Tohru Tsujimura; Noriaki Tsubota; Kazuya Fukuoka; Takashi Nakano; Seiki Hasegawa JOURNAL OF CLINICAL ONCOLOGY 30- (15) 2012/05
- 宮田義浩; 津谷康大; 多久和輝尚; 伊富貴雄太; 見前隆洋; 吉屋智晴; 福岡和也; 長谷川誠紀; 中野孝司; 岡田守人 肺癌 52- (5) 2012
- 福岡 和也 Clinical oncology 7- (6) 578 -584 2011/06
- Asuka Okada; Kazuya Fukuoka; Hisaya Okuwa; Hitomi Kamiya; Miki Honda; Eriko Masachika; Taiichiro Otsuki; Risa Maeda; Noriko Hirayama; Takayuki Terada; Aki Murakami; Syusai Yamada; Kuninobu Tamura; Chiharu Tabata; Takashi Nakano JOURNAL OF THORACIC ONCOLOGY 6- (6) S1202 -S1203 2011/06
- Asuka Okada; Kazuya Fukuoka; Syusai Yamada; Taiichiro Otsuki; Eriko Masachika; Hitomi Kamiya; Miki Honda; Hisaya Okuwa; Yoshitaka Nogi; Kouji Mikami; Risa Maeda; Kuninobu Tamura; Chiharu Tabata; Takashi Nakano JOURNAL OF THORACIC ONCOLOGY 6- (6) S1051 -S1052 2011/06
- Asuka Okada; Takashi Nakano; Kuninobu Tamura; Taiichiro Otsuki; Hisaya Okuwa; Hitomi Kamiya; Eriko Masachika; Miki Honda; Kouji Mikami; Yoshitaka Nogi; Chiharu Tabata; Risa Maeda; Kazuya Fukuoka JOURNAL OF THORACIC ONCOLOGY 6- (6) S1356 -S1356 2011/06
- 大槻 剛巳; 中野 孝司; 長谷川 誠紀; 岡田 守人; 辻村 亨; 関戸 好孝; 豊國 伸哉; 西本 寛; 福岡 和也; 田中 文啓; 熊谷 直子; 前田 恵; 松崎 秀紀; 李 順姫; 西村 泰光; 科学技術振興調整費平成18-22年度「アスベスト関連疾患への総括的取り組み」研究班 日本衛生学雑誌 66- (3) 543 -552 2011/05
- N. Hirayama; C. Tabata; R. Tabata; R. Maeda; A. Yasumitsu; S. Yamada; K. Kuribayashi; K. Fukuoka; T. Nakano AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 183- 2011
- Masaki Hashimto; Teruhisa Takuwa; Yoshitomo Okumura; Hayato Orui; Kazu Shiomi; Seiji Matsumoto; Nobuyuki Kondo; Fumihiro Tanaka; Noriaki Tsubota; Kazuya Fukuoka; Takashi Nakano; Seiki Hasegawa JOURNAL OF THORACIC ONCOLOGY 5- (12) S413 -S413 2010/12
- 科学技術振興調整費「アスベスト関連疾患への総括的取り組み」班 悪性中皮腫集学的治療に関する安全性確認試験ならびに基礎研究の進捗状況大槻 剛巳; 中野 孝司; 長谷川 誠紀; 岡田 守人; 辻村 享; 関戸 好孝; 豊國 伸哉; 西本 寛; 福岡 和也; 田中 文啓 日本職業・災害医学会会誌 58- (臨増) 別179 -別179 2010/10
- From the Special Session of the "Special Coordination Funds for Promoting Science and Technology (H18-13-3-1)" Entitled "Malignant Mesothelioma" in the 55^
Annual Meeting of the Japanese Society of Occupational Medicine and Traumatology : Brief Overview and Approaches from the Basic ScienceOTSUKI Takemi; NAKANO Takashi; HASEGAWA Seiki; OKADA Morihito; TSUJIMURA Tohru; SEKIDO Yoshitaka; TOYOKUNI Shinya; NISHIMOTO Hiroshi; FUKUOKA Kazuya; TANAKA Fumihiro Japanese journal of occupational medicine and traumatology 58- (1) 1 -8 2010/01 福岡 和也 最新医学 64- (12) 2616 -2620 2009/12科学技術振興調整費「アスベスト関連疾患への総括的取り組み」班 悪性中皮腫集学的治療に関する安全性確認試験の進捗状況大槻 剛巳; 長谷川 誠紀; 田中 文啓; 岡田 守人; 福岡 和也; 辻村 亨; 西本 寛; 関戸 好孝; 豊國 伸哉; 中野 孝司; 科学技術振興調整費; アスベスト関連疾患への総括的取り組み 日本職業・災害医学会会誌 57- (臨増) 別148 -別148 2009/10科学技術振興調整費「アスベスト関連疾患への総括的取り組み」班 登録事業の現状と、基礎研究よりアスベストの免疫系への影響について大槻 剛巳; 西本 寛; 前田 恵; 熊谷 直子; 林 宏明; 西村 泰光; 長谷川 誠紀; 田中 文啓; 岡田 守人; 福岡 和也; 辻村 亨; 関戸 好孝; 豊國 伸哉; 岸本 卓巳; 中野 孝司; 科学技術振興調整費; アスベスト関連疾患への総括的取り組み 日本職業・災害医学会会誌 57- (臨増) 別149 -別149 2009/10Kazuya Fukuoka; Takashi Nakano; Kozo Kuribayashi; Shin-ichiro Iida; Kunihiro Tamura; Chiharu Tabata JOURNAL OF THORACIC ONCOLOGY 4- (9) S771 -S771 2009/09Kazuya Fukuoka; Syusai Yamada; Kozo Kuribayashi; Takashi Nakano JOURNAL OF THORACIC ONCOLOGY 4- (9) S757 -S757 2009/09Kazuya Fukuoka; Asuka Okada; Ryoji Eguchi; Yoshihiro Fujimori; Masakazu Muramoto; Kozo Kuribayashi; Noriaki Tsubota; Takashi Nakano; Noriko Hirayama JOURNAL OF THORACIC ONCOLOGY 4- (9) S760 -S760 2009/09Kazuya Fukuoka; Akihiro Yasumitsu; Takayuki Terada; Noriko Hirayama; Kunihiro Tamura; Takashi Nakano JOURNAL OF THORACIC ONCOLOGY 4- (9) S475 -S475 2009/09Tohru Tsujimura; Ayuko Sato; Ikuko Torii; Tomoko Hashimoto-Tamaoki; Yoshie Yoshikawa; Kazuya Fukuoka; Fumihiro Tanaka; Seiki Hasegawa; Takashi Nakano Japanese Journal of Lung Cancer 49- (4) 376 -379 2009/08Kazuya Fukuoka; Takashi Nakano Japanese Journal of Lung Cancer 49- (4) 397 -402 2009/08Fumihiro Tanaka; Seiki Hasegawa; Morihito Okada; Takeharu Yamanaka; Kazuya Fukuoka; Toshinori Soejima; Norihiko Kamikonya; Kouki Inai; Tohru Tsujimura; Takashi Nakano Japanese Journal of Lung Cancer 49- (4) 403 -408 2009/08Tomonori Hirashima; Kazuya Fukuoka; Toyoaki Hida; Kunimitsu Kawahara; Takumi Kishimoto; Akihide Matsumura; Kikuo Nakano; Morihito Okada; Takashi Nakano Japanese Journal of Lung Cancer 49- (4) 380 -385 2009/08Fumihiro Tanaka; Masaki Hashimoto; Teruhisa Takuwa; Seiji Matsumoto; Nobuyuki Kondo; Yoshitomo Okumura; Aki Murakami; Syusai Yamada; Kunihiro Tamura; Shinichiro Iida; Kozo Kuribayashi; Mitsudomi Miyake; Kazuya Fukuoka; Noriaki Tsubota; Norihiko Kamikonya; Masayuki Fujiwara; Tohru Tsujimura; Seiki Hasegawa; Takashi Nakano Japanese Journal of Lung Cancer 49- (4) 392 -396 2009/08福岡 和也 Clinical oncology 3- (4) 464 -469 2009/04福岡和也 呼吸器症候群 452 -454 2009寺田 貴普; 栗林 康造; 安光 亮洋; 平山 倫子; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 福岡 和也; 中野 孝司 肺癌 48- (6) 781 -782 2008/10坂根 理矢; 栗林 康造; 池田 久美子; 平山 倫子; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 福岡 和也; 中野 孝司; 坪田 紀明 肺癌 48- (6) 779 -779 2008/10安光 亮洋; 福岡 和也; 寺田 貴普; 平山 倫子; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 中野 孝司 肺癌 48- (6) 777 -777 2008/10寺田 貴普; 栗林 康造; 安光 亮洋; 平山 倫子; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 福岡 和也; 中野 孝司 肺癌 48- (6) 781 -781 2008/10大槻 剛巳; 前田 恵; 村上 周子; 熊谷 直子; 林 宏明; 栗林 康造; 福岡 和也; 岸本 卓巳; 中野 孝司; 西村 泰光 肺癌 48- (5) 656 -656 2008/10田村 邦宣; 福岡 和也; 平山 倫子; 寺田 貴普; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明 肺癌 48- (5) 656 -656 2008/10飯田 慎一郎; 福岡 和也; 寺田 貴普; 平山 倫子; 安光 亮洋; 村上 亜紀; 山田 秀哉; 田村 邦宣; 田端 千春; 栗林 康造; 坪田 紀明; 中野 孝司 肺癌 48- (5) 597 -597 2008/10長谷川 誠紀; 田中 文啓; 山中 竹春; 岡田 守人; 副島 俊典; 辻村 亨; 上紺屋 憲彦; 福岡 和也; 中野 孝司 肺癌 48- (5) 442 -442 2008/10山田 秀哉; 福岡 和也; 栗林 康造; 田端 千春; 田村 邦宣; 飯田 慎一郎; 村上 亜紀; 安光 亮洋; 寺田 貴普; 平山 倫子; 中野 孝司; 坪田 紀明 肺癌 48- (5) 437 -437 2008/10田中 文啓; 米田 和恵; 橋本 昌樹; 多久和 輝尚; 松本 成司; 近藤 展行; 奥村 好邦; 長谷川 誠紀; 辻村 亨; 坪田 紀明; 安光 亮洋; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 田端 千春; 栗林 康造; 福岡 和也; 中野 孝司 肺癌 48- (5) 469 -469 2008/10奥村 好邦; 橋本 昌樹; 多久和 輝尚; 近藤 展行; 田中 文啓; 長谷川 誠紀; 栗林 康造; 福岡 和也; 中野 孝司; 坪田 紀明 肺癌 48- (5) 470 -470 2008/10安光 亮洋; 福岡 和也; 平山 倫子; 寺田 貴普; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 坪田 紀明; 中野 孝司 肺癌 48- (5) 470 -470 2008/10長谷川 誠紀; 田中 文啓; 福岡 和也; 中野 孝司; 辻村 亨 日本臨床細胞学会雑誌 47- (2) 370 -370 2008/09福岡 和也; 田中 文啓; 辻村 亨; 西本 寛; 長谷川 誠紀; 中野 孝司 日本臨床細胞学会雑誌 47- (2) 375 -375 2008/09村上 亜紀; 安光 亮洋; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 福岡 和也; 中野 孝司; 多久和 輝尚; 奥村 好邦; 田中 文啓; 長谷川 誠紀; 新長 真由美; 羽尾 裕之; 廣田 誠一; 井上 哲郎; 田口 善夫 肺癌 48- (2) 148 -148 2008/04田村 邦宣; 福岡 和也; 平山 倫子; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 中野 孝司; 坪田 紀明; 近藤 展行; 多久和 輝尚; 奥村 好邦; 田中 文啓; 長谷川 誠紀; 小野寺 正征; 辻村 亨 肺癌 48- (2) 152 -153 2008/04飯田 慎一郎; 安光 亮洋; 村上 亜紀; 山田 秀哉; 田村 邦宜; 田端 千春; 栗林 康造; 福岡 和也; 中野 孝司; 坪田 紀明; 多久和 輝尚; 松本 成司; 近藤 展行; 奥村 好邦; 田中 文啓; 長谷川 誠紀; 小野寺 正征; 辻村 亨 肺癌 48- (2) 153 -153 2008/04大槻 剛巳; 前田 恵; 村上 周子; 林 宏明; 福岡 和也; 栗林 康造; 岸本 卓巳; 草加 勝康; 中野 孝司; 西村 泰光 肺癌 47- (5) 608 -608 2007/10西村 泰光; 前田 恵; 村上 周子; 林 宏明; 三浦 由恵; 福岡 和也; 中野 孝司; 大槻 剛巳 肺癌 47- (5) 608 -608 2007/10飯田 慎一郎; 安光 亮洋; 村上 亜紀; 山田 秀哉; 田村 邦宣; 田端 千春; 栗林 康造; 宮田 茂; 三宅 光富; 福岡 和也; 坪田 紀明; 中野 孝司 肺癌 47- (5) 576 -576 2007/10田端 千春; 栗林 康造; 三宅 光富; 田村 邦宣; 飯田 慎一郎; 山田 秀哉; 村上 亜紀; 安光 亮洋; 福岡 和也; 中野 孝司 肺癌 47- (5) 517 -517 2007/10山田 秀哉; 福岡 和也; 安光 亮洋; 村上 亜紀; 栗林 康造; 飯田 慎一郎; 田村 邦宣; 田端 千春; 宮田 茂; 三宅 光富; 中野 孝司; 坪田 紀明 肺癌 47- (5) 516 -516 2007/10田中 文啓; 長谷川 誠紀; 岡田 守人; 副島 俊典; 上紺屋 憲彦; 山中 竹春; 福岡 和也; 中野 孝治 肺癌 47- (5) 473 -473 2007/10福岡 和也 肺癌 47- (5) 472 -472 2007/10安光 亮洋; 栗林 康造; 三宅 光富; 宮田 茂; 田端 千春; 田村 邦宣; 飯田 慎一郎; 山田 秀哉; 村上 亜紀; 冨士原 将之; 福岡 和也; 坪田 紀明; 中野 孝司 肺癌 47- (5) 490 -490 2007/10栗林 康造; 福岡 和也; 安光 亮洋; 三宅 光富; 宮田 茂; 田端 千春; 田村 邦宣; 飯田 慎一郎; 山田 秀哉; 村上 亜紀; 坪田 紀明; 中野 孝司 肺癌 47- (5) 490 -490 2007/10福岡 和也; 栗林 康造; 三宅 光富; 田村 邦宣; 飯田 慎一郎; 田端 千春; 安光 亮洋; 村上 亜紀; 山田 秀哉; 宮田 茂; 坪田 紀明; 中野 孝司 肺癌 47- (5) 490 -490 2007/10多久和 輝尚; 田中 文啓; 松本 成司; 奥村 好邦; 近藤 典行; 長谷川 誠紀; 橋本 昌樹; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 栗林 康造; 三宅 光富; 福岡 和也; 中野 孝司; 辻村 亨; 坪田 紀明 肺癌 47- (5) 578 -578 2007/10大槻 剛巳; 三浦 由恵; 前田 恵; 林 宏明; 村上 周子; 福岡 和也; 栗林 康造; 岸本 卓巳; 中野 孝司; 西村 泰光 肺癌 47- (5) 467 -467 2007/10田中 文啓; 橋本 昌樹; 多久和 輝尚; 松本 成司; 奥村 好邦; 近藤 展行; 長谷川 誠紀; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 栗林 康造; 三宅 光富; 福岡 和也; 中野 孝司; 辻村 亨; 坪田 紀明 肺癌 47- (5) 449 -449 2007/10近藤 展行; 橋本 昌樹; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀; 村上 亜紀; 山田 秀哉; 宮田 茂; 田村 邦宣; 飯田 慎一郎; 栗林 康造; 三宅 光富; 福岡 和也; 中野 孝司; 坪田 紀明 肺癌 47- (5) 468 -468 2007/10田村 邦宣; 福岡 和也; 安光 亮洋; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 田端 千春; 栗林 康造; 宮田 茂; 三宅 光富; 坪田 紀明; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 近藤 展行; 田中 文啓; 長谷川 誠紀 肺癌 47- (5) 542 -542 2007/10村上 亜紀; 安光 亮洋; 山田 秀哉; 飯田 慎一郎; 田村 邦宣; 田端 千春; 栗林 康造; 宮田 茂; 三宅 光富; 福岡 和也; 坪田 紀明; 中野 孝司 肺癌 47- (5) 657 -657 2007/10山田 秀哉; 福岡 和也; 安光 亮洋; 村上 亜紀; 栗林 康造; 飯田 慎一郎; 田村 邦宣; 田端 千春; 宮田 茂; 三宅 光富; 中野 孝司 肺癌 47- (4) 401 -401 2007/08永井 孝憲; 中嶋 泰典; 村上 亜紀; 山田 秀哉; 上坂 亜由子; 飯田 慎一郎; 田村 邦宣; 栗林 康造; 宮田 茂; 三宅 光富; 福岡 和也; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀; 新長 真由美; 廣田 誠一 肺癌 47- (2) 195 -195 2007/04中野 孝司; 福岡 和也; 長谷川 誠紀; 田中 文啓; 中野 孝司; 坪田 紀明; 辻村 亨; 岡田 守人; 三村 剛史; 西本 寛 肺癌 47- (2) 195 -195 2007/04武田 真幸; 福岡 和也; 小林 厚; 小林 真也; 本津 茂人; 木村 弘 肺癌 46- (5) 657 -657 2006/11宮田 茂; 福岡 和也; 上坂 亜由子; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 延山 誠一; 中嶋 泰典; 栗林 康造; 三宅 光富; 中野 孝司 肺癌 46- (5) 677 -677 2006/11村上 亜紀; 三宅 光富; 山田 秀哉; 上坂 亜由子; 飯田 慎一郎; 延山 誠一; 田村 邦宣; 中嶋 泰典; 栗林 康造; 宮田 茂; 福岡 和也; 中野 孝司; 廣田 誠一; 廣田 誠一 肺癌 46- (5) 576 -576 2006/11三宅 光富; 栗林 康造; 上坂 亜由子; 村上 亜紀; 山田 秀哉; 飯田 慎一郎; 延山 誠一; 田村 邦宣; 中嶋 泰典; 宮田 茂; 福岡 和也; 中野 孝司 肺癌 46- (5) 590 -590 2006/11福岡 和也; 上坂 亜由子; 栗林 康造; 三宅 光富; 宮田 茂; 中嶋 泰典; 飯田 慎一郎; 延山 誠一; 田村 邦宣; 山田 秀哉; 村上 亜紀; 中野 孝司 肺癌 46- (5) 588 -588 2006/11上坂 亜由子; 福岡 和也; 栗林 康造; 村上 亜紀; 山田 秀哉; 田村 邦宣; 飯田 慎一郎; 延山 誠一; 中嶋 泰典; 三宅 光富; 宮田 茂; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀 肺癌 46- (5) 633 -633 2006/11中野 孝司; 福岡 和也; 長谷川 誠紀; 田中 文啓 肺癌 46- (5) 483 -483 2006/11栗林 康造; 三宅 光富; 宮田 茂; 中嶋 泰典; 田村 邦宣; 延山 誠一; 飯田 慎一郎; 上坂 亜由子; 山田 秀哉; 村上 亜紀; 福岡 和也; 中野 孝司 肺癌 46- (5) 489 -489 2006/11福岡 和也; 上坂 亜由子; 栗林 康造; 三宅 光富; 宮田 茂; 中嶋 泰典; 飯田 慎一郎; 延山 誠一; 田村 邦宣; 山田 秀哉; 村上 亜紀; 中野 孝司 肺癌 46- (5) 449 -449 2006/11上坂 亜由子; 三宅 光富; 福岡 和也; 宮田 茂; 栗林 康造; 中嶋 泰典; 延山 誠一; 飯田 慎一郎; 田村 邦宣; 山田 秀哉; 村上 亜紀; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀 肺癌 46- (5) 537 -537 2006/11宮田 茂; 福岡 和也; 村上 亜紀; 山田 秀哉; 上坂 亜由子; 田村 邦宣; 延山 誠一; 飯田 慎一郎; 中嶋 泰典; 栗林 康造; 三宅 光富; 中野 孝司; 後藤 功 肺癌 46- (4) 389 -390 2006/08山田 秀哉; 田村 邦宣; 村上 亜紀; 上坂 亜由子; 栗林 康造; 飯田 慎一郎; 延山 誠一; 中嶋 泰典; 宮田 茂; 三宅 光富; 福岡 和也; 中野 孝司; 新長 真由美; 廣田 誠一 肺癌 46- (4) 383 -383 2006/08UESAKA Ayuko; MATSUDA Yoshinobu; YAMAGUCHI Atsushige; ASAI Mitsuko; YAMADA Syusai; FUKUOKA Kazuya; NAKANO Takashi 日本呼吸器学会雑誌 = The journal of the Japanese Respiratory Society 44- (7) 528 -531 2006/07上坂 亜由子; 山田 秀哉; 村上 亜紀; 延山 誠一; 飯田 慎一郎; 田村 邦宣; 栗林 康造; 宮田 茂; 三宅 光富; 福岡 和也; 中野 孝司; 竹中 雅彦; 陣 祥子; 松田 良信 肺癌 46- (2) 180 -180 2006/04小林 厚; 小林 真也; 武田 真幸; 木村 弘; 福岡 和也 肺癌 46- (2) 182 -182 2006/04飯田 慎一郎; 村上 亜紀; 山田 秀哉; 上坂 亜由子; 延山 誠一; 田村 邦宣; 栗林 康造; 宮田 茂; 三宅 光富; 福岡 和也; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 田中 文啓; 長谷川 誠紀 肺癌 46- (2) 185 -185 2006/04小林 厚; 福岡 和也; 小林 真也; 本津 茂人; 武田 真幸; 木村 弘; 高濱 誠; 東条 尚; 坂本 雅彦 肺癌 45- (5) 539 -539 2005/11宮田 茂; 山田 秀哉; 上坂 亜由子; 村上 亜紀; 延山 誠一; 飯田 慎一郎; 栗林 康造; 三宅 光富; 福岡 和也; 中野 孝司; 多久和 輝尚; 松本 成司; 奥村 好邦; 長谷川 誠紀 肺癌 45- (5) 548 -548 2005/11栗林 康造; 平野 博嗣; 三宅 光富; 宮田 茂; 延山 誠一; 飯田 慎一郎; 上坂 亜由子; 山田 秀哉; 村上 亜紀; 多久和 輝尚; 松本 成司; 奥村 好邦; 福岡 和也; 長谷川 誠紀; 中野 孝司 肺癌 45- (5) 475 -475 2005/11福岡 和也; 栗林 康造; 三宅 光富; 宮田 茂; 延山 誠一; 飯田 慎一郎; 上坂 亜由子; 山田 秀哉; 村上 亜紀; 中野 孝司; 奥村 好邦; 長谷川 誠紀 肺癌 45- (5) 474 -474 2005/11上坂 亜由子; 村上 亜紀; 山田 秀哉; 延山 誠一; 飯田 慎一郎; 栗林 康造; 三宅 光富; 宮田 茂; 福岡 和也; 中野 孝司 肺癌 45- (5) 581 -581 2005/11栗林 康造; 三宅 光富; 宮田 茂; 延山 誠一; 飯田 慎一郎; 上坂 亜由子; 山田 秀哉; 村上 亜紀; 福岡 和也; 中野 孝司 肺癌 45- (5) 583 -583 2005/11飯田 慎一郎; 村上 亜紀; 山田 秀哉; 上坂 亜由子; 延山 誠一; 栗林 康造; 三宅 光富; 宮田 茂; 福岡 和也; 中野 孝司 肺癌 45- (5) 658 -658 2005/11三宅 光富; 村上 亜紀; 奥窪 琢; 山田 秀哉; 栗林 康造; 上坂 亜由子; 延山 誠一; 飯田 慎一郎; 宮田 茂; 福岡 和也; 中野 孝司; 中正 恵二; 平野 博嗣 肺癌 45- (5) 659 -659 2005/11寺西 融; 小林 厚; 福岡 和也; 本津 茂人; 米田 和之; 児山 紀子; 牧之 段潔; 玉置 伸二; 友田 恒一; 濱田 薫; 木村 弘; 善本 英一郎; 前田 光一 肺癌 45- (6) 766 -766 2005/10新熊 悟; 玉置 伸二; 児山 紀子; 牧之段 潔; 米田 和之; 友田 恒一; 福岡 和也; 濱田 薫; 木村 弘; 善本 英一郎; 前田 光一 気管支学 27- (5) 417 -417 2005/07本津 茂人; 福岡 和也; 武田 真幸; 小林 真也; 木村 弘; 辰巳 晃子; 和中 明生; 小林 厚 肺癌 45- (1) 99 -99 2005/02岩井 一哲; 本津 茂人; 福岡 篤彦; 牧之段 潔; 友田 恒一; 福岡 和也; 濱田 薫; 木村 弘; 高濱 誠; 櫛部 圭司; 谷口 繁樹; 今井 照彦 肺癌 44- (6) 722 -722 2004/10福岡 和也; 武田 真幸; 本津 茂人; 小林 真也; 木村 弘 肺癌 44- (5) 643 -643 2004/10武田 真幸; 福岡 和也; 本津 茂人; 小池 真也; 木村 弘; 高濱 誠; 櫛部 圭司 肺癌 44- (5) 391 -391 2004/10本津 茂人; 福岡 和也; 武田 真幸; 小林 真也; 木村 弘 肺癌 44- (5) 511 -511 2004/10岡林 里枝; 前田 光一; 神野 正敏; 藤本 隆; 松村 雅彦; 藤本 眞一; 中村 忍; 玉置 伸二; 友田 恒一; 福岡 和也; 濱田 薫; 木村 弘; 善本 英一郎; 三笠 桂一 気管支学 26- (6) 575 -575 2004/09宇野 健司; 福岡 和也; 福岡 篤彦; 武田 真幸; 濱田 薫; 木村 弘; 野々村 昭孝 肺癌 44- (2) 144 -144 2004/04早川 正樹; 福岡 和也; 福岡 篤彦; 武田 真幸; 濱田 薫; 木村 弘; 中村 契; 高濱 誠; 櫛部 圭司; 谷口 繁樹 肺癌 44- (2) 142 -142 2004/04宇野 健司; 三宅 牧人; 田中 基幹; 植村 天受; 平尾 佳彦; 福岡 和也; 玉置 伸二; 善本 英一郎; 友田 恒一; 竹中 英昭; 濱田 薫; 木村 弘; 前田 光一 気管支学 26- (1) 97 -97 2004福岡 和也; 本津 茂人; 小林 真也; 武田 真幸; 木村 弘; 古林 郁乃; 浅田 秀夫; 宮川 幸子 肺癌 43- (5) 590 -590 2003/10藤田 幸男; 福岡 和也; 福岡 篤彦; 宇野 健司; 武田 真幸; 濱田 薫; 木村 弘; 堤 雅弘; 國安 弘基; 西本 優子 肺癌 43- (6) 772 -772 2003/10水野 陽花; 福岡 和也; 福岡 篤彦; 大屋 修一; 武田 真幸; 濱田 薫; 木村 弘; 山本 泰弘 肺癌 43- (6) 772 -772 2003/10武田 真幸; 福岡 和也; 本津 茂人; 小林 真也; 木村 弘; 高濱 誠; 櫛部 圭司; 谷口 繁樹; 今井 照彦; 坂本 雅彦 肺癌 43- (5) 529 -529 2003/10宇野 建司; 福岡 和也; 玉置 伸二; 本津 茂人; 武田 真幸; 濱田 薫; 木村 弘 肺癌 43- (2) 161 -161 2003/04藤田 幸男; 福岡 和也; 福岡 篤彦; 本津 茂人; 武田 真幸; 濱田 薫; 木村 弘 肺癌 43- (2) 158 -158 2003/04J Usuda; M Inomata; H Fukumoto; Y Iwamoto; T Suzuki; HJ Kuh; K Fukuoka; H Kato; N Saijo; K Nishio INTERNATIONAL JOURNAL OF ONCOLOGY 22- (1) 81 -86 2003/01福岡 和也; 本津 茂人; 木村 弘; 櫛部 圭司; 高濱 誠; 川口 剛史; 根津 邦基; 甲斐 吉郎; 小林 真也; 竹澤 祐一 肺癌 42- (5) 369 -369 2002/10甲斐 吉郎; 芳野 詠子; 福岡 和也; 伊藤 武文; 本津 茂人; 濱田 薫; 木村 弘; 藤田 千絵; 高群 美和; 上野 聡; 寺本 正治; 今井 照彦 肺癌 42- (6) 661 -661 2002/10田村 緑; 福岡 篤彦; 福岡 和也; 竹中 英昭; 本津 茂人; 濱田 薫; 木村 弘; 飯田 淳一; 榊 寿右 肺癌 42- (6) 660 -661 2002/10平川 遼一; 福岡 和也; 玉置 伸二; 本津 茂人; 濱田 薫; 木村 弘; 藤田 千絵; 高群 美和; 上野 聡 肺癌 42- (6) 661 -661 2002/10K Fukuoka; H Arioka; Y Iwamoto; H Fukumoto; H Kurokawa; T Ishida; A Tomonari; T Suzuki; J Usuda; F Kanzawa; H Kimura; N Saijo; K Nishio CANCER CHEMOTHERAPY AND PHARMACOLOGY 49- (5) 385 -390 2002/05芳野 詠子; 福岡 和也; 本津 茂人; 濱田 薫; 木村 弘 肺癌 42- (2) 149 -149 2002/04宮本 謙一; 福岡 和也; 本津 茂人; 福岡 篤彦; 木村 弘; 中島 啓 肺癌 42- (2) 150 -150 2002/04Y Tatsumi; H Arioka; S Ikeda; H Fukumoto; K Miyamoto; K Fukuoka; Y Ohe; N Saijo; K Nishio JAPANESE JOURNAL OF CANCER RESEARCH 92- (12) 1355 -1355 2001/12K Fukuoka; H Arioka; Y Iwamoto; H Fukumoto; H Kurokawa; T Ishida; A Tomonari; T Suzuki; J Usuda; F Kanzawa; N Saijo; K Nishio LUNG CANCER 34- (3) 451 -460 2001/12高橋 賢; 福岡 和也; 本津 茂人; 小林 真也; 濱田 薫; 米田 尚弘; 木村 弘; 川口 剛史; 根津 邦基; 谷口 繁樹; 北東 大督; 高山 智燮; 中島 祥介; 中江 大 肺癌 41- (6) 725 -725 2001/10本津 茂人; 福岡 和也; 小林 真也; 濱田 薫; 米田 弘; 木村 弘; 川原 誠; 熊澤 昌洋; 上野 聡 肺癌 41- (6) 714 -714 2001/10高橋 賢; 福岡 和也; 本津 茂人; 濱田 薫; 木村 弘 肺癌 41- (5) 488 -488 2001/09福岡 和也; 本津 茂人; 木村 弘 肺癌 41- (5) 447 -447 2001/09本津 茂人; 福岡 和也; 木村 弘 肺癌 41- (5) 567 -567 2001/09福岡 和也; 本津 茂人; 木村 弘; 西尾 和人; 西條 長宏 肺癌 41- (5) 531 -531 2001/09Y Tatsumi; H Arioka; S Ikeda; H Fukumoto; K Miyamoto; K Fukuoka; Y Ohe; N Saijo; K Nishio JAPANESE JOURNAL OF CANCER RESEARCH 92- (7) 768 -777 2001/07Y Tatsumi; H Arioka; S Ikeda; H Fukumoto; K Miyamoto; K Fukuoka; Y Ohe; N Saijo; K Nishio JAPANESE JOURNAL OF CANCER RESEARCH 92- (7) 768 -777 2001/07宮本 謙一; 福岡 和也; 善本 英一郎; 小林 真也; 濱田 薫; 米田 尚弘; 成田 亘啓; 安川 元章; 櫛部 圭司; 根津 邦基; 谷口 繁樹; 森 啓; 甲斐 吉郎; 竹澤 祐一; 山田 雄三 肺癌 41- (2) 175 -175 2001/04山本 佳史; 福岡 和也; 緑川 沢樹; 中村 孝人; 古西 満; 小林 真也; 濱田 薫; 米田 尚弘; 成田 亘啓; 安川 元章; 川口 剛史; 櫛部 圭司; 根津 邦基; 谷口 繁樹 肺癌 41- (2) 178 -179 2001/04眞島 利匡; 福岡 和也; 緑川 沢樹 日本胸部臨床 60- (2) 168 -172 2001/02K Fukuoka; J Usuda; Y Iwamoto; H Fukumoto; T Nakamura; T Yoneda; N Narita; N Saijo; K Nishio INVESTIGATIONAL NEW DRUGS 19- (3) 219 -227 2001K Fukuoka; J Usuda; Y Iwamoto; H Fukumoto; T Nakamura; T Yoneda; N Narita; N Saijo; K Nishio INVESTIGATIONAL NEW DRUGS 19- (3) 219 -227 2001K Fukuoka; T Yamagishi; T Ichihara; S Nakaike; K Iguchi; Y Yamada; H Fukumoto; T Yoneda; K Samata; H Ikeya; K Nanaumi; N Hirayama; N Narita; N Saijo; K Nishio INTERNATIONAL JOURNAL OF CANCER 88- (5) 810 -819 2000/12K Fukuoka; T Yamagishi; T Ichihara; S Nakaike; K Iguchi; Y Yamada; H Fukumoto; T Yoneda; K Samata; H Ikeya; K Nanaumi; N Hirayama; N Narita; N Saijo; K Nishio INTERNATIONAL JOURNAL OF CANCER 88- (5) 810 -819 2000/12本津 茂人; 福岡 和也; 善本 英一郎; 小林 真也; 濱田 薫; 米田 尚弘; 成田 亘啓; 村田 奈保; 中江 大; 小西 陽一 肺癌 40- (6) 682 -682 2000/10中野 優子; 福岡 和也; 小林 真也; 濱田 薫; 米田 尚弘; 成田 亘啓; 後藤 泰史; 田丸 司; 上野 聡 肺癌 40- (6) 680 -680 2000/10福岡 和也; 小林 真也; 米田 尚弘; 成田 亘啓 肺癌 40- (5) 430 -430 2000/09福岡 和也; 武田 研一; 小林 真也; 濱田 薫; 米田 尚弘; 成田 亘啓; 櫛部 圭司; 川口 剛史; 谷口 繁樹 肺癌 40- (5) 543 -543 2000/09小林 真也; 福岡 和也; 米田 和之; 濱田 薫; 米田 尚弘; 成田 亘啓; 楠岡 修; 堤 雅弘; 小西 陽一 肺癌 40- (2) 162 -162 2000/04本津 茂人; 福岡 和也; 米田 和之; 金山 清二; 小林 真也; 濱田 薫; 米田 尚弘; 成田 亘啓 肺癌 40- (2) 156 -157 2000/04K Fukuoka; K Nishio; H Fukumoto; H Arioka; H Kurokawa; T Ishida; Y Iwamoto; A Tomonari; T Suzuki; J Usuda; N Narita; N Saijo INTERNATIONAL JOURNAL OF CANCER 86- (2) 197 -203 2000/04K Fukuoka; K Nishio; H Fukumoto; H Arioka; H Kurokawa; T Ishida; Y Iwamoto; A Tomonari; T Suzuki; J Usuda; N Narita; N Saijo INTERNATIONAL JOURNAL OF CANCER 86- (2) 197 -203 2000/04J Usuda; N Saijo; K Fukuoka; H Fukumoto; HJ Kuh; T Nakamura; Y Koh; T Suzuki; F Koizumi; T Tamura; H Kato; K Nishio INTERNATIONAL JOURNAL OF CANCER 85- (2) 275 -280 2000/01J Usuda; N Saijo; K Fukuoka; H Fukumoto; HJ Kuh; T Nakamura; Y Koh; T Suzuki; F Koizumi; T Tamura; H Kato; K Nishio INTERNATIONAL JOURNAL OF CANCER 85- (2) 275 -280 2000/01眞島 利匡; 福岡 和也; 緑川 沢樹; 坂本 正洋; 三笠 桂一; 米田 尚弘; 成田 亘啓 肺癌 39- (6) 916 -916 1999/10眞島 利匡; 坂本 正洋; 三笠 桂一; 濱田 薫; 古西 満; 前田 光一; 福岡 和也; 善本 英一郎; 村川 幸市; 高橋 賢; 喜多 英二; 成田 亘啓 肺癌 39- (5) 667 -667 1999/09坂本 正洋; 三笠 桂一; 眞島 利匡; 濱田 薫; 古西 満; 前田 光一; 福岡 和也; 善本 英一郎; 村川 幸市; 高橋 賢; 喜多 英二; 成田 亘啓 肺癌 39- (5) 667 -667 1999/09福岡 和也; 中野 優子; 西本 優子; 幕谷 士郎; 今井 照彦; 大石 元; 打田 日出夫; 網本 学; 小林 真也; 米田 尚弘; 成田 亘啓 肺癌 39- (5) 644 -644 1999/09福岡 和也; 臼田 実男; 福本 久郎; 中村 貴; 西條 長宏; 成田 亘啓; 西尾 和人 日本癌学会総会記事 58回- 680 -680 1999/08H Fukumoto; K Nishio; S Ohta; N Hanai; K Fukuoka; Y Ohe; K Sugihara; T Kodama; N Saijo INTERNATIONAL JOURNAL OF CANCER 82- (5) 759 -764 1999/08H Fukumoto; K Nishio; S Ohta; N Hanai; K Fukuoka; Y Ohe; K Sugihara; T Kodama; N Saijo INTERNATIONAL JOURNAL OF CANCER 82- (5) 759 -764 1999/08F Kanzawa; K Nishio; K Fukuoka; T Sunami; N Saijo CANCER CHEMOTHERAPY AND PHARMACOLOGY 43- (5) 353 -363 1999/05T Sunami; K Nishio; F Kanzawa; K Fukuoka; S Kudoh; J Yoshikawa; N Saijo CANCER CHEMOTHERAPY AND PHARMACOLOGY 43- (5) 394 -401 1999/05T Sunami; K Nishio; F Kanzawa; K Fukuoka; S Kudoh; J Yoshikawa; N Saijo CANCER CHEMOTHERAPY AND PHARMACOLOGY 43- (5) 394 -401 1999/05F Kanzawa; K Nishio; K Fukuoka; T Sunami; N Saijo CANCER CHEMOTHERAPY AND PHARMACOLOGY 43- (5) 353 -363 1999/05小川 修平; 福岡 和也; 牧之 段潔; 寺元 正治; 三笠 桂一; 岡本 行功; 前田 光一; 坂本 正洋; 竹中 英昭; 善本 英一郎; 成田 亘啓; 佐々木 義明 肺癌 39- (2) 216 -216 1999/04K Nishio; K Fukuoka; H Fukumoto; T Sunami; Y Iwamoto; T Suzuki; J Usuda; N Saijo INTERNATIONAL JOURNAL OF ONCOLOGY 14- (3) 461 -469 1999/03K Nishio; K Fukuoka; H Fukumoto; T Sunami; Y Iwamoto; T Suzuki; J Usuda; N Saijo INTERNATIONAL JOURNAL OF ONCOLOGY 14- (3) 461 -469 1999/03H Arioka; K Nishio; T Ishida; H Fukumoto; K Fukuoka; T Nomoto; H Kurokawa; H Yokote; S Abe; N Saijo JAPANESE JOURNAL OF CANCER RESEARCH 90- (1) 108 -115 1999/01H Arioka; K Nishio; T Ishida; H Fukumoto; K Fukuoka; T Nomoto; H Kurokawa; H Yokote; S Abe; N Saijo JAPANESE JOURNAL OF CANCER RESEARCH 90- (1) 108 -115 1999/01H Yokote; K Nishio; H Arioka; H Kurokawa; K Fukuoka; H Fukumoto; T Ishida; T Terada; T Itakura; N Saijo MUTATION RESEARCH-DNA REPAIR 409- (3) 147 -162 1998/12H Yokote; K Nishio; H Arioka; H Kurokawa; K Fukuoka; H Fukumoto; T Ishida; T Terada; T Itakura; N Saijo MUTATION RESEARCH-DNA REPAIR 409- (3) 147 -162 1998/12植田 勝廣; 三笠 桂一; 福岡 和也; 坂本 正洋; 古西 満; 前田 光一; 辻本 正之; 真島 利匡; 成田 亘啓; 都築 俊英 肺癌 38- (5) 543 -543 1998/09植田 勝廣; 三笠 桂一; 濱田 薫; 坂本 正洋; 眞島 利匡; 古西 満; 前田 光一; 善本 英一郎; 福岡 和也; 成田 亘啓; 喜多 英二 肺癌 38- (5) 466 -466 1998/09西尾 和人; 鈴木 俊宏; 須波 俊彦; 臼田 実男; 福岡 和也; 岩本 康男; 成 清一郎; 西條 長宏 肺癌 38- (5) 442 -442 1998/09細胞周期制御因子に対する新規抗がん剤の感受性耐性要因臼田 実男; 福岡 和也; 岩本 康男; 須波 敏彦; 加藤 治文; 西條 長宏; 西尾 和人 肺癌 38- (5) 443 -443 1998/09新規抗腫瘍性ステロイド化合物アラグステロールA(YTA0040)の肺癌細胞に対する抗腫瘍効果の検討福岡 和也; 臼田 実男; 岩本 康男; 成田 亘啓; 西條 長宏; 西尾 和人 肺癌 38- (5) 564 -564 1998/09須波 敏彦; 西尾 和人; 福岡 和也; 岩本 康男; 臼田 実男; 成瀬 一郎; 田村 友秀; 西條 長宏 肺癌 38- (5) 567 -567 1998/09上森 栄和; 坂本 正洋; 福岡 和也; 前田 光一; 古西 満; 三笠 桂一; 成田 亘啓; 尾崎 京子; 田丸 司; 村田 顕也; 高柳 哲也; 田中 恵子; 犬塚 貴 肺癌 38- (4) 388 -388 1998/08新抗癌剤の評価と展望 UCN-01の感受性を規定する細胞内因子臼田 実男; 西尾 和人; 福岡 和也; 福本 久郎; 岩本 康男; 鈴木 俊宏; 加藤 治文; 西條 長宏 日本癌治療学会誌 33- (3) 93 -93 1998/08新規抗腫瘍性ステロイド化合物アラグステロールA(YTA0040)の作用機序の検討福岡 和也; 臼田 実男; 山岸 武弘; 市原 智子; 中池 司郎; 井口 和男; 山田 泰司; 成田 亘啓; 西條 長宏; 西尾 和人 日本癌学会総会記事 57回- 643 -643 1998/08TOMODA Koichi; HAMADA Kaoru; FUKUOKA Kazuya; TSUKAGUCHI Katsuhiko; TSUJIMOTO Masayuki; MIKASA Keiichi; CHOH Umito; YONEDA Takahiro; NARITA Nobuhiro 日本呼吸器学会雑誌 = The journal of the Japanese Respiratory Society 36- (6) 541 -544 1998/06K Fukuoka; N Narita; N Saijo LUNG CANCER 20- (2) 109 -116 1998/05K Fukuoka; N Narita; N Saijo LUNG CANCER 20- (2) 109 -116 1998/05J Usuda; K Nishio; K Fukuoka; H Fukumoto; Y Iwamoto; S Naruse; T Suzuki; H Kato; N Saijo ANNALS OF ONCOLOGY 9- 111 -111 1998The role of MAP kinase in the taxane-induced cytotoxicity. in " Cytoskeleton and G-proteins in The Regulation of Cancer" HHokkaido University School of Medicine, Sapporo, Japan, 172-179- 1998The role of MAP kinase in the taxane-induced cytotoxicity. (共著)Hokkaido University School of Medicine Medical Library Series : "Cytoskeleton and G-proteins in The Regulation of Cancer"Sapporo, Kokoku Printing Co. Ltd 37- 172 -179 1998H Ogasawara; K Nishio; T Ishida; H Arioka; K Fukuoka; N Saijo JAPANESE JOURNAL OF CANCER RESEARCH 88- (11) 1033 -1037 1997/11H Ogasawara; K Nishio; T Ishida; H Arioka; K Fukuoka; N Saijo JAPANESE JOURNAL OF CANCER RESEARCH 88- (11) 1033 -1037 1997/11西尾 誠人; 福岡 和也; 福本 久郎; 有岡 仁; 岩本 泰男; 臼田 実男; 友成 章; 須波 敏彦; 成清 一郎; 鈴木 俊宏; 西條 長宏 肺癌 37- (5) 691 -691 1997/10友成 章; 西尾 和人; 福本 久郎; 福岡 和也; 岩本 康男; 成清 一郎; 臼田 実男; 鈴木 俊宏; 須波 敏彦; 板倉 光夫; 西條 長宏 肺癌 37- (5) 690 -690 1997/10福岡 和也; 西尾 和人; 宮澤 文彦; 福本 久郎; 友成 章; 岩本 康男; 臼田 実男; 須波 敏彦; 成清 一郎; 成田 亘啓; 西條 長宏 肺癌 37- (5) 664 -664 1997/10岩本 康男; 西尾 和人; 福岡 和也; 友成 章; 福本 久郎; 臼田 実男; 須波 敏彦; 吉松 賢太郎; 山木戸 道郎; 西條 長宏 肺癌 37- (5) 740 -740 1997/10須波 敏彦; 宮澤 文彦; 臼田 実男; 岩本 康男; 福岡 和也; 西尾 和人; 西條 長宏 肺癌 37- (5) 740 -740 1997/10K Fukuoka; J Adachi; K Nishio; H Arioka; H Kurokawa; H Fukumoto; T Ishida; T Nomoto; H Yokote; A Tomonari; N Narita; J Yokota; N Saijo JAPANESE JOURNAL OF CANCER RESEARCH 88- (10) 1009 -1016 1997/10T Ishida; K Nishio; H Kurokawa; H Arioka; H Fukumoto; K Fukuoka; T Nomoto; H Yokote; S Hasegawa; N Saijo INTERNATIONAL JOURNAL OF CANCER 72- (5) 865 -870 1997/09T Ishida; K Nishio; H Kurokawa; H Arioka; H Fukumoto; K Fukuoka; T Nomoto; H Yokote; S Hasegawa; N Saijo INTERNATIONAL JOURNAL OF CANCER 72- (5) 865 -870 1997/09A Tomonari; K Nishio; H Kurokawa; H Fukumoto; K Fukuoka; Y Iwamoto; J Usuda; T Suzuki; M Itakura; N Saijo BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 236- (3) 616 -621 1997/07A Tomonari; K Nishio; H Kurokawa; H Fukumoto; K Fukuoka; Y Iwamoto; J Usuda; T Suzuki; M Itakura; N Saijo BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 236- (3) 616 -621 1997/07F Kanzawa; K Nishio; K Fukuoka; M Fukuda; T Kunimoto; N Saijo INTERNATIONAL JOURNAL OF CANCER 71- (3) 311 -319 1997/05H Fukumoto; M Nishio; K Nishio; Y Heike; H Arioka; H Kurokawa; T Ishida; K Fukuoka; T Nomoto; Y Ohe; N Saijo JAPANESE JOURNAL OF CANCER RESEARCH 88- (5) 501 -505 1997/05H Fukumoto; M Nishio; K Nishio; Y Heike; H Arioka; H Kurokawa; T Ishida; K Fukuoka; T Nomoto; Y Ohe; N Saijo JAPANESE JOURNAL OF CANCER RESEARCH 88- (5) 501 -505 1997/05F Kanzawa; K Nishio; K Fukuoka; M Fukuda; T Kunimoto; N Saijo INTERNATIONAL JOURNAL OF CANCER 71- (3) 311 -319 1997/05A Tomonari; K Nishio; H Kurokawa; H Arioka; T Ishida; H Fukumoto; K Fukuoka; T Nomoto; Y Iwamoto; Y Hieke; M Itakura; N Saijo BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 232- (2) 522 -527 1997/03A Tomonari; K Nishio; H Kurokawa; H Arioka; T Ishida; H Fukumoto; K Fukuoka; T Nomoto; Y Iwamoto; Y Hieke; M Itakura; N Saijo BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 232- (2) 522 -527 1997/03H Kurokawa; K Nishio; T Ishida; H Arioka; K Fukuoka; T Nomoto; H Fukumoto; H Yokote; N Saijo JAPANESE JOURNAL OF CANCER RESEARCH 88- (2) 108 -110 1997/02H Kurokawa; K Nishio; T Ishida; H Arioka; K Fukuoka; T Nomoto; H Fukumoto; H Yokote; N Saijo JAPANESE JOURNAL OF CANCER RESEARCH 88- (2) 108 -110 1997/02西尾和人; 黒川博一; 石田智之; 福岡和也; 西条長宏 癌と化学療法 24- (4) 1997F Kanzawa; K Nishio; T Ishida; M Fukuda; H Kurokawa; H Fukumoto; Y Nomoto; K Fukuoka; K Bojanowski; N Saijo BRITISH JOURNAL OF CANCER 76- (5) 571 -581 1997F Kanzawa; K Nishio; T Ishida; M Fukuda; H Kurokawa; H Fukumoto; Y Nomoto; K Fukuoka; K Bojanowski; N Saijo BRITISH JOURNAL OF CANCER 76- (5) 571 -581 1997MIKASA Keiichi; SAWAKI Masayoshi; KITA Eiji; HAMADA Kaoru; SAKAMOTO Masahiro; KONISHI Mitsuru; MAEDA Koichi; TERAMOTO Shoji; TSUJIMOTO Masayuki; MORI Kei; UEDA Katsuhiro; FUKUOKA Kazuya; SEGAWA Kotaro; KATAOKA Tateshi; NARITA Nobuhiro 日本化学療法学会雜誌 = Japanese journal of chemotherapy 44- (12) 883 -889 1996/12K Nishio; T Ishida; H Arioka; H Kurokawa; K Fukuoka; T Nomoto; H Fukumoto; H Yokote; N Saijo ANTICANCER RESEARCH 16- (6B) 3387 -3395 1996/11K Nishio; T Ishida; H Arioka; H Kurokawa; K Fukuoka; T Nomoto; H Fukumoto; H Yokote; N Saijo ANTICANCER RESEARCH 16- (6B) 3387 -3395 1996/11M Fukuda; M Inomata; K Nishio; K Fukuoka; F Kanzawa; H Arioka; T Ishida; H Fukumoto; H Kurokawa; M Oka; N Saijo JAPANESE JOURNAL OF CANCER RESEARCH 87- (10) 1086 -1091 1996/10M Fukuda; M Inomata; K Nishio; K Fukuoka; F Kanzawa; H Arioka; T Ishida; H Fukumoto; H Kurokawa; M Oka; N Saijo JAPANESE JOURNAL OF CANCER RESEARCH 87- (10) 1086 -1091 1996/10濱田 薫; 徳山 猛; 米田 尚弘; 岡本 行功; 森川 暁; 春日 宏友; 三笠 桂一; 田村 猛夏; 宮崎 隆治; 鴻池 義純; 福岡 和也; 成田 亘啓 肺癌 36- (5) 506 -506 1996/09三笠 桂一; 澤木 政好; 喜多 英二; 浜田 薫; 坂本 正洋; 古西 満; 前田 光一; 寺本 正治; 辻本 正之; 森 啓; 植田 勝廣; 福岡 和也; 瀬川 耕太郎; 片岡 達治; 成田 亘啓 肺癌 36- (5) 527 -527 1996/09友田 恒一; 福岡 和也; 長 澄人; 竹中 英昭; 仲谷 宗裕; 小林 厚; 鈴木 夕子; 薄葉 恵史; 鴻池 義純; 米田 尚弘; 成田 亘啓 肺癌 36- (5) 672 -672 1996/09黒川 博一; 西尾 和人; 石田 智之; 有岡 仁; 福本 久郎; 福岡 和也; 野本 泰介; 友成 章; 横手 秀行; 岩本 康男; 鈴木 俊宏; 平家 勇司; 西條 長宏 肺癌 36- (5) 624 -624 1996/09福岡 和也; 安達 淳一; 西尾 和人; 有岡 仁; 黒川 博一; 福本 久郎; 石田 智之; 野本 泰介; 横手 秀行; 友成 章; 鈴木 俊宏; 岩本 康男; 成田 亘啓; 横田 淳; 西條 長宏 肺癌 36- (5) 623 -623 1996/09野本 泰介; 西尾 和人; 石田 智之; 有岡 仁; 黒川 博一; 福本 久郎; 福岡 和也; 横手 秀行; 友成 章; 岩本 康男; 鈴木 俊宏; 西條 長宏 肺癌 36- (5) 623 -623 1996/09石田 智之; 西尾 和人; 有岡 仁; 黒川 博一; 福本 久郎; 福岡 和也; 野本 泰介; 友成 章; 横手 秀行; 岩本 康男; 鈴木 俊宏; 西條 長宏 肺癌 36- (5) 691 -691 1996/09眞島 利匡; 徳山 猛; 濱田 薫; 岡本 行功; 福岡 和也; 辻本 正之; 酢谷 喜世子; 薄葉 恵史; 稲田 浩; 米田 尚弘; 成田 亘啓 肺癌 36- (2) 187 -187 1996/04福岡 和也; 西条 長宏 日本臨床 54- (1) 250 -258 1996/01N Saijo; K Nishio; S Ohta; H Arioka; Y Funayama; K Fukuoka; H Kurokawa; T Nomoto; T Ishida; N Yamamoto; T Tamura; T Shinkai; K Eguchi; Y Ohe; H Kunito; T Ohtsu; Y Sasaki CANCER CHEMOTHERAPY AND PHARMACOLOGY 38- S11 -S15 1996N Saijo; K Nishio; S Ohta; H Arioka; Y Funayama; K Fukuoka; H Kurokawa; T Nomoto; T Ishida; N Yamamoto; T Tamura; T Shinkai; K Eguchi; Y Ohe; H Kunito; T Ohtsu; Y Sasaki CANCER CHEMOTHERAPY AND PHARMACOLOGY 38- S11 -S15 1996N Saijo; K Nishio; Y Takeda; H Arioka; T Ishida; T Nomoto; K Fukuoka; H Kurokawa; H Fukumoto AMERICAN JOURNAL OF MEDICINE 99- S35 -S39 1995/12N Saijo; K Nishio; Y Takeda; H Arioka; T Ishida; T Nomoto; K Fukuoka; H Kurokawa; H Fukumoto AMERICAN JOURNAL OF MEDICINE 99- S35 -S39 1995/12井前 徳久; 鈴木 夕子; 福岡 和也; 前田 光一; 森井 武志; 徳山 猛; 濱田 薫; 三笠 桂一; 成田 亘啓 肺癌 35- (6) 826 -826 1995/10有岡 仁; 舩山 康則; 西尾 和人; 石田 智之; 福本 久郎; 黒川 博一; 佐田 誠; 福田 実; 福岡 和也; 野本 泰介; 平家勇司; 西條 長安 肺癌 35- (5) 571 -571 1995/09石田 智之; 西尾 和人; 有岡 仁; 黒川 博一; 福本 久郎; 福田 実; 福岡 和也; 野本 泰介; 西篠 長宏 肺癌 35- (5) 573 -573 1995/09黒川 博一; 西尾 和人; 石田 智之; 有岡 仁; 福本 久郎; 野本 泰介; 福岡 和也; 三浦 傳; 西條 長宏 肺癌 35- (5) 572 -572 1995/09福岡 和也; 西尾 和人; 有岡 仁; 石田 智之; 黒川 博一; 福本 久郎; 野本 泰介; 西條 長宏 肺癌 35- (5) 572 -572 1995/09福田 実; 猪俣 素子; 西尾 和人; 官澤 文彦; 有岡 仁; 石田 智之; 福本 久郎; 黒川 博一; 福岡 和也; 野本 泰介; 岡 三喜男; 西條 長宏 肺癌 35- (5) 619 -619 1995/09福本 久郎; 西尾 和人; 平家 勇司; 有岡 仁; 石田 智之; 黒川 博一; 野本 泰介; 福岡 和也; 山本 信之; 大江 裕一郎; 西條 長宏 肺癌 35- (5) 620 -620 1995/09西尾 和人; 有岡 仁; 石田 智之; 黒川 博一; 福岡 和也; 野本 泰介; 福本 久郎; 西條 長宏 肺癌 35- (5) 535 -535 1995/09野本 泰介; 西尾 和人; 小笠原 勇人; 有岡 仁; 石田 智之; 黒川 博一; 福本 久郎; 福岡 和也; 官澤 文彦; 西篠 長宏 肺癌 35- (5) 573 -573 1995/09福岡和也 結核 7- 111 -115 1995林 宏明; 米田 尚弘; 福岡 和也; 吉川 雅則; 夫 彰啓; 徳山 猛; 山本 智生; 竹中 英昭; 友田 恒一; 仲谷 宗裕; 成田 亘啓 肺癌 34- (5) 676 -676 1994/10長 澄人; 竹中 英昭; 生駒 行拡; 福岡 和也; 成田 亘啓 肺癌 34- (5) 816 -816 1994/10竹中 英昭; 福岡 和也; 長 澄人; 生駒 行拡; 吉川 雅則; 夫 彰啓; 徳山 猛; 山本 智生; 友田 恒一; 福岡 篤彦; 仲谷 宗裕; 林 宏明; 米田 尚弘; 成田 亘啓 肺癌 34- (5) 708 -708 1994/10福岡 和也; 米田 尚弘; 長 澄人; 濱田 薫; 竹中 英昭; 生駒 行拡; 塚口 信彦; 吉川 雅則; 徳山 猛; 夫 彰啓; 山本 智生; 友田 恒一; 仲谷 宗裕; 成田 亘啓 肺癌 34- (5) 778 -778 1994/10三笠 桂一; 澤木 政好; 喜多 英二; 濱田 薫; 古西 満; 前田 光一; 寺本 正治; 竹内 章治; 福岡 和也; 坂本 正洋; 辻本 正之; 森 啓; 国松 幹和; 成田 亘啓 肺癌 34- (5) 625 -625 1994/10福岡 和也; 塚口 信彦; 長 澄人; 濱田 薫; 鴻池 義純; 友田 恒一; 米田 尚弘; 成田 亘啓 肺癌 33- (5) 760 -760 1993/10松澤 邦明; 浜田 薫; 徳山 猛; 三笠 桂一; 田村 猛夏; 古西 満; 前田 光一; 福岡 和也; 澤木 政好; 成田 亘啓; 澤端 章好; 櫛部 圭司; 根津 邦基; 飯岡 壮吾; 北村 惣一郎 肺癌 33- (3) 449 -449 1993/06鴻池 義純; 夫 彰啓; 竹内 章治; 三笠 桂一; 濱田 薫; 長 澄人; 北村 和道; 福岡 和也; 龍神 良忠; 前川 純子; 成田 亘啓 肺癌 32- (5) 651 -651 1992/10古西 満; 三笠 桂一; 福岡 和也; 前田 光一; 友田 恒一; 佐々木 義明; 鴻池 義純; 澤木 政好; 成田 亘啓 肺癌 32- (5) 683 -683 1992/10Fukuoka Kazuya; Kohnoike Yoshizumi; Narita Nobuhiro; Kushibe Keishi; Ioka Sougo; Shirai Fumio Japanese Journal of Lung Cancer 32- (3) 389 -395 1992/06Nobuyoshi Shimizu et al Japanese Journal of Lung Cancer 31- (7) 1011 -1019 1991/12友田 恒一; 古西 満; 西川 潔; 森井 武志; 福岡 和也; 長 澄人; 濱田 薫; 鳩池 義純; 成田 亘啓; 大澤 政彦; 青笹 克之 肺癌 31- (6) 979 -979 1991/10玉置 伸二; 岡村 英生; 佐々木 義明; 長 澄人; 福岡 和也; 濱田 薫; 鴻池 義純; 成田 亘啓; 近藤 哲; 堤 雅弘; 丸山 博司; 小西 陽一 肺癌 31- (6) 978 -978 1991/10八木 秀男; 森井 武志; 鴻池 義純; 徳山 猛; 濱田 薫; 長 澄人; 福岡 和也; 吉川 雅則; 成田 亘啓; 日浅 義雄 肺癌 31- (6) 978 -978 1991/10福岡 和也; 塩崎 道明; 板橋 司; 久保田 靖; 古西 満; 濱田 薫; 長 澄人; 鴻池 義純; 成田 亘啓; 小路 徹二; 森井 外吉 肺癌 31- (6) 977 -978 1991/10古西 満; 三笠 桂一; 佐々木 義明; 福岡 和也; 前田 光一; 友田 恒一; 鴻池 義純; 澤木 政好; 成田 亘啓 肺癌 31- (5) 655 -655 1991/10斉藤 圭一; 古西 満; 鴻池 義純; 福岡 和也; 濱田 薫; 長 澄人; 澤木 政好; 成田 亘成; 小西 登; 青笹 克之 肺癌 31- (3) 441 -441 1991/06天野 逸人; 長 澄人; 古西 満; 福岡 和也; 濱田 薫; 鴻池 義純; 澤木 政好; 宮崎 隆治; 成田 亘啓; 日浅 義雄; 吉川 雅則; 竹下 修治 肺癌 30- (7) 1079 -1079 1990/12友田 恒一; 斎藤 圭一; 阿児 博文; 古西 満; 福岡 和也; 長 澄人; 濱田 薫; 鴻池 義純; 澤木 政好; 成田 亘啓; 吉岡 哲也; 尾辻 秀章; 折田 日出夫 肺癌 30- (7) 1079 -1080 1990/12塚口 信彦; 濱田 薫; 長 澄人; 福岡 和也; 鴻池 義純; 田村 猛夏; 春日 宏友; 澤木 政好; 成田 亘啓; 沢田 泉; 東条 尚; 飯岡 壮吾; 北村 惣一郎; 宮崎 隆治 肺癌 30- (7) 1086 -1087 1990/12古西 満; 福岡 和也; 鴻池 義純; 澤木 政好; 三笠 桂一; 竹内 章治; 佐々木 義明; 濱田 薫; 国松 幹和; 成田 亘啓 肺癌 30- (5) 750 -750 1990/10鴻池 義純; 福岡 和也; 阿児 博文; 春日 宏友; 森川 暁; 濱田 薫; 長 澄人; 田村 猛夏; 米田 尚弘; 堅田 均; 宮崎 隆治; 成田 亘啓 肺癌 30- (5) 706 -706 1990/10福岡 和也; 米田 尚弘; 鴻池 義純; 澤木 政好; 成田 亘啓; 飯岡 壮吾; 北村 惣一郎; 小西 陽一 肺癌 30- (4) 595 -595 1990/08小林 秀明; 古西 満; 福岡 和也; 濱田 薫; 鴻池 義純; 澤木 政好; 成田 亘啓; 櫛部 圭司; 飯岡 壮吾; 北村 惣一郎; 宮内 義純; 三井 宣夫; 玉井 進 肺癌 30- (4) 603 -603 1990/08中尾 宰子; 古西 満; 福岡 和也; 鴻池 義純; 澤木 政好; 成田 亘啓; 榮本 弘行; 丸山 博司; 小西 陽一 肺癌 30- (4) 606 -606 1990/08Morikawa S. Japanese journal of industrial health 31- (7) 719 -719 1989/12福岡 和也; 鴻池 義純; 堅田 均; 澤木 政好; 成田 亘啓; 櫛部 圭司; 東条 栄; 飯岡 壮吾; 北村 惣一郎; 白井 史朗 肺癌 29- (7) 811 -812 1989/12福岡 和也; 堅田 均; 三笠 桂一; 古西 満; 前田 光一; 辻本 正之; 中尾 宰子; 鴻池 義純; 澤木 政好; 成田 亘啓 肺癌 29- (7) 814 -814 1989/12辻本 正之; 福岡 和也; 鴻池 義純; 藤村 昌史; 杉村 裕子; 堅田 均; 澤木 政好; 成田 亘啓; 今井 照彦; 大石 元; 飯岡 壮荘; 北村 惣一郎 肺癌 29- (7) 818 -818 1989/12江川 信一; 米田 尚弘; 塚口 勝彦; 吉川 雅則; 鴻池 義純; 福岡 和也; 成田 亘啓 肺癌 29- (5) 597 -597 1989/10浜崎 直樹; 古西 満; 福岡 和也; 坂本 正洋; 友田 恒一; 佐々木 義明; 三笠 桂一; 堅田 均; 澤木 政好; 成田 亘啓 肺癌 29- (5) 496 -496 1989/10福岡 和也; 春日 宏友; 中尾 宰子; 森川 暁; 阿児 博文; 長 澄人; 渡辺 裕之; 鴻池 義純; 米田 尚弘; 堅田 均; 澤木 政好; 成田 亘啓; 今井 照彦; 大石 元 肺癌 29- (5) 502 -502 1989/10米田 尚弘; 吉川 雅則; 塚口 勝彦; 江川 信一; 鴻池 義純; 福岡 和也; 成田 亘啓 肺癌 29- (5) 563 -563 1989/10鴻池 義純; 福岡 和也; 江川 信一; 米田 尚弘; 堅田 均; 西川 潔; 澤木 政好; 成田 亘啓 肺癌 29- (5) 506 -506 1989/10岡村 英生; 福岡 和也; 古西 満; 三笠 桂一; 鴻池 義純; 堅田 均; 澤木 政好; 成田 亘啓; 村上 宣也; 生駒 一憲; 高柳 哲也; 杉本 充彦; 今井 俊介; 日浅 義雄 肺癌 29- (4) 422 -422 1989/08竹中 英昭; 福岡 和也; 前田 光一; 鴻池 義純; 古西 満; 三笠 桂一; 堅田 均; 沢木 政好; 成田 亘啓; 今井 照彦; 大石 元 肺癌 29- (4) 414 -414 1989/08坂本 正洋; 堅田 均; 三笠 桂一; 鴻池 義純; 古西 満; 福岡 和也; 澤木 政好; 成田 亘啓 肺癌 29- (4) 416 -416 1989/08福岡 和也; 堅田 均; 鴻池 義純; 澤木 政好; 成田 亘啓; 今井 照彦; 永田 清; 金 良根; 京井 喜久男; 内海 庄三郎 肺癌 29- (1) 98 -99 1989/02下山 丈人; 堅田 均; 鴻池 義純; 福岡 和也; 阿児 博文; 森川 暁; 澤木 政好; 成田 亘啓 肺癌 29- (1) 105 -105 1989/02吉田 英里; 堅田 均; 吉岡 真理子; 阿児 博文; 福岡 和也; 鴻池 義純; 澤木 政好; 成田 亘啓; 柳本 真一; 高柳 哲也 肺癌 29- (1) 101 -101 1989/02吉川 雅則; 堅田 均; 米田 尚弘; 福岡 和也; 鴻池 義純; 澤木 政好; 成田 亘啓; 今井 照彦 肺癌 29- (1) 106 -106 1989/02福岡 和也; 米田 尚弘; 澤木 政好; 成田 亘啓; 飯岡 壮吾; 東条 尚; 北村 惣一郎 肺癌 28- (5) 588 -588 1988/09今井 照彦; 大石 元; 吉村 均; 堅田 均; 鴻池 義純; 福岡 和也; 沢木 政好; 成田 亘啓; 東条 尚; 飯岡 壮吾 肺癌 28- (5) 564 -564 1988/09畠山 雅行; 西村 幸洋; 玉田 俊明; 佐藤 典子; 久保田 靖; 尾辻 秀章; 打田 日出夫; 今井 照彦; 吉村 均; 大石 元; 福岡 和也; 鴻池 義純; 堅田 均; 成田 亘啓; 東条 尚; 飯岡 壮吾; 北村 惣一郎; 小西 陽一 肺癌 28- (5) 559 -559 1988/09鴻池 義純; 西川 潔; 福岡 和也; 堅田 均; 成田 亘啓 肺癌 28- (5) 572 -572 1988/09前田 光一; 堅田 均; 三笠 桂一; 福岡 和也; 辻本 正之; 吉田 英里; 今井 照彦; 成田 亘啓 肺癌 28- (3) 414 -414 1988/06福岡 和也; 堅田 均; 三笠 桂一; 佐々木 義明; 古西 満; 渡辺 裕之; 前田 光一; 吉田 英里; 成田 亘啓 肺癌 28- (3) 414 -414 1988/06米田 尚弘; 鴻池 義純; 福岡 和也; 堅田 均; 成田 亘啓 肺癌 27- (5) 482 -482 1987/09堅田 均; 渡辺 裕之; 三笠 桂一; 鴻池 義純; 西川 潔; 吉岡 真理子; 吉田 恵里; 福岡 和也; 前田 光一; 成田 亘啓 肺癌 27- (5) 611 -611 1987/09Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells.(共著)Lung Cancer (IASLC) (in press)-Books and other publications
- 日本肺癌学会 (Contributor第8章 悪性胸膜中皮腫)金原出版 2021/11 9784307204491 203p
- Textbook of Medical Oncology, 3rd EditionJapanese Society of Medical Oncology (Joint workMesothelioma (Pleura, Peritoneum, etc))Nankodo 2020/07 9784524225422
- 1から学ぶ医師主導臨床研究の基本ーがん研究推進のために知っておきたい最新情報ー福岡 和也 (Single work)株式会社A・M・S 2018/02 9784990455286
Affiliated academic society
- THE JAPANESE SOCIETY OF CLINICAL PHARMACOLOGY AND THERAPEUTICS THE JAPAN LUNG CANCER SOCIETY THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY Japanese Society of Medical Oncology American Society of Clinical Oncology 日本呼吸器学会 日本内科学会 International Association for the Study of Lung Cancer American Association for Cancer Research
Research Themes
- Based on the experience of 8,000 cases multiomics analysis, research on patient reduction of whole genome analysis日本医療研究開発機構(AMED):革新的がん医療実用化研究事業Date (from‐to) : 2021/04 -2023/03
- Development of an education program utilizing hands-on training to train experts with outstanding knowledge and skills on lung cancer biomarker testingPfizer:Pfizer Global Medical GrantsDate (from‐to) : 2020/10 -2022/08Author : Chikara Hirase; Yasuhiro Kidera; HIroto Shimano; Kazuto Nishio; Kazuko Sakai; Masayuki Takeda
- Development of remote learning method utilizing AR (Augmented Reality) in the field of university and graduate school educationKindai University:令和2年度“オール近大”新型コロナウイルス感染症 対策支援プロジェクトDate (from‐to) : 2020/07 -2021/02Author : Kazuto Nishio; Yoshihiro Yamaguchi
- Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)Date (from‐to) : 2015/04 -2018/03Author : FUKUOKA KazuyaMalignant pleural mesothelioma (MPM) is an aggressive and highly-refractory tumor caused by asbestos exposure. To date, the standard treatment for MPM remains to be established. In the present study, to explore the gene mutations for the targets of molecular targeted therapy against MPM, we performed the gene expression analyses using next-generation sequencer. Of the gene mutations which were commonly identified in both MPM cell lines and pleural tumor tissues, NOTCH1, FBXW7, TSC1, and BRCA2 might be novel targets for molecular targeted therapy. NOTCH1 and FBXW7 are involved in survival and proliferation of cancer stem cells (CSCs). TSC1 and BRCA2 are causing genes of other genetic malignancies, on which existing molecular targeted agents show the anti-tumor activities. The present study indicated that these genes and CSCs can be applied for the promising targets of novel molecular targeted therapy against MPM.
- Research on the Establishment of Multidisciplinary Treatment Methods for Resectable Malignant Pleural Mesothelioma厚生労働省:厚生労働科学研究費補助金(厚生科研費)Date (from‐to) : 2011/04 -2014/03
- Comprehensive Approach to Asbestos-Related Diseases科学技術振興機構(JST):科学技術戦略推進費(旧:科学技術振興調整費)Date (from‐to) : 2006/04 -2011/03
- Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)Date (from‐to) : 2008 -2010Author : TAMAOKI Tomoko; TSUJIMURA Toru; NAKANO Takashi; FUKUOKA Kazuya; MORINAGA Tomonori; YOSHIKAWA Reigetsu; SAITO Yuko; YOSHIKAWA YoshieMalignant mesothelioma(MM) is an asbestos-related tumor. Array-based CGH was performed using MM primary-cultured cells established in Hyogo College of Medicine(HCM). In HCM-MM cell samples, frequent deletions were detected in 1p, 3p21, 4q, 9p21, 16p13 and 22q. We also used ATCC and Riken MM cells. All 21 MM cells showed homozygous deletions in the 9p21 region carrying the CDKN2A/p16 and CDKN2B/p15 genes. Homozygous or heterozygous deletions in the 22q region carrying the NF2 gene were detected in 80% of HCC-MM cells, and deletions in 3p21.1-21.31 in 50%. We focused on the 3p21 region because it was specific to the epithelioid type. Since 3p21.1 and 3p21.31 regions contain Semaphorin family genes that inhibit VEGF activity, we analyzed gene expression profiles and found that lower expression of several SEMA genes and higher expression of VEGFA in epithelioid MMs than in Met5a, a normal mesothelial cell line, suggesting that VEGFA biological activity may be higher in epithelioid MMs. Genome alterations of BAP1, located in 3p21.1, was detected in 15 of 16 epithelioid MMs ; biallelic deletions or monoallelic deletions with or without mutations. Immunostaining with anti-BAP1 antibody showed negative nuclear staining in most of epithelioid MMs. These BAP1 mutations and deletions were somatic, since no germinal mutations were detected. These results showed that BAP1 mutation plays a significant role in the pathogenesis of epithelioid MMs.
- 肺癌に対する分子標的治療に関する基礎的研究
- Study on Expression of Carbohydrate Autigens on Lung Cancer Tissue
- Basic Research on Target-based therapy for Lung Cancer
- Clinical Research on Chemotherapy and Radiotherapy for Lung Cancer
Other Link
researchmap